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Résumé 
Le cancer est la principale cause de mortalité au Canada. Les taxanes (e.g. le 
paclitaxel et le docétaxel (DCTX)) constituent des remèdes efficaces contre une série 
de tumeurs solides telles que les cancers du sein, du poumon et de l’ovaire. Par 
ailleurs, des acides nucléiques (e.g. les oligonucléotides antisens (AON) ou les petits 
ARN interférents (siRNAs)), capables de supprimer sélectivement certains oncogènes 
impliqués dans la carcinogénèse, sont actuellement étudiés pour traiter une large 
gamme de cancers. Bien que l’activité des taxanes et des acides nucléiques soit bien 
établie sur des modèles humains et/ou animaux, plusieurs aspects physico-chimiques 
et cliniques restent encore à améliorer. Leur solubilité limitée (pour les taxanes), leur 
dégradation rapide dans le sang (pour les acides nucléiques), leur élimination 
précoce, leur absence de sélectivité et leur toxicité envers les tissus sains sont les 
principaux facteurs limitant leur efficacité. C’est pourquoi de nombreux efforts ont 
porté sur l’élaboration de systèmes de vectorisation ciblés à base de polymères, dans 
le but de surmonter les problèmes associés aux thérapies actuelles. Dans cette thèse, 
deux types de micelles polymères ont été développés pour la vectorisation de DCTX 
et d’acides nucléiques. D’une part, des micelles de poly(oxyde d’éthylène)-bloc-
poly(oxyde de butylène/styrène) ont été étudiées pour la première fois pour 
solubiliser le DCTX et le protéger de l’hydrolyse. Ces polymères se sont révélés 
moins toxiques que le surfactant utilisé commercialement pour solubiliser le DCTX 
(i.e. polysorbate 80) et ont permis une libération prolongée du principe actif. D’autre 
part, deux systèmes différents de micelles polyioniques (PICM) ont été mis au  point 
pour la vectorisation d’acides nucléiques. De nouveaux conjugués de poly(éthylène 
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glycol) (PEG)-oligonucléotide ont été proposés pour la protection et la libération 
contrôlée d’AON. Lorsque ces conjugués ont été formulés avec des dendrimères de 
poly(amidoamine) (PAMAM), des complexes de taille homogène ont été obtenus. 
Ces PICM ont permis de prolonger la libération de l’AON et de le protéger 
efficacement contre la dégradation enzymatique. De plus, des polymères de 
poly(oxyde d’éthylène)-bloc-poly(méthacrylate de propyle-co-acide méthacrylique) 
ont été incorporés afin de conférer des propriétés acido-sensibles aux PICM. Dans 
ces micelles, formées de ce dernier polymère formulé avec le dendrimère PAMAM, 
des oligonucléotides (AON et siRNA) ciblant l’oncogène Bcl-2 ont été encapsulés. 
L’internalisation cellulaire fut assurée par un fragment d’anticorps monoclonal (Fab’) 
situé à l’extrémité de la couronne de PEG. Après l’internalisation cellulaire et la 
protonation des unités d’acide méthacrylique sous l’effet de l’acidification des 
endosomes, les micelles se sont affranchies de leur couronne. Elles ont ainsi exposé 
leur cœur composé d’acide nucléique et de dendrimère PAMAM, qui possède une 
charge positive et des propriétés endosomolytiques. En effet, ces PICM acido-
sensibles ciblées ont permis d’augmenter la biodisponibilité des acides nucléiques 
vectorisés et se sont avérées plus efficaces pour silencer l’oncoprotéine Bcl-2 que les 
micelles non ciblées ou que le dendrimère de PAMAM commercial seul. Finalement, 
les nanovecteurs polymères présentés dans cette thèse se révèlent être des systèmes 
prometteurs pour la vectorisation des anticancéreux et des acides nucléiques. 
 
Mots-clés : micelles polymères, micelles polyioniques, docétaxel, oligonucléotide 
antisens, siRNA, dendrimères de poly(amidoamine), vectorisation de médicament, 
vectorisation d’acides nucléiques, sensibilité au pH, ciblage. 
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Abstract 
Cancer is considered as the leading cause of premature death in Canada. 
Taxanes (e.g. paclitaxel and docetaxel (DCTX)) are effective against a range of solid 
tumors including breast, lung, and ovarian malignancies. In addition, nucleic acids 
(e.g. antisense oligonucleotides (AON) and short interfering RNA (siRNA)) which 
are capable of selectively suppressing oncogenes involved in carcinogenesis are 
currently being investigated for the treatment of a wide variety of cancers. Although 
the activity of taxanes and nucleic acid drugs is well-established in human and/or 
animal models, several physicochemical and clinical issues still need to be addressed. 
Low aqueous solubility (i.e. taxanes), rapid degradation in the blood (i.e. nucleic 
acids), fast clearance, non-selectivity and toxicity to normal tissues are limiting 
factors to their effectiveness. Hence, many efforts have been focused on developing 
targeted polymeric delivery systems to overcome the problems associated with the 
current therapies. In this thesis, two types of polymeric micelles have been developed 
for the delivery of DCTX and nucleic acids. On the one hand, poly(ethylene oxide)-
block-poly(butylene oxide/styrene oxide) micelles were tested for the first time to 
solubilize and protect DCTX from hydrolytic degradation. The polymers showed less 
toxicity than the surfactant used commercially to dissolve DCTX (i.e. polysorbate 80) 
and released the drug in a sustained fashion. On the other hand, two different systems 
of polyion complex micelles (PICM) were developed for the sustained release and 
intracellular delivery of nucleic acids. Novel poly(ethylene glycol) (PEG)-
oligonucleotide conjugates were assessed to protect AON against degradation and 
release them in a sustained manner. When these conjugates were mixed with 
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poly(amidoamine) (PAMAM) dendrimers, monodisperse PICM were formed. These 
PICM further slowed down AON release and significantly protected it against 
enzymatic degradation. In addition, the incorporation of poly(ethylene oxide)-block-
poly(propyl methacrylate-co-methacrylic acid) was exploited to impart pH-sensitivity 
to PAMAM-based PICM. This system was composed of the previous copolymer 
mixed with PAMAM dendrimer. Such PICM were loaded with AON or siRNA 
targeting the Bcl-2 oncogene. Micelles uptake by the cancer cells was mediated by a 
monoclonal antibody fragment (i.e. Fab') positioned at the extremity of the PEG 
corona. Upon cellular uptake and protonation of the methacrylic acid units in the 
acidic endosomal environment, the micelles lost their corona, thereby exposing their 
positively-charged endosomolytic PAMAM/nucleic acid core. The targeted, pH-
sensitive PICM were found to increase the intracellular bioavailability of the 
entrapped nucleic acids and knock down the Bcl-2 oncoprotein more than either non-
targeted micelles or commercial PAMAM dendrimers. The polymeric nanocarriers 
reported in this thesis appear to be promising vehicles for the delivery of anticancer 
drugs and nucleic acids.   
 
Keywords: Polymeric micelles, polyion complex micelles, docetaxel, antisense 
oligonucleotide, siRNA, poly(amidoamine) dendrimers, drug delivery, nucleic acid 
delivery, pH-sensitivity, targeted delivery. 
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CHAPTER 1 - General overview 
Cancer is the uncontrolled division of cells. Cancerous cells are abnormal and 
can invade and damage nearby tissues or separate from the tumor and spread to other 
parts of the body1. Cancer is considered to be the leading cause of premature death in 
Canada. In 2003, 2.5% of Canadian men and 2.8% of Canadian women were 
diagnosed with cancer. According to Canadian cancer statistics, 171,000 new cases 
of cancer and 75,300 deaths from cancer are anticipated in Canada in 2009.  
Many factors, such as, tobacco smoking, prolonged exposure to radiation, free 
radicals and alcohol can cause cancer2-5. In addition, cancer can occur due to viral 
infections6. There are over 100 distinct types of cancer which are classified according 
to the type of initially-affected cell7.   
Tumorigenesis, a multistep process, reflects the accumulation of genetic 
damages that drives the progressive transformation of normal cells into malignant 
cells8. These mutations usually produce oncogenes with dominant gain of function 
and tumor suppressor genes with recessive loss of function. Both activation of 
oncogenes and loss of tumor suppressor genes allow cancer cells to avoid apoptosis 
(programmed cell death). The normal function of proteins encoded by tumor 
suppressor genes is to provide growth restraint9. Oncogenes are mutated genes that 
allow unregulated cell growth by yielding a large number of proteins required for 
tumor progression10. These proteins are usually expressed in normal cells. However, 
they can be made oncogenic by mutation or overexpression. For example, epidermal 
growth factor receptors and platelet-derived growth factor receptors are either 
mutated or overexpressed in tumor cells10.  
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Cancer cells usually have distinct properties: evading apoptosis, limitless 
replicative potential, self-sufficiency of growth factors, insensitivity to anti-growth 
signals, angiogenesis (recruitment of new blood vessels from pre-existing ones), 
invasion and metastasis7. In addition, some morphological changes are characteristic 
of tumor cells, such as, variations in cell shape and nuclear size with loss of normal 
tissue organization11. These alterations can be characteristic of a given tumor type 
and stage.   
Cancer is treated by different modalities, such as, surgery12,13, radiation13,14, 
immunotherapy15,16, hormonal therapy17,18, angiogenesis inhibition19-21 and 
chemotherapy22-26. The choice of treatment depends on tumor location and grade. 
Two or more of these therapies are often combined. 
Tumor mass can be completely removed by surgery. However, the tendency 
of cancer to spread to other sites limits its effectiveness12,13. Therefore, dissection of 
cancer is usually followed by chemotherapy and/or radiotherapy13.  
Radiotherapy employs ionizing radiation to kill cancer cells and shrink 
tumors. It usually acts by destroying genetic materials to prevent cell growth and 
division14. It is included after surgery, sometimes in combination with chemotherapy, 
to prevent the spread of cancer13. Different types of radiation can be administered, 
depending on the tumor site and grade. Some can reach deep areas while others can 
be controlled to treat only small sites14. Nevertheless, radiotherapy is toxic to normal 
tissues, and this restricts its clinical application27. 
Immunotherapy can be specific or non-specific. Non-specific immunotherapy 
consists of cytokine-based regimens to modulate the immune response15,16. Specific 
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immunotherapies, designed to elicit or enhance the immune response to tumor 
antigens, involve the administration of cancer cells obtained from the patient (after 
certain manipulations and are usually combined with immunity activators) to 
strengthen immunity against specific tumor types28.  In addition, specific 
immunotherapies deploy antibodies or immunotoxins against tumor antigens29. The 
main problem with immunotherapies is immunological tolerance. The tumor can 
violate regulatory mechanisms (e.g. loss of tumor antigens) which diminish the 
activities of these antibodies30. 
Hormonal therapy generally targets tumors that are sensitive to hormones 
(e.g. breast and prostate cancers). In these tumors, certain hormones (e.g. estrogen 
and testosterone) can bind to cancer cell receptors and promote cellular proliferation. 
Blocking these receptors17, or inhibiting hormonal production18 can reduce tumor 
growth. Drugs that interfere with estrogen binding to breast cancer cell receptors (e.g. 
tamoxifen), or turn off its production from the ovaries (e.g. aromatase inhibitors), can 
serve to treat breast cancer17,18.  
Angiogenesis inhibitors prevent the extensive growth of blood vessels 
required for tumor growth19-21. These inhibitors can prevent vascular endothelial cells 
from proliferating or migrating in response to a spectrum of pro-angiogenic proteins 
(e.g. vascular endothelial growth factor, VEGF)19-21. In addition, they can inhibit the 
expression of angiogenic proteins (e.g. via RNA interference, RNAi)31-34.  
Cancer chemotherapy relies on the use of drugs that prevent the dissemination 
of neoplasias by interfering with specific molecules involved in tumor growth22, 23, 
26,35. Although these drugs are effective in killing tumoral cells, they are usually 
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harmful to normal tissues and cause toxicity22. Alternatively, by focusing on the 
molecular and cellular changes that are specific to cancer (e.g. expression of specific 
extracellular receptors or differences in pH inside the cancer cells), targeted cancer 
therapies can be more effective and less harmful than current interventions23. 
Taxanes (e.g. paclitaxel and docetaxel) are used against a range of solid tumors 
including breast, lung, and ovarian malignancies36,37. In addition, nucleic acids (e.g. 
antisense oligonucleotides (AON) and short interfering RNA (siRNA)) which are 
capable of selectively suppressing oncogenes (e.g. Bcl-2) involved in carcinogenesis 
have been investigated for the treatment of a wide variety of cancers38,39. The 
mechanisms of action of taxanes, AON and siRNA will be discussed in details in the 
following sections. Although the effectiveness of both types of compounds is well-
established in human and/or animal models, the clinical outcomes still need to be 
improved. Low aqueous solubility (i.e. taxanes), rapid degradation in the blood (i.e. 
nucleic acids), rapid clearance, non-selectivity and toxicity to normal tissues are 
limiting factors to an optimal activity. Hence, many efforts have been focused on 
developing targeted polymeric delivery systems to overcome the problems associated 
with current therapies40-43.  
Targeted polymeric carriers, such as liposomes44, lipoplexes45, polyplexes46 
and polymeric micelles47 (PM), have been tested for the delivery of taxanes, nucleic 
acids and other drugs. These delivery systems provide a reservoir for either 
solubilizing water-insoluble agents (e.g. antitumor drugs) or accommodating and 
protecting charged biomacromolecules (e.g. proteins and nucleic acids) from 
enzymatic degradation. These systems are usually coated with a non-ionic 
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hydrophilic shell to prevent the adsorption of opsonins, thereby limiting the rapid 
uptake by the mononuclear phagocyte system (MPS) and prolonging the circulation 
half-life of the encapsulated drug. Prolonged circulation time allows the passive 
targeting of the nanoparticles into tumors via the enhanced permeation and retention 
(EPR) effect (Chapter 2, Figure 2)48. The EPR effect is explained by the vascular 
leakage and impaired lymphatic drainage at tumor sites, resulting in the peripheral 
deposition of colloidal particles. In addition, colloids can be decorated with specific 
ligands that bind to extracellular receptors over-expressed by tumors. In this chapter, 
some delivery systems that have been examined for the delivery of hydrophobic 
drugs (e.g. taxanes) and nucleic acids will be discussed (Tables 1 and 2).   
 
1. Formulations of taxanes 
Taxanes are mitotic inhibitors that include paclitaxel and docetaxel. Their 
anticancer activity is achieved through binding to tubulins, thus inhibiting cell 
mitosis at the G2/M phase by stabilizing the microtubules, which triggers apoptosis49. 
Taxanes are effective against a range of solid tumors, such as breast, lung, and 
ovarian malignancies. However, conventional use of taxanes can be very toxic and 
only a small proportion of injected drug molecules reaches target cells, whereas the 
rest damages healthy cells and tissues. In addition, taxanes have poor aqueous 
solubility. For example, the aqueous solubility of paclitaxel and docetaxel is 1.6 and 
2 µg/mL, respectively50,51. To improve their solubility, a vehicle composed of 
polyethoxylated castor oil (Cremophor® EL) and ethanol is used for paclitaxel 
(commercial formulation Taxol®) while docetaxel is formulated in polysorbate 80 
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(Tween® 80) and ethanol (commercial formulation Taxotere®). These solvents can 
cause histamine-mediated hypersensitivity reactions which usually requires 
premedication22. Even with prophylactic antihistaminic agents and corticosteroids, 
severe reactions can still occur. Furthermore, these surfactants modulate the 
disposition profiles of paclitaxel and docetaxel after intravenous administration, 
resulting in non-linear pharmacokinetics22,52. To overcome the disadvantages of 
current formulations and to increase the therapeutic index of taxanes, various 
colloidal drug carriers, such as emulsions, liposomes, nanoparticles, and PM, are 
currently being studied (Table 1 and Figure 1).  
 
 
Table 1. Examples of colloidal taxane formulations currently being tested in clinical 
trials or approved for cancer treatment. 
  
Formulation Drug Carrier Reference 
Taxol® Paclitaxel Cremophor® EL 53 
Taxotere® Docetaxel Tween® 80 38 
Xyotax® Polymeric conjugate Paclitaxel Poly(L-glutamic acid) 54 
Tocosol® Emulsion Paclitaxel Tocopherol 55 
Abraxane® Nanoparticles Paclitaxel Albumin nanoparticles 56 
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Figure 1. Some delivery systems (liposomes, PM and polymeric-drug conjugates) 
currently being exploited for the delivery of anticancer drugs.  
 
 
 
1.1 Polymeric macromolecular carriers 
Chemotherapeutic agents can be conjugated to hydrophilic polymeric 
backbones to increase their aqueous solubility (Figure 1). This conjugation can 
modulate the pharmacokinetics and decrease the side-effects of drugs. Moreover, it 
can be applied for active targeting by attaching a targeting moiety to the polymeric 
carrier so as to favor its recognition by a specific cell receptor. The idea was first 
proposed by Ringsdorf in the mid-1970s and then extended to many therapeutic 
applications57. Several polymers have been employed for these purposes, such as 
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poly(ethylene glycol) (PEG), poly(N-(2-hydroxypropyl) methacrylamide) and 
poly(glutamic acid)54,58. Among all these polymeric-drug conjugates, poly(L-
glutamic acid)-paclitaxel (Xyotax®) (Table 1) has received special impetus. In this 
system, paclitaxel is conjugated to poly(L-glutamic acid) via ester linkage. The 
resulting conjugate is highly water-soluble. The active drug is then released by 
enzymatic cleavage of the poly(glutamic acid) backbone through the action of 
cellular proteases in tumors, particularly cathepsin B, which is upregulated by 
malignant tissues54. Xyotax® has demonstrated significantly enhanced antitumor 
efficacy and improved safety compared to paclitaxel in preclinical studies and 
advanced to phase III clinical trials59. 
1.2 Emulsions 
Emulsion is an heterogeneous mixture of two immiscible liquids with emulsifier 
that stabilizes the dispersed droplets. They can be utilized as carriers for hydrophilic 
or hydrophobic drugs for different therapeutic applications. For instance, oil-in-water 
emulsions have served as carriers for lipophilic drugs and many of them are available 
commercially60. These emulsions can alter the biodistribution of the incorporated 
drugs and enhance their accumulation in target tissues. For example, Constantinides 
et al.61 have formulated a submicron emulsion of paclitaxel using vitamin E 
(tocopherol) as the internal phase (Tocosol®-paclitaxel) (Table 1). When the 
emulsion was injected into melanoma-bearing mice, it was found to be less toxic and 
had greater antitumor activity than Taxol®. However, Tocosol®-paclitaxel, 
unexpectedly, failed in a phase III study conducted in breast cancer patients. The 
response rate was 37% for Tocosol®-paclitaxel vs. 45% for Taxol®, and it was linked 
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to more side effects than Taxol®62. Although there is no clear explanation for this 
failure, the weak interactions between tocopherol and paclitaxel might explain the 
lower efficacy of the formulation.  
1.3 Liposomes 
Liposomes are spherical vesicles composed of lipid bilayers with an 
hydrophilic core (Figure 1). They are usually classified according to the number of 
lipid bilayers into unilamellar and multilamellar vesicles. Normally, both hydrophilic 
and lipophilic drugs can be loaded into the core and lipid bilayer of liposomes, 
respectively63. However, the loading of hydrophobic drugs can be limited by the 
space in the hydrophobic lipid layers. Steric stabilization is usually required to avoid 
the rapid clearance by the MPS and is usually achieved by grafting hydrophilic 
polymers (i.e. PEG) to the surface of the liposomes. Active targeting can also be 
carried out by attaching targeting moieties to the surface coating. Liposomes have 
been employed as delivery vehicles for various chemotherapeutic agents63. In 
particular, doxorubicin-loaded liposomes (DoxilTM) have been approved for the 
treatment of ovarian cancer44. These liposomes showed extended circulation time and 
enhanced accumulation in tumors, compared to the free drug. Liposomes have been 
tested with several other anticancer drugs, such as paclitaxel and docetaxel51,64. For 
instance, Immordino et al.64 reported that upon intravenous injection of docetaxel 
formulated in polysorbate 80, the β half-life was 52.3 min. Conversely, the half life 
rose to 665 min when docetaxel was formulated in PEGylated liposomes. 
Nevertheless, the low loading capacity of liposomes for taxanes and poor physical 
stability limited their progress to the clinic51. 
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1.4 Polymeric micelles 
PM are formed via the self-assembly of amphiphilic copolymer chains in 
aqueous milieu. They present a core/shell architecture wherein the hydrophobic core 
serves as a microenvironment for the solubilization of poorly water-soluble drugs 
while the hydrophilic corona acts as a stabilizing interface between the core and the 
external medium (Figure 1). In water, hydrophobic interactions are generally the 
main driving force behind the micellization process. PM usually have fairly narrow 
size distributions with diameters ranging from 10 to 100 nm. Incorporation of the 
drug inside the micelles often decreases the toxicity of the entrapped drug, allowing 
for higher doses to be administered and greater efficacy. For example, D. Le Garrec 
et al.65 demonstrated that paclitaxel incorporated in poly(N-vinylpyrrolidone)-b-
poly(D,L-lactide) (PVP-b-PDLLA) did not reach the maximum tolerated dose 
(MTD) even at 100 mg/kg and showed greater antitumor activity than Cremophor® 
EL micelles whose MTD was established at 20 mg/kg. Because of the higher MTD, 
paclitaxel could be injected at higher doses (60 mg/kg) where it induced three- and 
twofold increases in the plasma and tumor area under the concentration-time curves, 
respectively, vs. Cremophor® EL (20 mg/kg). Indeed, paclitaxel formulated in PEG-
b-PDLLA micelles is now in phase II clinical trials, either alone or in combination 
with cisplatin66,67. The applications of PM to deliver various therapeutic agents will 
be discussed in detail in Chapter 2. 
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1.5 Nanoparticles 
Nanoparticles are colloidal particles with a rigid core. They are either made 
from i) a polymeric or lipidic matrix in which a drug is dissolved or dispersed or ii) 
from drug nanocrystals stabilized by a polymer56, 68,69. They are usually larger than 
micelles (100-200 nm) and are generally more polydisperse. Amphiphilic copolymers 
have been exploited as emulsifiers for the preparation of nanoparticles. They form 
stable films, where the hydrophobic block is oriented toward the core while the 
hydrophilic block creates a hydrated corona and provides steric stabilization for the 
nanoparticles. Many copolymers have been employed in the preparation of 
nanoparticles for the delivery of anticancer drugs. Examples of these polymers 
include PEG-b-PDLLA and PEG-b-poly(lactide-co-glycolide)68-71. Alternatively, 
albumin nanoparticles (nab-paclitaxel; Abraxane®) have been used for paclitaxel 
delivery (Table 1)56,72. These protein nanoparticles consist of albumin-bound 
paclitaxel with a mean particle size of 130 nm. They facilitate drug transport into 
tumors through albumin receptors and caveolae-mediated transport across endothelial 
cells, which increase the intratumoral accumulation of paclitaxel56. Preliminary 
evidence suggests that this process may be facilitated through binding of albumin to 
SPARC (secreted protein acid and rich in cysteine), an extracellular matrix 
glycoprotein that is overexpressed and associated with poor prognosis in a variety of 
cancers. In a recent in vivo study, intratumoral paclitaxel accumulation was found to 
be 33% higher for nab-paclitaxel compared to Cremophor® EL-paclitaxel when each 
formulation was administered using equal doses of paclitaxel37. These nanoparticles 
have been recently approved for patients with metastatic breast cancer.  
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2. Formulations of nucleic acids 
The introduction of nucleic acids into eukaryotic cells to investigate gene 
function and regulate gene expression has drawn considerable attention. Nucleic 
acids, such as plasmid DNA (pDNA), AON and siRNA have been tested to treat 
several diseases including cancer33,34,38,73-76. For example, AON and siRNA have 
been implicated in the downregulation of oncogenes involved in the carcinogenesis, 
such as Bcl-2, an important antiapoptotic protein found in a wide variety of human 
cancer cells. Bcl-2 protein controls the mitochondrial outer membrane 
permeabilization. Overexpression of Bcl-2 causes stabilization of the mitochondrial 
membrane and prevents the release of cytochrome c (which plays a role in apoptosis) 
thus interrupting the intrinsic apoptotic pathway. The latter confers resistance to 
malignant cells against chemotherapeutic agents that work by inducing apoptosis39. 
Bcl-2 Inhibition would sensitize cancer cells to chemotherapy. Bcl-2 expression can 
be downregulated by both AON and siRNA (Figure 2)77. AON cause protein 
knockdown by selectively binding to mRNA, blocking mRNA translation or inducing 
its degradation by activating RNase H endonuclease activity that cleaves RNA in 
RNA–DNA heteroduplexes. This leads to the selective degradation of target mRNA 
while leaving AON intact. Alternatively, RNAi cleaves the mRNA and knocks down 
a target protein via a different mechanism. In the RNAi process, long double stranded 
RNA are cleaved into shorter double stranded RNA segments (siRNA) by the Dicer 
protein, ribonuclease III type protein. siRNA possesses a well-defined structure 
consisting of a short (19-22 nucleotides) double stranded RNA with 2-nucleotides 3′ 
overhangs on each strand. After cellular entry, the siRNA duplex is assembled into 
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large protein assemblies, called the RNA-induced silencing complexes (RISC), where 
the sense strand of siRNA is removed by a helicase associated with the RISC. The 
RISC with the antisense strand specifically cleaves target mRNA which has a 
complementary sequence to the antisense strand78. Both AON and siRNA lead at the 
end to the target gene downregulation (Figure 2). To date, one AON has been 
approved for local administration to treat cytomegalovirus (fomivirsen). However, 
other AON and siRNA are currently in various stages of clinical development (Table 
2)73,79,80.  
 
 
Figure 2. Mechanism of action of AON and siRNA. AON pair with their 
complementary target RNA and block mRNA translation or induce its degradation. 
siRNA duplexes are assembled into the RISC where the sense strand is cleaved and 
unwound, leaving single-stranded RNA associated with the RISC. These complexes 
hybridize and cleave complementary target mRNA. Both actions result in target 
protein downregulation. 
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Table 2. Some AON and siRNA currently in clinical trials for the treatment of 
cancer73,79,80.  
 
AON or siRNA Molecular target Status Sponsor 
Oblimersen AON 
(Genasense, G3139) 
Bcl-2 Phase II/III Aventis/Genta 
LY900003 AON 
(Affinitak, ISIS 3521) 
Protein kinase C-α Phase II/III Lilly/Isis 
ISIS 2503 AON Ha-ras Phase II ISIS Pharmaceuticals 
Oncomyc-NG AON c-myc Phase I/II AVI BioPharma 
CALAA-01 siRNA RPM2 Phase I Calando Pharmaceuticals 
ALN-VSP siRNA KSP and VEGF Phase I Alnylam Pharmaceuticals 
 
However, the clinical use of nucleic acid-based drugs is still largely hampered 
by their inability to reach their site of action in sufficient amounts. Parameters, such 
as circulation time in the blood stream81,82, deposition at the target site and 
intracellular transport83, play a detrimental role in their in vivo activity. Unmodified 
nucleic acids have very limited cellular uptake due to their polyanionic nature and 
high molecular weight. In addition, naked AON or siRNA usually have a short half-
life in serum (usually a few minutes) due to enzymatic degradation, and are rapidly 
cleared from the body. Numerous efforts have been made to develop efficient vectors 
for nucleic acid delivery and various methods have been proposed to accomplish 
their transfer into eukaryotic cells. 
2.1 Chemical modifications 
Unmodified oligonucleotides (ONs) are seldom tested in animal models as 
they rapidly degrade in biological fluids and cells84-87. The chemical instability issue 
has been partially solved through specific modifications of the ON backbone.  
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Among all ON derivatives, phosphorothioate (PS) analogs have been widely 
studied (Figure 3)79,84. In PS modifications, one of the non-bridging oxygen atoms of 
the phosphodiester linkage is substituted by a sulfur atom. PS modifications confer 
moderate resistance against nuclease degradation and increase the half-life in human 
serum compared to the native ON. The major disadvantage of the PS modification is 
that the sulfur atom promotes non-specific binding to certain proteins, which can 
cause severe adverse reactions (especially at high doses)82,88. Another shortcoming is 
the reduced affinity towards the mRNA compared to the phosphodiester ON82,88.  
Regarding sugar modifications, 2'-O-methylation is one of the most widely- 
studied sugar modifications for both AON and siRNA (Figure 3) because it increases 
their nuclease stability79,84. However, many groups have found that large numbers of 
2'-O-methyl modifications do not induce the RNase H endonuclease activity and 
decrease siRNA potency89,90. Other modifications of ribose sugar include peptide 
nucleic acid (PNA) and locked nucleic acid (LNA) (Figure 3)73,79. PNA is a synthetic 
DNA in which the deoxyribose phosphate backbone is replaced by polyamide 
linkages. LNA is a conformationally restricted nucleotide containing a 2'-O, 4'-C-
methylene bridge in the β-D-ribofuranosyl configuration. Both PNA and LNA can 
bind to complementary DNA or RNA with high affinity and specificity. In addition, 
they have high stability against nuclease degradation. However, both PNA and LNA 
do not elicit target RNA cleavage by RNase H. Therefore, their applications might be 
limited as antisense agents and they can be exploited to modulate gene expression91.  
Alternatively, 2′-deoxy-2′-fluoro-β-D-arabinonucleic acid (2′F-ANA) sugar 
modifications of the ON have been found to maintain high intracellular 
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concentrations for prolonged periods of time leading to long-term gene silencing 
(Figure 3)92. This was explained by increased serum stability and higher binding 
affinity to the target mRNA. The 2′F-ANA modifications have been successfully 
applied to both AON and siRNA78. They are well-tolerated throughout both sense 
and antisense strands of siRNA92-94. Although the use of modified nucleic acids has 
partially overcome the problem of rapid degradation, most chemical modifications 
are partially ineffective in reducing their renal clearance or improving their 
intracellular and site-specific delivery. 
 
 
 
Figure 3. Chemical structure of PS DNA, 2′-O-methyl RNA, PNA, LNA and 2′F-
ANA 
 
 
Likewise, conjugates have been employed to enhance transfection efficiency 
and resistance to nucleases. Covalent conjugation to hydrophilic polymers (e.g. PEG) 
or lipophilic moieties (e.g. cholesterol) have been shown to improve the 
pharmacokinetics and enhance the efficacy of many nucleic acids95-97. For instance, 
conjugation to cholesterol has been reported to slow ON clearance95,98 and enhance 
cellular association and transport96. However, these conjugates are mainly taken up 
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by the liver by interacting with lipoprotein particles97, and their applications to target 
other tissues are limited.  
 
2.2 Viral vectors 
Viruses are composed of an envelope or capsid that contains genetic material 
(DNA or RNA) in a compact form. They possess sizes ranging from 20 to 100 nm99. 
A variety of these viruses have been converted to vectors to deliver genes to cells 
(e.g. adenoviruses, retroviruses and adeno-associated viruses). Some viruses and their 
characteristics are presented in Table 3. Although a detailed discussion of viral 
vectors in nucleic acid delivery is beyond the scope of this introduction, it is worth 
mentioning that they have been implicated in 70% of gene therapy clinical trials99. 
Indeed, viral vectors offer superior transfection efficiency than their synthetic 
counterparts, can infect most kinds of cells and are among the first carriers adopted 
for the delivery of different nucleic acid materials. Nevertheless, their use is limited 
because of inherent safety concerns. The use of viral vectors for gene therapy can be 
associated with severe inflammation and immunological problems100,101. The toxicity 
of viral vectors is usually due to random integration of the transported genes99,102. In 
addition, the size of the DNA and the type of the genetic material that can be 
encapsulated into viral vectors restrict their applicability. Hence, there is a need for 
alternative synthetic approaches for the delivery of nucleic acids. 
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Table 3. Characteristics of viral vectors. Adapted from reference99. 
 
Features Adenovirus Adeno-associated 
virus 
Retrovirus 
Particle size 70-100 20-25 100 
Insert size (kb) 8-10 4.9 8 
Chromosomal  integration No No Yes 
Long-term expression Weeks to months >1 year Long-term 
Emergence of replication-
competent vector in vivo? 
Possible 
 
Possible 
 
Risk 
 
 
2.3 Non-viral vectors 
2.3.1 Non-complexing polymers 
Amphiphilic copolymers such as, poloxamers, have been exploited as non-
viral gene vectors to deliver different genetic materials103. Poloxamers consist of 
linear triblock copolymers with an A-B-A structure ((ethylene oxide)x-(propylene 
oxide)x-(ethylene oxide)x). For instance, poloxamer 407 has been used to deliver 
AON by intravenous injection into mdx mice for the treatment of Duchene muscular 
dystrophy (DMD). DMD is a degenerative muscle disease caused by the low 
expression of dystrophin protein in skeletal muscles evoked by a mutation in the 
dystrophin gene. Repeated injections of this formulation enhanced dystrophin 
induction in skeletal muscles by restoring the dystrophin gene104.  
Polymeric nanocapsules have also been deployed for the delivery of nucleic 
acids105. This method was developed by Lambert et al.106 who prepared 
poly(isobutylcyanoacrylate) nanocapsules containing an aqueous core. The 
incorporation of AON into the aqueous core of nanocapsules improved their stability 
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against enzymatic degradation and increased their serum half-lives as compared to 
naked AON. Alternatively, the incorporation of AON and siRNA into the aqueous 
core of non-ionic polymersomes was achieved recently by Discher and coworkers107. 
The exact mechanism of interactions between these non-charged (i.e. non-
complexing) polymers and nucleic acids is still unclear and needs further 
investigation. Indeed, the delivery of nucleic acids by complexing them with cationic 
lipids and polymers has stirred more interest and has produced promising results. 
2.3.2 Lipoplexes and polyplexes  
A common approach to enhance the stability of nucleic acids and improve 
their transfection efficiency consists in complexing them with positively-charged 
lipids and polymers to form lipoplexes and polyplexes, respectively. Both cationic 
lipids and polymers (e.g. polyethylenimine108,109 (PEI) and poly(amidoamine)110,111 
(PAMAM)) have been studied as non-viral gene carriers because of their ability to 
protect DNA/RNA from enzymatic degradation and to increase cellular uptake by 
adsorptive endocytosis. Usually, excess positive charges are required for high 
transfection efficiency. Although, lipoplexes and polyplexes are considered to be the 
most promising candidates for non-viral gene delivery systems, they are rapidly 
inactivated in the presence of serum. This inactivation is probably elicited by 
interactions with negatively-charged serum proteins which shield the positive charges 
on the surface of lipoplexes and polyplexes112. Moreover, after intravenous injection, 
the large size and positive character of these complexes result in rapid opsonization, 
clearance from the circulation and the risk of occlusion of lung capillaries. In many 
situations, intravenous injection of those complexes led to damage of body tissues 
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and a high rate of mortality in laboratory animals113-115. On the other hand, when 
these complexes are prepared at stoichiometric (+/-) molar ratios, they tend to 
aggregate. In addition, these neutralized complexes usually have poor cellular uptake 
and limited stability.  
2.3.3 PEGylated lipoplexes and PICM 
The limited stability and rapid elimination of lipoplexes and polyplexes can 
be partially solved by the use of hydrophilic polymers, such as PEG, to from a shell 
surrounding the neutralized particles. The PEGylated polyplexes are often referred to 
as polyion complex micelles (PICM), which form through the complexation of 
oppositely-charged polyions, followed by the self-association of the neutralized 
condensates into micelles (Chapter 2, Figure 1). This self-assembly requires at least 
one of the polymers to have a hydrophilic uncharged segment. The PEGylation of 
lipoplexes and polyplexes reduces the toxicity and increases their circulation time in 
the body, allowing passive targeting of tumors via the EPR effect. Loading of nucleic 
acids into these carriers also helps protecting them from enzymatic degradation. For 
example, when PEG-b-poly(L-lysine)/pDNA PICM were intravenously injected to 
mice, an intact pDNA was observed in the blood circulation even at 3-h post injection 
whereas the naked pDNA was degraded within 5 min116. On the other hand, stable 
nucleic-acid-lipid particles (SNALP) have been successfully exploited for the 
delivery of siRNA117,118. These SNALP consist of PEGylated lipoplexes that contain 
a mixture of cationic and fusogenic lipids. Many of these systems have been 
employed for the delivery of pDNA, AON and siRNA and could enhance their 
stability 32, 34, 119-121. Some of them were successfully adopted for the in vivo delivery 
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of nucleic acids to their target sites and were able to partially knockdown the targeted 
proteins. Despite promising data obtained, there are still hurdles to be overcome 
before such systems can be considered for a clinical application. Among them, it is 
imperative to develop a system sufficiently stable to withstand long-term storage and 
sufficient circulation in the bloodstream while at the same time rapidly releasing the 
polynucleotide in the appropriate cellular compartment after uptake. 
2.3.4 Targeted complexes  
The PEGylation of complexes sterically hinders the cellular uptake of the 
lipoplexes and polyplexes. One way of circumventing this problem consists in 
attaching targeting ligands at their surface which will bind to specific cellular 
receptors and promote uptake of the micelles by receptor-mediated endocytosis 
(Chapter 2, Figure 2). For efficient targeting, the receptors must be over-expressed by 
target cells (e.g. tumor cells) compared to normal tissues122. The ligands can be 
attached either before or after assembly of the carrier. A variety of molecules 
including monoclonal antibodies123,124, peptides125,126, aptamers23,127 and sugar 
moieties128 have been employed to achieve cell targeting. Usually, the ligand should 
be available on the surface of the carrier for efficient binding to the receptors. In one 
study, PEGylated PEI/pDNA/transferrin was shown to have a long circulation in 
vivo113. However, the transferrin was not attached at the PEG surface but rather 
conjugated with the PEI in the core. Therefore, selective uptake of these formulations 
by specific target cells was not demonstrated. In contrast, Oishi et al.46 attached 
lactose on the surface of PEGylated polyplexes. These formulations allowed the 
specific uptake of their cargo (pDNA) by hepatocytes through the asialoglycoprotein 
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receptor-mediated endocytosis. Selecting monoclonal antibodies as targeting moieties 
has the advantage of selectivity, high affinity, and minimal competition for the 
receptor, contrary to what is observed with endogenous molecules such as folic acid 
or transferrin129-131. Whole or fragmented antibodies (e.g. fragment antigen binding 
(Fab')) have been used to functionalize micelles. In general, targeted micelles showed 
higher cellular uptake than non-targeted micelles124,132. The whole antibody, 
however, presents a large size, potentially putting strain on micelle self-assembly. 
Moreover, it can favor the systemic clearance of the carrier via Fc region recognition 
by the MPS. 
2.3.5 pH-sensitive PICM 
Despite the afore-mentioned endeavors to prepare targeted, long-circulating 
and stable nanocarriers, improvement of intracellular delivery remains an important 
issue to be addressed. Targeted micellar carriers are taken up by cells via 
endocytosis. During this process, the delivery system is first internalized into 
endosomes and then processed to lysosomes, where degradation occurs. Different 
groups have investigated the use of pH-sensitive PICM to destabilize 
endosomes/lysosomes and enhance the intracellular bioavailability of nucleic acids. 
A detailed discussion of the subject is provided in Chapter 2 (Section 8).  
Now, it can be seen how controlled drug delivery systems can offer benefits 
by improving the biodistribution of anticancer drugs and nucleic acids in terms of 
protection from hydrolytic or enzymatic degradation, prolonged circulation in the 
bloodstream and tumor-specific accumulation.  
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The strategies exploited in this thesis rely on the rational development of 
delivery vectors based on PM and PICM, which are aimed at increasing the solubility 
and chemical stability of docetaxel and enhancing the intracellular bioavailability of 
nucleic acids. Chapter 2 provides a detailed overview of the critical features of both 
PM and PICM as delivery systems for different anticancer and nucleotide-based 
drugs.   
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Abstract 
Polymeric micelles (PM) are a promising nanomedicine platform for drug and 
nucleic acid delivery. In aqueous solution, PM are formed via the self-assembly of 
amphiphilic copolymers into nanoscopic core/shell architectures presenting a 
hydrophobic core surrounded by a hydrophilic corona. Polyion complex micelles 
(PICM) are a subclass of PM and are obtained from electrostatic interactions between 
oppositely-charged copolymer and drug followed by self-assembly of the charge-
neutralized blocks.  Both PM and PICM typically have fairly narrow size 
distributions, with diameters ranging from 10 to 100 nm, and demonstrate a series of 
attractive properties that warrant them interest as drug delivery carriers. The core of 
both PM and PICM can serve as a reservoir for drugs, which may be loaded by 
chemical, physical, or electrostatic means depending on the chemistry of the drug and 
of the core-forming block. Solubilization, protection and delivery of either 
hydrophobic or charged macromolecules (i.e. antisense-oligonucleotides and short 
interfering RNA) can then be achieved with the nanocarriers. Furthermore, the 
composition of the micelles can be tailored to reduce the drug toxicity and enhance 
the specificity of the drug-loaded micelles. Finally, the properties of the micelles can 
be adjusted to comply with both intravenous and oral drug delivery requirements. 
This chapter provides an overview of the critical features of both PM and PICM as 
delivery systems and discusses the recent advances in their preparation, 
characterization and pharmaceutical evaluation.  
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1. Introduction 
 
Polymeric micelles (PM) are formed via the self-assembly of amphiphilic 
copolymer chains in aqueous milieu. They present a core/shell architecture wherein 
the hydrophobic core serves as a microenvironment for the incorporation of drugs 
while the hydrophilic corona acts as a stabilizing interface between the core and the 
external medium. In water, hydrophobic interactions are generally the main driving 
force behind the micellization process (Figure 1, A and B). However, the self-
association of polymeric chains can involve additional forces. For example, 
electrostatic interactions were shown to induce the complexation and neutralization 
of oppositely-charged polymers, thereby allowing the formation of polyion complex 
micelles (PICM) (Figure 1, C-E). In addition, substitution of ligands on a metal drug 
by charged groups of the copolymer through coordination bonds can trigger micelle 
formation (Figure 1F). The latter are termed polymer-metal complex micelles. Most 
of these self-assemblies have fairly narrow size distributions with diameters ranging 
from 10 to 100 nm. 
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Figure 1. Conventional PM (A); drug-conjugated PM (B); and PICM with the 
polyionic block consisting of cationic polymer (C) or polynucleic acid (antisense 
oligonucleotide (AON) or short interfering RNA (siRNA)) (D and E). In D and E, the 
core forming agent is either linear or branched cationic polymer, respectively. 
Polymer-metal complex micelles formed via the ligand substitution reaction where M 
and Y are the metal and the ligand, respectively (F). 
 
Many important therapeutic compounds present a low aqueous solubility and 
poor accumulation at their target site which lower their efficacy and can promote 
systemic adverse effects. Alternatively, macromolecular drugs such as peptides, 
DNA and RNA suffer from premature degradation upon administration, low 
bioavailability and inefficient cellular entry, compromising their therapeutic 
outcome. The versatile attributes of PM and PICM make these systems an attractive 
nanomedicine platform for the delivery of various therapeutic agents via both 
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parenteral (i.e. intravenous) and oral routes. Indeed, micelles provide a reservoir for 
either solubilizing water-insoluble drugs or accommodating charged compounds. 
Sequestration of the drug inside the micellar core may protect it from premature 
degradation by the surrounding environment. When intravenous applications are 
sought, the nonionic hydrophilic corona can prevent the adsorption of opsonins, 
thereby limiting the rapid uptake by the mononuclear phagocyte system (MPS) and 
prolonging the circulation half-life of the encapsulated drug [1]. Amphiphilic 
copolymers can be also designed to express low toxicity, biocompatibility and/or 
biodegradability making them attractive alternatives to low molecular weight 
surfactants, such as Cremophor® EL, which have been associated with serious side-
effects [2]. Finally, PM can be used to target the drug either passively or actively [3]. 
In passive targeting, the drug-loaded micelles can permeate in pathological sites with 
leaky vasculature (such as tumors) and accumulate due to impaired lymphatic 
drainage at these areas (this phenomenon is best known as the enhanced permeation 
and retention (EPR) effect; Figure 2A) [1]. On the other hand, active targeting is 
achieved through the attachment of targeting ligands to the micelle surface so as to 
favor its recognition by a specific cell receptor (Figure 2B) [4]. Alternatively, 
stimuli-responsive polymers can be used to induce a response to external stimuli such 
as pH or temperature variations [5-9].  
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Figure 2. Passive (A) and active (B) targeting. In passive targeting, the non-
functionalized micelles extravasate in tissues presenting leaky vasculatures (e.g. 
tumors) and accumulate through the EPR effect. In active targeting, the micelles bind 
to specific receptors expressed on the surface of the target cells, after which they are 
internalized. The entrapped drug should be able to escape from the endosomes in 
order to reach to the cytoplasm and/or nucleus (the solid lines). 
 
Normal 
tissues 
Tumor
tissues 
Continuous capillary Tumor leaky 
vasculature 
MPS uptake 
(A) Passive targeting 
(B) Active targeting 
Cytoplasm 
Nucleus 
Lysosomes 
Endosomes 
----- +++++
X 
 72
As will be highlighted later in this chapter, all these attributes allow the use of 
micelles as nanocarriers to deliver various drugs including anti-tumor agents and 
small nucleic acid-based drugs (antisense oligonucleotides (AON) and short 
interfering RNA (siRNA)). While similar systems have been used to deliver plasmid 
DNA (pDNA) [10-12], this chapter will focus mainly on the delivery of small nucleic 
acid fragments for which the molecular weight (MW) of both the drug and cationic 
polymer are of the same size range. This chapter provides a comprehensive analysis 
of the critical features of PM as drug carriers, including control over size, 
morphology, stability, drug-loading and release of the incorporated drugs. 
Furthermore, advanced features, such as site-specific delivery to reduce the toxicity 
and enhance the specificity of the drug-loaded micelles, are presented.    
 
2. Micellization 
The micellization process can simplistically be described as a fine tuned 
equilibrium between attractive and repulsive forces. In an aqueous milieu, the 
attractive forces are associated to the core-forming block of the copolymers and can 
be either purely hydrophobic or involve other mechanisms such as electrostatic 
interactions or polymer-metal coordination interactions. Regardless of the nature of 
the attraction, the segregation or coalescence of polymeric chains is entropically 
driven, with the loss in entropy originating from the ordering of the polymer chains 
being counter-balanced by the solvent contribution to the entropy. Indeed, it is argued 
that solvent molecules organize themselves to form a clathrate cage around the 
hydrophobic segment of the free copolymer chains, prior to micellization, and that 
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this organized structure decreases the entropy of water [13]. To offset this high free 
energy, the hydrophobic segments tend to withdraw from the aqueous phase and herd 
into small clusters or micelles. Segregation of the non-polar moieties decreases their 
contacts with water molecules, thereby increasing the entropy of the solvent. The 
formation of PICM, on the other hand, can be best described as the sequential 
complexation of the polyions followed by the self-association of the neutralized 
condensates into micelles. The driving force for the cooperative electrostatic 
interactions between polyions in aqueous solution comes from the entropy gain 
associated with the release of low molecular weight counter ions [14]. Condensation 
of the polyions yields neutral and water-insoluble moieties that self-assemble in the 
same fashion as copolymers featuring a hydrophobic block.  Polymer–metal complex 
micelles is yet another class of PM that has been used for the delivery of platinous 
anticancer drugs such as cisplatin [cis-dichlorodiamineplatinum (II)] and 1,2-
diaminocyclohexane platinum (II) [12]. In this case, micellization occurs via 
substitution of the metal ligand (i.e. chloride of platinum (II)) by the carboxylate 
groups of the copolymer, with the polymer establishing multiple coordination bonds 
with the drug (Figure 1F).  
The repulsive forces controlling the micellization process, on the other hand, 
are mostly brought about by the shell-forming blocks of the copolymers. The 
hydrophilic segments generally present large degrees of hydration and large 
exclusion volumes. They contribute to micelle formation by limiting the interactions 
between the core and external medium and stabilizing the hydrophobic/hydrophilic 
interface [15]. Hydrophilic segments are also known to limit or hinder micelle growth 
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by providing steric repulsions between the hydrated chains. These repulsive forces 
further hamper secondary aggregation and coagulation by overwhelming the 
attractive forces operating between micelles. Coronas obtained from nonionic chains 
are usually preferred over those obtained from charged polymers in order to diminish 
the non-specific adsorption of opsonins in vivo and limit the toxicity of the PM. 
It can now be seen how factors such as the nature of the hydrophobic block 
(being more or less hydrophobic) or hydrophilic segment (neutral vs. charged) and 
their respective length may alter the attraction/repulsion balance and dictate the size, 
morphology and stability of the resulting micelles. Understanding the underlying 
dynamics of micellization clearly provides insight for the design of micelles with 
tailored properties. 
 
3. Composition of the micellar carriers 
Several polymers have been characterized for their ability to form PM and 
PICM and are presented in Table 1. The hydrophilic segment can consist of 
polysaccharides, such as chitosan [16] and pullulan [17], or synthetic polymers, such 
as poly(ethylene glycol) (PEG) [18], poly(N-vinylpyrrolidone) (PVP) [19, 20], 
poly(N-isopropylacrylamide) (PNIPAM) [21], poly(2-ethyl-2-oxazoline) [22] and 
poly(acrylic acid) [23]. Of all hydrophilic polymers, PEG (with a molecular weight 
of 1-20 kD) is undoubtedly the most widely used shell forming component of both 
PM and PICM. The neutrality, hydrophilicity and flexibility of PEG diminish the 
possibility of undesirable electrostatic interactions with plasma proteins [24]. 
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Furthermore, the presence of reactive groups at both chain ends can be exploited for 
further micelle derivatization, such as attachment of ligands for active targeting. 
 
 
Table 1. Selection of polymers most often used for the preparation of micelles in 
drug delivery 
 
Core-component Shell-component Ref Hydrophobic Ref Polyion Ref 
Chitosan 
Pullulan 
Poly(2-ethyl-2-oxazoline) 
Poly(acrylic acid) 
Poly(ethylene glycol) 
Poly(N-(2-
hydroxypopyl)methacrylamide) 
Poly(N-isopropylacrylamide) 
Poly(N-vinyl-2-pyrrolidone) 
[16] 
[17] 
[22] 
[23] 
[18] 
[26] 
 
[21] 
[19, 
20] 
 
 
Poly(D,L-lactide) 
Poly(D,L-lactide-
co-glycolide) 
Poly(ε-
caprolactone) 
Poly(alkyl 
methacrylate) 
Poly(alkyl 
(meth)acrylate-co-
methacrylic acid) 
Poly(propylene 
oxide) 
Poly(butylene 
oxide) 
Poly(styrene oxide) 
Poly(β-benzyl-L-
aspartate) 
Poly(γ-benzyl-L-
glutamate) 
Poly(N-hexyl 
stearate L-
aspartamide) 
Poly(propylene 
sulfide) 
Phospholipid 
residues 
Attached 
hydrophobic drugs 
(e.g. covalently 
linked doxorubicin) 
[19] 
[109]
 
[25, 
26] 
[30] 
 
[182, 
183] 
 
[29] 
 
[48] 
 
[48] 
[61] 
 
[27] 
 
[28] 
 
 
[200]
 
[31, 
32] 
[106]
Poly((alkyl)aminoethyl 
methacrylate) 
Poly(ethyleneimine) 
Poly(amidoamine) 
Poly(L-aspartic acid) 
Poly(L-lysine) 
Oligonucleotide1 
siRNA1 
[39, 
64] 
[35] 
[66] 
[41] 
[34] 
[44] 
[45] 
 
1The oligonucleotide or siRNA is attached to the non-ionic polymer via a covalent 
link. 
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It is seen from Table 1 that while a relatively limited selection of hydrophilic 
segments is available, a host of hydrophobic polymers can be used as core-forming 
segments.  These include biodegradable polymers such as poly(D,L-lactide) 
(PDLLA) [19], poly(ε-caprolactone) (PCL) [25, 26], poly(γ-benzyl-L-glutamate) 
(PBLG) [27], and poly(N-hexyl stearate L-aspartamide) [28], and non-biodegradable 
hydrophobic polymers like poly(propylene oxide) (PPO) [29] and poly(vinyl) 
derivatives [30]. The hydrophobic segment can be inert or can possess reactive 
groups for post-functionalization. A special group of micelles can finally be obtained 
from lipid conjugates such as PEG-phosphatidyl ethanolamine (PEG-PE) [31-33].  
The core-forming blocks of PICM include polycations such as poly(L-lysine) 
(PLL) [34], poly(ethylenimine) (PEI) [35-37], derivatives of amine methacrylate [38, 
39] and polyanions such as poly(aspartic acid). These are typically covalently 
attached to the hydrophilic polymer and interact with charged macromolecules such 
as AON, siRNA, porphyrins, and enzymes [40, 41] to form PICM, as illustrated in 
Figure 1C. Alternatively, the drug can be conjugated to the hydrophilic polymer and 
then serve as the core segment. Examples include conjugates of PEG-b-AON [42-44] 
and PEG-b-siRNA [45]. In this case, interactions with either linear or branched 
cationic polymers such PEI, poly(amidoamine) (PAMAM) or poly(amino acids) 
promotes the formation of PICM (Figure 1, D and E).  
Of the spectrum of polymers that can in theory form micelles, the 
requirements of biocompatibility and/or biodegradability have greatly limited the 
choice of copolymers used in clinical applications. In the case of non-biodegradable 
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polymers, careful attention should be taken to maintain their molecular weight below 
the renal excretion threshold in order to ensure their systemic elimination. 
 
4. Micelle stability 
4.1 Significance 
The physical stability of a micellar drug delivery system is essential to benefit 
from its favorable pharmacokinetic parameters [46, 47]. Premature disassembly of 
the micelles after entry into the bloodstream can, for instance, compromise the 
circulation times and delivery of the encapsulated drug to its target site. Poor stability 
can also bring about early drug release (burst release) and toxicity problems. For 
labile drugs such as nucleic acids, stability of the micelles is further crucial to 
maintain the therapeutic activity of the drug by protecting it from premature 
degradation. Clearly, the integrity of micelles is a crucial factor governing their 
effectiveness and success at delivering incorporated drugs.  
The stability of micelles can be described with respect to two different 
properties, namely thermodynamic stability and kinetic stability. Because PICM are 
obtained through electrostatic interactions, their stability can be further evaluated by 
their ability to withstand dissociation in presence of salts and other polyions (such as 
proteins present in vivo) and to protect their cargo against enzymatic degradation. 
These aspects will be discussed in the following sections.  
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4.2 Thermodynamic stability 
A micelle is thermodynamically stable with respect to its micelle-to-unimer 
equilibrium. At low concentrations in aqueous medium, amphiphilic molecules exist 
as discrete chains (unimers). However, as their concentration is increased above a 
critical concentration, aggregation becomes energetically favorable and the 
amphiphilic molecules self-assemble into micelles. The concentration at which 
micelles start to appear is called the critical micelle concentration (CMC). Following 
that definition, it appears that a lower CMC value is indicative of a greater stability 
upon dilution. Generally speaking, the more hydrophobic or the longer the water-
insoluble block, the greater the entropy gain ensuing from micellization and the lower 
the CMC. For instance, the CMC of PEG-b-poly(styrene oxide) (PEG-b-PSO) was 
shown to be 2-fold lower than that of PEG-b-poly(butylene oxide) (PEG-b-PBO), in 
accordance with the greater hydrophobicity conferred by the aromatic ring of the SO 
unit [48]. Alternatively, increasing the length of the SO or BO block further 
decreased the CMC values [48]. In contrast, increasing the length of the hydrophilic 
block results in an increase of the CMC when the length of the hydrophobic block is 
held constant [15]. A rapid calculation suggests that CMC values around 10 mg/L, 
which are typically found for amphiphilic polymers [48], should prevent the rapid 
dissociation of the micelles following intravenous administration to humans. This is 
assuming that a drug-loaded PM formulation is administered to a 70 kg human at a 
dose of 10 mg/kg. In this particular case, a polymer concentration of 1.3 g/L would 
be obtained upon injection (considering that the blood takes up a volume of 5 L), 
which is about 130 times higher than the CMC.  
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In principle, any technique detecting discontinuities in the physical properties 
of a solution (such as molar conductivity, surface tension or osmotic pressure) can be 
used to evaluate the CMC. If this holds true for low molecular weight surfactants 
(which usually exhibit CMCs in the g/L range), it can rarely apply to copolymer 
solutions as they present CMCs at concentrations generally too low for any of these 
changes to be detected experimentally. A preferred method to determine the CMC of 
polymers is to use hydrophobic fluorescent probes for which the spectral properties 
are sensitive to the polarity of the surroundings. Pyrene, a condensed aromatic 
hydrocarbon, is probably the most widely used fluorescent marker for this 
application. Below the CMC, pyrene is solubilized in water, a medium of high 
polarity. When micelles are formed, pyrene partitions preferentially within the 
hydrophobic domain afforded by the micellar core and experiences a less polar 
environment. Consequently, numerous changes such as an increase in the 
fluorescence intensity, a change in the vibrational fine structure of the emission 
spectrum, and a red shift of the (0,0) band in the excitation spectrum of pyrene can be 
observed. The apparent CMC is then obtained from plots of either the I1/I3 (the ratios 
of the fluorescence intensity of the first and third peaks in the pyrene emission 
spectra) or the I335-339 /I333 (the exact wavelength depends on the polymer) ratio from 
the excitation spectra versus concentration (Figure 3). An abrupt change in the slope 
as the concentration increases indicates the onset of micellization. The CMC 
determined by fluorescence techniques needs to be carefully interpreted for two 
reasons. First, the concentration of pyrene should be kept extremely low (~ 10-7 M) 
so that a change in slope can be precisely detected as micellization occurs. Second, a 
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gradual change in the fluorescence spectrum can sometimes be attributed to the 
presence of hydrophobic impurities or association of the probe with individual 
polymeric chains or premicellar aggregates [1], thereby underestimating the CMC.  
 
 
 
 
Figure 3. Plot of the intensity ratio I336/I333 or I339/I333 (from pyrene excitation 
spectra) as a function of PEG45-b-PBO15 (▲) and PEG45-b-PSO15K (●) concentration. 
Each value is the mean of three independent measurements. Values of the CMC are 
indicated by arrows. Inset: Excitation spectra of pyrene (2 × 10–7 M aqueous 
solution) monitored at λem 390 nm below (▲) and above (●) the PEG45-b-PSO15 
copolymer’s CMC. 
 
Other techniques have also been employed to measure the CMC of PM and 
include light scattering, isothermal titration calorimetry (ITC) and gel permeation 
chromatography (GPC) [49, 50]. The light scattering technique relies on the fact that 
the molecular weight of the colloids undergoes a sharp increase as the unimers 
associate into micellar aggregates. This increase in molecular weight translates into a 
significant increase of the scattered light. The onset of micellization, however, can 
 81
only be detected if the CMC falls within the detection limit of the instrument. The 
ITC experiment, on the other hand, is carried out by injecting small aliquots of a 
concentrated micellar solution into water and directly measuring the enthalpy 
changes occurring after each addition at constant temperature. Each injection below 
the CMC produces an exothermic peak which is the sum of several contributions: the 
heat of dilution of the micelles, the enthalpy of demicellization, and the heat of 
dilution of individual polymer molecules [51]. When the polymer concentration in 
the cell of the instrument exceeds the CMC, the heat evolved levels off, signaling that 
the injected micelles remain associated rather than disintegrating into unimers. The 
CMC is obtained from the plot of the enthalpy change following each injection as a 
function of polymer concentration where the break point in the slope corresponds to 
the onset of polymer association. The advantage of using the ITC is that, in addition 
to the CMC determination, other thermodynamic parameters can be measured such as 
the enthalpy and entropy of micellization [52]. GPC under aqueous conditions can 
finally be employed to evaluate CMC and rests on the fact that unimers and micelles 
exhibit different elution volumes. The method is particularly appealing in that it can 
simultaneously permit the determination of the micellar MW and aggregation number 
(Nagg). However, for this technique to be valid, it is important that the integrity of the 
PM be maintained during their elution through the size exclusion column. Adsorption 
of the polymer on the column may also present a problem, especially at 
concentrations close to the CMC where micelles consist of large loose aggregates. 
The same methods used to determine the CMC of amphiphilic PM can in 
theory serve to evaluate the CMC of PICM. For instance, reports can be found where 
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fluorescence (pyrene) [53] and light scattering techniques [34] are being used. The 
CMC values for PICM are comparable to those of PM which indicates that, despite a 
partly different self-association mechanism, the PICM are also susceptible to 
dissociation upon dilution. 
4.3 Kinetic stability 
Another crucial factor characterizing PM is their kinetic stability. The kinetic 
stability of micelles refers to the actual rate of micelle dissociation below the CMC. 
Thus, even below the CMC, PM may still be kinetically stable, provided that the 
dissociation into unimers proceeds slowly. Systems for which dissociation takes 
place over hours or even days have been reported, as opposed to low molecular 
weight surfactants that dissociate within milliseconds below their CMC [54, 55]. 
Several properties of the copolymer can be modified to improve the kinetic stability. 
These include the hydrophobic/hydrophilic balance, the physical state of the micelle 
core, the size of the hydrophobic block, and the incorporation of hydrophobic 
compounds (Figure 4) [56]. For instance, Creutz et al. [57] showed that the rate of 
disassembly could be slowed down by increasing the hydrophobic/hydrophilic 
balance of the core-forming block. Increases in the hydrophobicity of the copolymers 
led to reduced rates of unimer exchanges, which is indicative of increased stability. 
Alternatively, increased kinetic stability can be met by using hydrophobic segments 
that will yield micelles with crystalline or highly viscous cores below their glass 
transition temperature. In this light, monodisperse stereocomplex PMs were prepared 
through the self-assembly of equimolar mixtures of PEG-b-poly(L-lactide) (PLLA) 
and PEG-b-poly(D-lactide) (PDLA) in water [58]. When present in an equimolar 
 83
ratio, PDLA and PLLA form a crystalline triclinic unit cell in which the chains 
exhibit a 31 helical conformation and display a melting point 50°C above that 
reported for the enantiomeric component. The micelles presenting such 
stereocomplexes exhibited enhanced kinetic stability and were less prone to 
secondary aggregation than either PEG-b-PLLA or PEG-b-PDLA micelles. The gain 
in stability ensues from limited and hindered mobility of the hydrophobic chains [18]. 
The viscosity of the micellar core, which serves as an indicator of kinetic stability, 
can be evaluated using fluorescent probes, such as 1,2-(1,1'-dipyrenyl)propane, for 
which the intensity ratio of excimer to monomer can be related to the fluidity of the 
environment [48, 59] and by 1H nuclear magnetic resonance [60]. Finally, Kataoka 
and colleagues [61, 62] reported instances where micellar stability increased 
following incorporation of a hydrophobic drug (doxorubicin (DOX)) in the core of 
PM. It was proposed that the occurrence of π-π stacking between the hydrophobic 
drug and the side groups of the core-forming segments as well as increased 
hydrophobic interactions both contributed to this gain in kinetic stability. 
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Figure 4. Interactions in the micellar core that enhance the kinetic stability of PM. 
Reproduced from Carstens, M. et al. [56] Copyright 2008, with permission from 
Springer Science. 
 
4.4 Stability of PICM towards dissociation 
The stability of PICM towards dissociation can be assessed by displacement 
assays in which the micelles are incubated with macromolecular polyions of identical 
charge to the loaded drug. Polyanions (such as heparin, which is typically found in 
the blood, or synthetic polymers such as poly(methacrylic acid)) have been used to 
displace negatively-charged drugs (e.g. nucleic acids). In such situations, both the 
drug and the added polyanion can interact with the cationic polymer so that a 
competition for the cationic sites is set. At high enough concentrations, the polyanion 
will eventually occupy all cationic sites, thereby expelling the complexed compounds 
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out of the micellar system. The release of the nucleic acids is typically monitored by 
gel electrophoresis or fluorescence techniques (in which case ethidium bromide is 
often used). Similar to amphiphilic micelles, the balance between the charged and the 
hydrophilic (nonionic) segments affects the stability of the micelles. Generally 
speaking, the longer the charged components (either the genetic material or the 
cationic moiety) are, the greater the cooperativity of the electrostatic interactions and 
the less favorable the exchange reactions [63]. In contrast, at constant ionic block 
length, the longer the hydrophilic nonionic segment, the less stable the micelles. This 
was demonstrated by Dufresne et al. [64] who prepared PICM of an AON and 
copolymers of the type PEG-b-poly(aminoethyl methacrylate) of increasing PEG 
length. Other factors can influence the electrostatic binding with the cationic 
polymers. These include the nitrogen-to-phosphate (N/P) ratio, hydrophobicity, pH 
and the ionic strength of the medium [53, 65, 66]. 
4.5 Protection of the drugs towards enzymatic degradation 
 Incorporation of peptides, nucleic acids or other macromolecules in the core 
of PICM prevents the action of the enzyme by limiting the access of the enzyme to 
the drug either through the steric hindrance afforded by the corona segments or the 
protection ensuing from complexation with the cationic segments [34]. Usually, a 
correlation between PICM stability against dissociation and the ability of the micelles 
to protect their cargo against enzymatic degradation can be established. It comes out 
that factors such as the balance between the ionic and nonionic hydrophilic segments, 
the N/P ratio or degree of ionization also affect protection of the drugs towards 
enzymatic degradation. For instance, Elsabahy et al. [66] have recently studied the 
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effect of different molecular weight PAMAM on the stability of PICM formed 
through the interaction with a PEGylated oligonucleotide duplex. It was found that 
the stability of the entrapped oligonucleotide increased with an increase in the 
PAMAM molecular weight. This was attributed to the enhanced cooperative 
interaction afforded by the greater surface amine density of the highly branched 
PAMAM. It is also worth mentioning that an increase in the N/P ratio of the 
PAMAM/oligonucleotide duplex within the PICM resulted in enhanced stability 
against degradation by nucleases (Figure 5). 
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Figure 5. Dequenching of fluorescein-labeled sense oligonucleotide (SON) 
fluorescence following the incubation of PEG10K-SON/AON-PAMAM generation 3 
(Mw = 6,909) PICM at N/P ratios of 1:1 (■), 2:1 (▲), 3:1 (●), 4:1 (∆) and 5:1 (□) 
with DNase 1 (60 U/µg oligonucleotide, 37°C, pH 7.4). Mean ± SD (n=3). The λex 
and λem were measured at 490 and 520 nm, respectively. The SON release was 
indirectly assessed by measuring the dequenching of the SON fluorescence. The 
fluorescence intensity corresponding to 100% release was determined at the end of 
the experiment by adding an excess of heparin to destabilize the micelles followed by 
the addition of DNase 1 and letting the reaction run for another 24 h. 
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4.6 Towards greater micelle stability  
Despite these efforts in adjusting the properties of the block copolymers to 
yield carriers presenting increasing stability, PM remain equilibrium systems that are 
intrinsically susceptible to dilution. Strategies which rely on the chemical bonding or 
cross-linking of the different micelle components have thus been explored to 
proscribe dissociation (Figure 6). There generally are three approaches to the 
preparation of core cross-linked micelles: polymerization or cross-linking (i) of 
entrapped low molecular weight monomers, (ii) of reactive groups present at the core 
chain end or (iii) of reactive groups introduced on the side chain. Kim et al. [67] 
revealed that the stability of a micelles could be improved by incorporating and 
polymerizing low molecular weight monomers (namely ethylene glycol 
dimethacrylate) in the core. Interestingly, the drug loading in core-polymerized 
micelles was at the same level as that of the non-crosslinked micelles. Iijima et al. 
[68] have prepared copolymers of PEG-b-PDLLA presenting a methacryloyl 
polymerizable group at the lactide chain end. They showed that the polymerization of 
the methacryloyl groups in the core of pre-formed micelles conferred increased 
stability to the system towards the presence of sodium dodecyl sulfate or following 
dissolution in organic solvents. Kakizawa et al. [69], have synthesized PEG-b-PLL 
copolymers presenting side-chain thiol groups to complex AON. Oxidation of the 
thiol groups of pre-formed PICM yielded complexes with cross-linked cores. This 
method of micelles stabilization has been applied successfully and permitted the 
dissociation of the complexes into cells due to the cleavage of the disulfide bonds in 
the intracellular reducing medium.  
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Figure 6. Crosslinking of the micellar corona or core as means to interplay with the 
micellar stability and drug release. 
 
An alternative scheme to the chemical stabilization of the cores is to fix the 
shell blocks of the micelles. Particularly, the group of Wooley has gained expertise in 
preparing shell cross-linked PM [70]. A common strategy is to react carboxylic acid 
groups present along the shell segment with diamines to form amide bonds.  
However, if not optimized properly, shell cross-linking presents inherent limitations 
in that cross-linking restrains the mobility of the hydrophilic segments, which in turn 
reduces the entropy factor and impairs the stabilizing capabilities of the shell. 
Furthermore, shell cross-linking must be carried out at high dilution in order to avoid 
extensive intermicellar cross-linking. Armes and colleagues [71, 72] have 
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successfully addressed these issues by using ABC triblock copolymers rather than 
conventional AB diblocks. ABC triblock copolymers yield onion-like micelles for 
which the inner corona (B) can be selectively cross-linked. For instance, a 
bifunctional alkyl iodide was used to quaternize (and cross-link) the tertiary amine 
units of the center segment of PEG-b-poly(2-(N,N-dimethylamino)ethyl 
methacrylate) (DMAEMA)-b-poly(2-(N,N-diethylamino)ethyl methacrylate) 
triblocks [71]. The PEG outer corona provided the steric repulsion that ensured 
minimal interpenetration of the micelles just as minimal intermicellar cross-linking. 
One concern associated with such chemical stabilization of micelles is that it 
may impair the end elimination of the system, especially in the case of non-
biodegradable materials. Cross-linked or polymerized micelles are often large entities 
that can no longer be eliminated by glomerular filtration. Likewise, cross-linking may 
impair the biodegradability of some polymers. To overcome these potential 
problems, hydrolysable cross-links have recently been used [73].  
Small assemblies that topologically mimic the micelle architecture but that 
present covalently bound amphiphilic chains have been synthesized as an alternative 
approach to provide intrinsic stability. These nanocarriers are referred to as 
unimolecular polymeric micelles (UPM) and consist of single macromolecules such 
that their formation and dissociation are intrinsically independent on polymer 
concentration (no apparent CMC). UPM can be obtained from both dendrimers [74] 
and star-block copolymers [26, 75], with the latter form involving fewer synthetic 
steps and being simpler to prepare.  
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5. Micelle dimensions and morphology  
5.1 Theoretical prediction of the micelle morphology 
The interaction forces between amphiphiles within aggregates and the strength 
of forces between aggregates, determine the equilibrium structure of the assemblies, 
and are affected by the relative block length, temperature, and solution conditions 
(i.e. ionic strength and pH of the solution). As micelles are entities formed by the 
non-covalent aggregation of individual amphiphilic polymers, they can self-assemble 
into different morphologies including spherical, small rod, worm-like and vesicular 
geometries [76-79]. Spherical micelles can grow one- or two-dimensionally into 
cylindrical or bilayer structures, respectively. This growth is controlled primarily by 
the nature of the corona segments since both one and two-dimensional growth require 
bringing the polymer heads in close proximity to each other in order to reduce the 
curvature of the micelle surface, and hence the available area per polymer molecule 
at the micelle surface [80]. Generally, the interior of the spherical micelle presents a 
radius of approximately the length of the fully extended hydrophobic chains. Based 
on the geometry of various monomers and the space occupied by the hydrophilic and 
hydrophobic groups of the amphiphilic polymer, it is possible to predict the 
morphology of a micelle. One of the most common methods used to this end is to 
calculate the packing parameter (P) according to Equation 1: 
°
=
acl
vP           (1) 
where ν corresponds to the volume of the hydrophobic group in the micellar core, lc 
is the length of the hydrophobic group and a◦ is the cross-sectional area occupied by 
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the hydrophilic group at the micelle-solution interface [80, 81]. The P values of 
spherical, cylindrical and lamellar micelles are usually 0-⅓, ⅓-½ and ½-1, 
respectively. These values can be explained by the fact that core volumes increase on 
going from spherical to cylindrical and lamellar micelles. Concomitantly, the surface 
area per monomer, averaged over the entire surface, decreases as the micelle size 
increases. Thus, it can be predicted that if the molecular shape of an amphiphile is in 
the form of a cone, wedge or cylinder, then spherical, rod-like, or vesicular 
morphologies will respectively be obtained (Table 2). This average molecular shape 
can be more simply expressed as the hydrophilic-to-total mass or volume ratio (f). 
Here, it can be seen that as the monomer shape goes from cone to wedge to cylinder, 
the fhydrophilic decreases and the fhydrophobic increases. A survey of the literature indicates 
that spherical micelles are observed when fhydrophilic > 0.5 while cylindrical and 
vesicular morphologies are observed when  fhydrophilic is 0.4-0.5 and 0.25-0.45, 
respectively (Table 2) [48, 76, 79, 82-88]. If the f ratio can be useful in predicting the 
morphology of various polymeric assemblies, it remains an empirical rule and 
deviations have been found upon changing the molecular weight and chemistry of the 
copolymer. 
 
5.2 Analysis of the micelle morphology 
A common method to examine the morphology of the formed micelles is to 
compute the ratio of the radius of gyration over the hydrodynamic radius (Rg/Rh). 
This ratio takes a value of 0.78 for a polymer chain in a hard sphere conformation 
while it reaches 1.30 or higher for polymers in a random coil and 1 or less for 
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vesicles (Table 2) [89, 90]. In the case of PM, values close to 0.78 are typically 
obtained, indicating that PM often form spherical aggregates in solution. Deviations 
from this predicted value can be encountered and are explained by a higher Rg 
measured when the polymeric chains of the micelles expand in water to adopt other 
conformations (i.e. cylinders and vesicles) [48, 91].  
 
Table 2. Different parameters that can be used to predict the micelle morphology 
 
 
 
 
 
Other methodologies only allow establishing whether micelles are spherical or 
not. For instance, the sphericity of PM can be confirmed by performing dynamic light 
scattering measurements at multiple angles. For spherical particles, the intensity of 
the scattered light is equal in all directions such that plots of the diameter as a 
function of the scattering vectors (K2) are linear [92]. Angular dependency is then 
indicative of non-spherical morphologies [48]. Alternatively, deviation from 
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spherical morphology can be confirmed by comparing experimental Nagg to 
theoretical values predicted for a sphere using equation 2.  
m
Nr AN 3
4 3
max
ρπ
=          (2) 
In Equation 2, r stands for the maximum possible radius for an anhydrous 
core of a spherical micelle (i.e. the extended chain length of the hydrophobic 
segment), ρ  is the density of the hydrophobic segment, NA is Avogadro's number 
and m is the molecular weight of the hydrophobic part. Since no void can exist in the 
center of the micelles, and as the hydrophobic chains in the liquid state are not 
usually fully extended, one dimension is always limited by the maximum possible 
extension of the hydrophobic chain. Therefore, the equation allows the calculation of 
the maximum possible aggregation number (Nmax) for spherical micelles. If Nagg 
exceeds the maximum theoretical number, an expanded morphology has to be 
assumed and deviation from sphericity is inferred. The main limitation of this 
approach is that a lower value of Nagg compared to Nmax cannot confirm a spherical 
morphology. In addition, predictions lose in precision for micelles of large diameter. 
Finally, the morphology of PM can be directly visualized by microscopic 
methods such as transmission electron microscopy (TEM) and atomic force 
microscopy. Protocols where the micelles are imaged in their hydrated state are to be 
preferred for better agreement with reality. 
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5.3 Transformation between different morphologies 
In addition to adjusting polymer composition, various morphologies are 
attainable by changing the solution conditions (i.e. water content, ionic strength and 
pH). This is illustrated by the work of Eisenberg and coworkers [86, 93] who have 
shown how the solution properties can control the architecture of aggregates from 
spherical micelles to other closely related structures such as rods, vesicles, tubules, 
and lamellae in a reversible fashion (depending on the polymer concentration and 
block length). For example, TEM images for a solution of 1% (w/w) poly(styrene)310-
b-poly(acrylic acid)52 in dioxane (Figure 7) revealed that the water content in the 
solution determined the shape and size of the formed aggregates. The spheres in 
solution at 9.1% (w/w) water, for example, morphed into short rods when the water 
content was increased to 11.5% (w/w) and into long rods and vesicles when the water 
content was further increased. An increase in water content makes the solvent of 
poorer quality for the hydrophobic block. In response to this, the system tends to 
minimize the total interfacial area by increasing the micellar size (i.e. by increasing 
the Nagg) while reducing the total number of aggregates. However, this increase in 
micellar radius is accompanied by a thermodynamically unfavorable increase in core-
chain stretching and in corona chain repulsion. When the thermodynamic penalty 
associated with these factors exceeds the gain met with reducing the interfacial area, 
the spherical micelles undergo a morphological transition into smaller-diameter rods 
so as to reduce the core-chain stretching, the intercorona repulsion and, ultimately, 
the total free energy of the system. With further increases in the water content, a 
similar tendency to reduce to the total free energy of the system drives the 
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transformation of rods into vesicles. For the same copolymer, different morphologies 
can be attained by varying the polymer concentration at a given water content. 
Another interesting concept for engineering uniform rod PM while controlling the 
rod length has recently been introduced through the use of molecular recognition. 
Spherical 22-mer-oligonucleotide-b-PPO115 micelles were hybridized with long 
single stranded-DNA template molecules that encode the complementary sequence of 
the micelle corona multiple times. Upon this molecular recognition event, the shape 
of the micelles changed from spheres to uniform rods as confirmed by scanning force 
microscopy and fluorescence correlation spectroscopy [94].  
 
 
 
Figure 7. The control of micelles morphology by changing the solvent conditions. 
Representative TEM pictures showing the reversibility of various morphological 
transitions for a solution of 1% (w/w) poly(styrene)310-b-poly(acrylic acid)52. 
Reprinted from Shen, H. et al. [93] Copyright 1999, with permission from American 
Chemical Society. 
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5.4 Morphologies attainable with PICM 
Similar to PM, PICM with different morphologies can be obtained. Most of 
the PICM reported to date were of spherical morphology although other 
morphologies are attainable depending on the polymer composition and the genetic 
material structure [38, 43, 66]. For instance, complexes of pDNA and PDMAEMA20-
b-poly[2-methacryloyloxyethyl phosphorylcholine]30 copolymer formed rod-like 
aggregates as confirmed by TEM [95].  
5.5 Significance in drug delivery 
Aggregates of different morphologies have received significant attention since 
they have the potential to display different characteristics. For example, assemblies of 
cylindrical shape are usually associated with greater solubilization capacity, given 
their higher Nagg and core volume, than spherical ones [48, 88, 96, 97]. The 
pharmacokinetics of micelles of different morphologies is also expected to vary. 
Discher and coworkers [83-85] have prepared PM of PEG-b-PCL and PEG-b-
polyethylethylene known as filomicelles (fhydrophilic = 0.42-0.44) and compared them 
with spheres of similar chemistry. In rodents, filomicelles provided drastically 
different pharmacokinetic properties and persisted in the circulation about ten times 
longer than their spherical counterparts. It was found that the long filomicelles were 
not taken up by the macrophages. On the contrary, shorter micelles are taken up by 
cells, thus resulting in more rapid clearance. The clearance of the filomicelles 
occurred upon the persistent decrease in length which was more significant for the 
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biodegradable PCL than the non-degradable polyethylethylene due to the hydrolysis 
of PCL over time.  
 
6. Drug incorporation 
6.1 Drug loading procedures 
Several procedures have been considered for the incorporation of hydrophobic 
drugs into micelles (Figure 8), the most direct of which consists in the dissolution of 
the drug into a solution of pre-formed micelles. Unfortunately, this simple 
equilibration process can only be used with the most hydrophilic copolymers and 
often results in low levels of loading given that diffusion of the drug in the PM core 
is slow. Instead, physical entrapment of the drug performed in tandem with the 
micellization procedure is preferred and is often achieved using the dialysis or oil-in-
water emulsion methods. The dialysis method involves the solubilization of both the 
polymer and drug in a common water-miscible organic solvent (such as ethanol or N-
N-dimethylformamide). As the good solvent is replaced with water, the surface free 
energy associated with both the drug and hydrophobic segment of the copolymer 
increases, thereby driving their segregation into the core of drug loaded-micelles. 
Extensive dialysis (over several days) ensures complete removal of the organic 
solvents. The oil-in-water emulsion method, on the other hand, consists in the 
emulsification of a water-insoluble organic drug solution into an aqueous polymer 
solution. The copolymer partitions at the solvent/water interface of the organic 
droplets and drug incorporation proceeds as the solvent evaporates. Solution casting 
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is yet another drug encapsulation method whereby a drug/polymer solid dispersion is 
obtained after dissolving both the polymer and drug in an organic solvent and 
evaporating the solvent. Drug-loaded micelles are obtained as the film is rehydrated 
with hot water. The success of this procedure was shown to depend on the nature of 
the organic solvent employed to form the polymer/drug matrix. In an attempt to 
incorporate paclitaxel in PEG-b-PDLLA, Zhang et al. [60] found that of an extensive 
list of solvents, only acetonitrile gave a clear solution following reconstitution in 
water. Furthermore, the use of this method remains limited to drugs and copolymers 
that are thermally stable. Another efficient procedure for the production of drug-
loaded PM consists in dissolving both the drug and copolymer in a tert-butanol 
(TBA)/water mixture and freeze-drying the solvents to produce a drug/copolymer 
cake [98]. The presence of TBA in the solvent mixture induces the formation of a 
pre-micellar structure with a swollen core where the drug can easily diffuse and 
partition. Dynamic light scattering studies revealed that the greater the TBA fraction, 
the larger and the more swollen the micelles [98]. Rehydration of the freeze-dried 
cake produces an aqueous solution of drug-loaded micelles. Of marked interest is the 
fact that the drug/polymer TBA/water solution can easily be sterilized by filtration 
and freeze-dried under aseptic conditions. Using this method, paclitaxel and 
docetaxel were incorporated into the PM with efficiencies reaching almost 100% 
[98]. 
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Figure 8. Most often used drug-loading procedures; simple equilibrium (A), dialysis 
(B), oil-in-water emulsion (C), solution casting (D) and freeze-drying (E). 
Reproduced from Dufresne et al. [46]. 
 
The incorporation of charged drugs or polyanions into the core of PICM, in 
contrast, results from the straightforward mixing of an aqueous drug solution and an 
aqueous polymer solution (Figure 1, C-E). Electrostatic interactions between the 
copolymer and the oppositely-charged drug provoke condensation, neutralization and 
self-association of the condensates into PICM. Drug entrapment proceeds 
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simultaneously with micelle formation [14]. Usually, most of the nucleic acid is 
incorporated in the PICM at an N/P ratio approaching 1. 
 
6.2 Achieving high drug loading 
Optimization of the loading efficiency is crucial in order to reduce the amount 
of vehicle to be administered. Not only is this vital to limit the toxicity or adverse 
effects that could be associated with the carrier, but also to minimize the overall cost 
of the formulation. Achieving high drug loading is also desirable considering that the 
micelle core, i.e. the space available for drug incorporation, only makes up a small 
volume of the micelle solution. This is particularly true for UPM where the free 
loading space is limited by the length and number of the core-forming blocks.  
Several properties of both the copolymer and drug are known to affect the drug 
loading and are discussed below. 
If different loading procedures can lead to varying entrapment efficiencies, 
the extent of incorporation of drugs is still mostly influenced by the nature of the 
polymer/drug combination. In a study where the degree of solubilization of different 
aromatic and aliphatic hydrocarbons in PM was evaluated, Nagarajan et al. [99] 
showed that the affinity between the core and solubilizate dictated the magnitude of 
incorporation. The Flory-Huggins interaction parameter χsc was used as an adequate 
variable to correlate and evaluate solubilization in block copolymer micelles [99]. 
The value of χsc can be computed as follows: 
( )
RT
Vδδχ s
2
cs
sc
−
=          (3) 
 101
where δs and δc are the Scatchard-Hildebrand solubility parameters of the solubilizate 
and core-forming polymer block respectively, and Vs is the molar volume of the 
solubilizate. The lower the interaction parameter χsc, the greater the compatibility 
between the solubilizate and the micelle core. The relevance of the Flory-Huggins 
interaction parameter is that it shows that no universal delivery system is likely to be 
ever designed; each drug presents unique properties that will be best complimented 
by selective copolymer systems [15, 100]. Some caution, however, should be 
exercised in using χsc for a quantitative description of the extent of solubilization 
because only positive χsc values can be obtained from this simplified equation and, in 
addition, concentration dependence cannot be studied.  
Another predictor of the drug affinity for the PM is the partition coefficient 
(Kv) of the solubilizate between the core and the surrounding environment. The 
higher the Kv value, the higher the affinity of the drug toward the micellar phase. Kv 
values can be obtained by plotting the ratio of drug solubility in the presence of PM 
(Stot) over that in pure water (Sw) against micellar concentration according to 
Equation 4 [101]: 
mmicv1
w
tot VCK
S
S
⋅⋅+=         (4) 
where Cmic is the micellar concentration (defined as the polymer concentration minus 
the CMC divided by Nagg). Vm is the micellar partial molar volume and is given by: 
h
hwmic
m d
QM
V
⋅
=          (5) 
where Mwmic is the micellar molecular weight, Qh is the hydrophobic block weight 
fraction and dh is the density of the core. The Kv of docetaxel between water and 
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copolymer micelles of PEG-b-PBO, PEG-b-PSO and PVP-b-PDLLA were calculated 
according to Equations 4 and 5 [48, 98]. The Kv values ranged from 2 x 104 to 36 x 
104 with the highest affinity found towards the PSO micelles. The difference in the 
Kv values between those micelles might be explained by the higher hydrophobicity of 
the PSO core as well as better compatibility between their aromatic structure and 
docetaxel. Kv values are calculated under the assumption that the drug partitions 
between two phases, namely the PM (as a whole) and water. Under such a premise, 
Kv should remain constant as a function of the drug concentration. However, 
deviations from this behavior have been observed, with Kv decreasing as the drug 
concentration increases. In such cases, solubilization of the drug occurs at the 
micellar interface, which becomes saturated at higher drug concentration. Thus, 
solubilization takes place in an adsorption-like manner and the data can be best fitted 
to the Langmuir adsorption isotherm [102]. 
The above discussion reveals that the maximum drug loading might be 
achieved when high affinity exists between the core-forming block and the drug to be 
loaded. The loading capacity of micelles can also be influenced by other important 
variables such as the occurrence of interactions between the drug and hydrophilic 
block of the copolymer [19]. For instance, higher entrapment efficiencies could be 
attained when using PVP rather than PEG as the hydrophilic segment. This might be 
due to the binding of the drug (i.e. indomethacin) to PVP probably via intermolecular 
hydrogen bonding between the drug hydroxyl and PVP carbonyl groups [19, 103]. 
Drugs with high affinity for both the core and shell blocks are likely to be solubilized 
in the core of micelles but also at the core/shell interface, and even within the shell 
 103
[15]. Alternatively, the efficiency of drug incorporation can be affected by the length 
of both the core-forming and corona-forming blocks [104]. The longer the 
hydrophobic block, the larger the hydrophobic core or cargo space available, and the 
higher the ability to entrap hydrophobic drugs. In contrast, a significant increase in 
the hydrophilic block length can result in an increase of the CMC, which reflects a 
smaller fraction of amphiphilic copolymers present in micellar form and a drop in the 
hydrophobic volume available for solubilization. Furthermore, copolymers presenting 
increased hydrophilic block lengths will experience increased surface densities and 
produce small particles with reduced cargo space. Another factor affecting drug 
loading is the state of the core. While crystallinity enhances micelle stability, it may 
well reduce drug loading. Crystalline cores are highly ordered and their physical 
cross-linking reduces the free cargo space and hinders diffusion of drugs into the core 
[105]. The drug loading can be increased by covalently linking drug molecule to the 
hydrophobic segment [62, 106]. For example, the chemical fixation of DOX on PEG-
b-poly(aspartic acid) (PEG-b-P(Asp)) was shown to cause an increase in the level of 
physically loaded drug due to enhanced affinity resulting from π-π interactions [62]. 
Finally, entrapment efficiencies can depend on the initial amount of drug to be 
solubilized. Trying to solubilize larger amounts of drug than what can be 
accommodated by the micelle core can induce precipitation of the drug and reduce 
the loading yield [107, 108]. 
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7. Drug release 
7.1 Release from PM 
In the previous sections, it was emphasized how PM need to retain their 
integrity following the large in vivo dilution to achieve applications such as passive 
targeting and sustained release. Moreover, maximization of the drug loading revealed 
to be crucial given the small cargo volume available. An issue now to be addressed is 
the identification of the parameters affecting the drug release and, ultimately, the 
effectiveness of the system. 
One such parameter is micelle stability. Indeed, it is easily seen how 
dissociation of micelles into single chains will free the entrapped molecules. 
Likewise, erosion or biodegradation of the carrier could provoke the escape of drug 
molecules. For instance, biodegradable poly(D,L-lactide-co-glycolide) (PLGA)-AON 
conjugates were shown to release the AON in a sustained manner by controlled 
degradation of the hydrophobic PLGA chains [109].  
In cases where the system is stable, slowly biodegradable or non-
biodegradable and above the CMC, however, drug release will instead depend on the 
rate of diffusion from the micelle. The rate of diffusion was shown to be influenced 
by various factors, most of which concurrently affect micelle stability and drug 
loading. Of those factors, one can state the core-forming block length, the micelle 
morphology, the physical state of the core, the presence of cross-links (within either 
the core or the corona segments), and the compatibility of the copolymer/drug pair. 
For instance, an increase in the length of the core forming block is known to favor the 
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self-association of amphiphilic copolymers into micelles and to provide a larger 
cargo space where more drug can be accommodated. The consequence on drug 
release is such that drugs located in the core have to diffuse through a longer path 
(larger core radius) and present a slower release rate [110]. Similarly, various micelle 
morphologies (spherical, cylindrical, bilayer, etc.) are associated with different 
diameters and surface (and interface) areas per micelle, thus affecting the release rate. 
The physical state of the micelle core, whether solid-like or liquid-like, was also 
shown to influence micelle stability and, in parallel, the release of the entrapped drug. 
For example, Teng et al. [111] revealed that the diffusion constant of a fluorescent 
probe from a poly(styrene) core was smaller than from a poly(tert-butyl acrylate) 
core. This tendency could be qualitatively correlated with the respective glass 
transition temperatures of the core components (i.e. 100 vs. 40-43°C) and indicated 
that the diffusion of a drug through a glassy core was slower than through a more 
mobile core. In turn, cross-linking of the corona-forming blocks affects the 
permeability of the corona and the period within which drugs diffuse [112]. The 
polymer/drug compatibility can concurrently influence drug release and drug 
incorporation. Just as the Flory-Huggins interaction parameter was used to predict the 
extent of drug incorporation, it can be used to infer the characteristics of drug release 
of a system. Generally speaking, the stronger the interaction between the drug and the 
core-forming block, the slower its release from the micelle.  
In addition to factors affecting the properties of the micelles, the localization 
of the drug within the micellar assembly is expected to influence the release, with 
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molecules located at the core/corona interface or within the corona diffusing faster 
than those located in the core [111].  
Other properties influencing the release kinetics include properties inherent to 
the drug molecule such as its molecular volume and its physical state in the micelle 
core. On the one hand, a relationship between the molecular volume of the drug and 
diffusion constant can be obtained by studying differences in the release rates of 
different probes from a particular micellar system [111]. Such data suggest that the 
larger the molecular volume, the smaller the diffusion constant and the release rate. 
On the other hand, the physical state of a drug in the micelle core can alter the drug 
release profile. Jeong et al. [110] showed that an increase in the amount of 
clonazepam loaded into PEG-b-PBLG micelles (12.1 to 32.8% (w/w)) resulted in a 
slower drug release. Differential scanning calorimetry thermograms revealed that 
crystallization of the drug occurred at the higher loading.  
Release kinetics are often biphasic and exhibit an initial burst associated to 
the fast release of drug molecules located in the shell or at the core-shell interface 
[111], followed by a slow release phase corresponding to the diffusion of the drug 
from the core. If drug release profiles determined in vitro are useful to compare drug 
formulations within each other and gain some insight on the properties of the 
formulation, they rarely correlate with the in vivo behavior, the release being 
accelerated in vivo. For instance, while the in vitro release of hydroxycamptothecin 
loaded in PEG-b-PCL micelles occurred over several days, the drug was cleared from 
plasma within few hours following i.v. administration of the micelles (Figure 9A) 
[113]. Results by Savic et al. [114] showing the loss of integrity of PM of similar 
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structure 1 h after intramuscular or subcutaneous injection suggest that the poor 
pharmacokinetics of the drug might be due to premature micelle disassembly. 
Likewise, paclitaxel loaded into PEG-b-PDLLA was found to have lower plasma 
levels than the copolymer and a different biodistribution profile following injection, 
indicating micelle disassembly [115]. It was recently demonstrated that the 
destabilization of the PM and the release of the loaded drug in vivo is possibly due to 
interactions with plasma proteins (Figure 9B) [116]. However, additional factors, 
such as the destabilization of the micelles by other molecules in blood, the 
translocation of hydrophobic drugs to the lipid components in the blood and the 
degradation of the copolymers, can also contribute to the disassembly of the micelles 
and the fast release of the drug.  
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Figure 9. (A) In vitro release (left panel) and plasma concentration-time curve (right 
panel) after i.v. administration of hydroxycamptothecin loaded in PEG-b-PCL 
micelles to rats. (B) Destabilization of the PM possibly occurs due to the adsorption 
of plasma proteins. Reprinted from Shi, B. et al. [113] and Chen, H. et al. [116] 
Copyright 2005 and 2008, with permission from Springer Science and American 
Chemical Society, respectively. 
 
 
7.2 Release from other micellar systems 
In the case of PICM, which result from electrostatic interactions between 
oppositely charged ions, drug release is not diffusion-based but rather occurs through 
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dissociation of the assemblies. The dissociation mostly follows from exchange events 
with charged ions (i.e. salts, heparin) which are typically found in vivo. Similarly, the 
dissociation of the polymer-metal complex micelles occurs through the substitution 
of the metal from the coordinating groups of the copolymer by ions in the medium, 
thus resulting in the micellar dissociation and subsequent release of the drug.  
 
7.3 Triggered drug release 
Although the above mentioned mechanisms of drug release from the micellar 
carriers are the most common, other can be involved. Some micellar systems have 
been adapted to trigger the release of their contents following a change in pH, 
temperature or in the redox state of the surrounding medium. Ultrasounds have also 
been utilized to trigger drug release from micellar systems in vitro and in vivo. 
However, this chapter will not address this rather specialized subject and the readers 
are referred to the references [117, 118] for more information.  
 
7.3.1 pH-sensitivity 
Changes in pH are one of the most exploited stimuli to trigger drug release. 
Indeed, pH variations occur at different pathological/physiological sites permitting 
applications where micelles release their contents upon experiencing a change in the 
environmental pH. Firstly, the microenvironment in tumors is generally more acidic 
than in normal tissues. This acidic pH might be explained by the characteristics of 
cancer cells which have glycolytic rates higher than in normal tissues [119]. 
However, the pH differences at tumor sites are usually small so that adequately 
 110
sensitive systems should be used. Changes in pH are also encountered upon cellular 
internalization of the drug-loaded carriers via clathrin-mediated endocytosis, a 
process which is accompanied by an increase of acidity inside the endosome. Finally, 
drugs administered by the oral route experience a pH gradient as they transit from the 
stomach to the jejunum.   
Several strategies have been exploited to achieve pH-sensitivity, most of which 
rely on changes in the polymer properties following the protonation/deprotonation of 
acidic and basic groups present along the polymer chain or on the hydrolytic cleavage 
of hydrophobic functionalities or cross-links. For instance, the pH-sensitivity can be 
imparted by using a corona composed of a PNIPAM copolymer bearing carboxylic 
acid functionalities. At neutral pH, the carboxylic acid groups make the PNIPAM 
segment soluble. As the pH is lowered, a sharp decrease in the solubility of the 
corona occurs. As a result, mixing of the PNIPAM chains and core region takes 
place, increasing the polarity of the core and promoting the release of the entrapped 
drug [120]. Another approach consists in conferring amphiphilicity to a copolymer 
by conjugating hydrophobic moieties to one of the polymer block (the core block) via 
pH-sensitive links. As the pH decreases, the links hydrolyze to expose back polar 
groups on the core forming block, thus destabilizing the micelles and releasing any 
encapsulated drug. This was for example achieved by Gillies et al. [121, 122] who 
developed block copolymers of PEG and either PLL or polyester dendrons and 
attached hydrophobic groups to the dendrimer periphery by highly acid-sensitive 
cyclic acetals (Figure 10). These polymers self-assembled into micelles that were 
stable in neutral aqueous solution but disintegrated into unimers at mildly acidic pH 
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following loss of the hydrophobic groups upon acetal hydrolysis [122]. The same 
group extended this strategy by directly conjugating a hydrophobic anticancer agent 
(DOX) to copolymers, thereby producing pH-sensitive micelles able to release the 
drug at acidic pH values similar to that found in tumor tissues [121]. However, a 
disadvantage of this method is the requirement of functional groups on the drug 
molecule that can be covalently modified, and since not all drugs are capable of being 
conjugated to a polymer in such a way, the scope of this method is limited. 
 
 
 
 
 
Figure 10. Hydrolysis of acetals on the dendrimer periphery of the micelle-forming 
copolymer 1 leads to a solubility change which disrupts micelle formation and 
triggers the drug release. Reprinted from Gillies, E. et al. [121] Copyright 2005, with 
permission from American Chemical Society. 
 
 
 
 
7.3.2 Temperature-sensitivity 
Some disease states are associated with local hyperthermia. Alternatively, local 
increases in body temperature can be induced by exterior means, making 
 112
temperature-directed drug release another viable triggered release strategy. To that 
aim, polymers presenting a lower critical solution temperature (LCST) transition can 
be incorporated in the composition of micelles. The most widely used polymer for 
that purpose is PNIPAM. The LCST of PNIPAM can be adjusted within a desired 
range by copolymerizing it with hydrophilic or hydrophobic monomers which 
strengthen or weaken the interactions between polymer chains and water, resulting in 
an increase or decrease in water solubility, respectively [8, 123, 124]. Below the 
LCST, the nonpolar core is segregated from the hydrated PNIPAM corona. At higher 
temperature (above the LCST), collapse of the corona is accompanied by increased 
mixing of the NIPAM corona units and hydrophobic core units, similar to lowering 
of the pH. This mixing increases the core polarity and releases the micelle-
incorporated drug [7, 8, 120, 125].  
 
7.3.3 Redox-sensitivity 
The presence of oxygen-reactive species released by activated macrophages in 
the inflamed tissues and certain tumors has been investigated as yet another stimulus 
to trigger the release of drugs from the polymeric carriers [126]. Block copolymers of 
PEG-b-poly(propylene sulfide) (PEG-b-PPS) that respond to oxidative conditions 
show promise for that purpose. The hydrophobic PPS is readily converted to 
hydrophilic poly(sulfoxide) or poly(sulfone) by mild oxidizing agents. Micelles 
obtained from this polymer could therefore accommodate hydrophobic drugs that 
would be released during the solubilization or swelling of the polysulfide upon 
oxidation, as was demonstrated for polymeric vesicles [127, 128]. Another 
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mechanism could be to take advantage of the reductive conditions met in the cytosol. 
For example, the cleavage of a disulfide bond linking an AON or siRNA to a PEG 
segment in the cytosol will cause release of the drug [45, 129]. 
 
8. Cellular barriers-Endosomal escape 
Micellar carriers can be taken up by cells via endocytosis. During this process, 
the micelles are internalized into vesicles (i.e. the endosomes) which end later in 
lysosomes. Sequestration of the micelles in the endosomal compartments can 
preclude the drugs from reaching their cytoplasmic or nuclear targets and, in some 
cases (mostly hydrophilic drugs), is a bottleneck to their efficacy. In such cases, the 
transient destabilization of (and escape from) the endosomal/lysosomal 
compartments becomes crucial. This destabilization can, for instance, be achieved 
using amine-containing polymers exhibiting pKa values between physiological and 
lysosomal pH in the preparation of PICM. As the endosomes are acidified, these 
cationic polymers undergo large changes in their ionization state and become 
protonated. This protonation of unbound amine groups causes an influx of chloride 
ions and induces osmotic swelling and subsequent disruption of the endosome [130]. 
This effect is referred to as the “proton sponge effect” [131]. Both PEI and PAMAM, 
which have pKas of 5.5 and 6.9 (for primary amino groups), respectively, have been 
used for this purpose [132]. Although some controversy exists about the contribution 
of the proton sponge effect to endosomal release, PEI and PAMAM have undeniably 
been shown throughout the literature to facilitate efficient delivery of pDNA, AON, 
and siRNA [133]. The buffering capacity of these cationic polymers depends on the 
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number of unbound amino groups and may be hampered by complexation with the 
genetic material [11, 134]. It is possible to overcome this issue by increasing the 
polymer proportion in the PICM composition (i.e. by increasing the N/P ratio). 
However, this may come at the price of cell toxicity. Hence, A-B-C triblock 
copolymers forming 3-layered micelles with segments of different pKas have been 
proposed (Figure 11A) [11]. Specifically, the micelles consist of PEG as the outer 
layer, poly[(3-morpholinopropyl) aspartamide] (PMPA) as a low-pKa middle layer 
and PLL as a high pKa inner layer. PLL (pKa of 9.4) is highly ionized at pH 7.4 and 
preferentially interacts with the negatively-charged genetic material. On the contrary, 
the low-pKa PMPA is only partially ionized at pH 7.4 (~ 10%), providing an 
opportunity to buffer and prevent acidification of the endosomes. These micelles 
showed superior transfection efficiency than either PEG-b-PLL or a mixture of PEG-
b-PLL and PEG-b-PMPA due to the high buffering capacity of the PMPA segment 
remaining free in the intermediate layer. Similarly, a PEG-b-polycation possessing a 
diamine structure with 2 distinct pKas (i.e. primary and secondary amino groups in 
the poly(3-[(3-aminopropyl)amino]propylaspartamide) (PDPT) side chain), was 
found to be remarkably effective for siRNA delivery (Figure 11B) [135]. It is 
expected that this unique structure of PEG-b-PDPT allows that only the primary 
amino groups be involved in the PICM formation, thereby maintaining the buffering 
capacity of the secondary amino groups. Yessine et al. [53] took a different approach 
to promote endosomal destabilization and integrated a synthetic membrane-active 
polyanion, namely poly(methacrylic acid-co-ethyl acrylate-co-butyl methacrylate) 
(P(MAA-co-EA-co-BMA)) in the composition of PICM. The incorporated polymer 
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was shown to effectively destabilize the endosomal membrane and promote the 
release the AON in the cytoplasm.  
 
(A) 
 
 
 
 
 
(B) 
 
 
 
Figure 11. Three-layered micelles (A) and micelles with diamine structure (B) as 
strategies to enhance endosomal escape and transfection efficiency. Reprinted from 
Oishi, M. et al. and Itaka, K. et al. [10, 135] Copyright 2006 and 2004, respectively, 
with permission from American Chemical Society. 
 
While the endosomal compartments hamper the efficacy of many hydrophilic 
drugs, it is not a real barrier for most hydrophobic drugs as the later can partition in 
membranes. In a recent study, Chen, H. et al. [136] found that during micelle-
membrane interactions, the core-loaded molecules were transferred to the plasma 
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membrane, from which they could be taken up, independent of the copolymer 
micelles. 
 
9. In vitro and in vivo applications 
It is one thing to design micelles with targeted properties and behavior yet 
another to evidence their in vitro and in vivo applicability. To our benefit, there are 
numerous instances where the formulation of drugs as PM reduced their cytotoxity, 
increased the maximum tolerated dose (MTD) or permitted passive accumulation at 
target sites while accounting for improved therapeutic effects compared to control 
formulations [137-140]. Some PM and PICM systems are summarized in Tables 3 
and 4, respectively, and their performance discussed below.  
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Table 3. Examples of PM loaded with various antitumor drugs 
 
Polymer composition Targeting 
moiety 
Micelle-
incorporated 
drug 
Size 
(nm) 
Ref 
PEG-b-PLLA-DOX - DOX 90 [201] 
Poloxamers 181 (PEG2-PPO30-PEG2) and 
407 (PEG99-PPO65-PEG99) 
- DOX 21-27 [141, 
144] 
PEG-b-P(Asp)-DOX - DOX 40 [142] 
Poloxamer 181 (PEG2-PPO30-PEG2) - DOX - [202] 
PEG-b-PLGA-DOX and FOL-PEG-b-
PLGA 
Folic acid DOX 95-115 [176] 
cRGD-PEG-b-PCL cRGD DOX 20-27 [173] 
PEG-b-P(Asp)-DOX - DOX 65 [203] 
PNIPAM-b-PBMA - DOX 340 [8] 
PEG-b-PDLLA - Paclitaxel 20-25 [143] 
Galactose-PEG-b-PBLG Galactose Paclitaxel 105 [179] 
PEG-PE mAb 2C5 
mAb 2G4 
Paclitaxel 20 [168] 
PEG-b-PBO or PEG-b-PSO - Docetaxel 16-21 [48] 
P(NIPAM-co-MAA-co-ODA) - AlClPc 13-35 [6, 
125] 
P(NIPAM-co-VP-co-MAA-co-ODA) - AlClPc 20-34 [5] 
PEG-b-P(Asp) - Cisplatin 20 [146, 
204, 
205] 
PEG-PE - Dequalinium - [104] 
Poloxamer 235 (PEG27-PPO40-PEG27) - Digoxin - [206] 
PEG-b-poly(N-hexyl-L-aspartamide)-
stearic acid 
- Amphotericin B - [150] 
PVP-b-PDLLA - Paclitaxel 
Docetaxel 
Indomethacin 
40-100 [19, 
98, 
149] 
Pullulan-Cholesterol - Insulin 20-30 [17] 
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Table 4. Examples of PM loaded with heparin, pDNA, AON or siRNA 
 
Composition Targeting 
moiety 
Drug 
(target gene) 
Size 
(nm) 
Ref 
PEG-b-P(DMAEMA) - Heparin 31 [38] 
PEG-SON/AON and PAMAM G5 and G3 - AON 70-100 [66] 
PEG-b-P(AEMA) and P(MAA-co-EA-co-BMA) - AON 30 [53] 
AON-PLGA - AON 
(c-myc) 
80 [109] 
PEG-AON and PEI - AON 
(c-raf) 
70 [42, 
43] 
PEG-AON and KALA - AON 
(c-myb) 
70 [44] 
FOL-PEG-AON and lipofectamine Folic acid AON 
(GFP) 
70-90 [4] 
PEG-b-PLL 
 
- AON 
(c-Ha-ras or 
VEGF) 
40-50 [34, 
69] 
PEG-siRNA and PEI - siRNA 
(VEGF) 
- [45] 
PEG-siRNA and KALA - siRNA 
(VEGF) 
<200 [129] 
PEG-b-DPT - siRNA 
(luciferase) 
- [135] 
Transferrin-PEG-cyclodextrin-containing 
polycations 
Transferrin siRNA 
(EWS-FLI1) 
50 [171] 
cRGD-PEG-PEI cRGD siRNA 
(VEGF) 
100 [36] 
Lactose-PEG-siRNA and PLL Lactose siRNA 
(luciferase) 
117 [180] 
Fab'-PEG-PEI Fab' pDNA 
(luciferase) 
150 [159] 
 
9.1 Non-targeted micelles  
The preferential accumulation of micelles in pathological sites presenting 
leaky vasculature (i.e. inflammation and tumors) can increase the efficacy of micelle-
encapsulated drugs. This passive targeting, however, is only achievable if the drug-
loaded micelles circulate for a long time in the blood to allow for their slow 
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deposition in the compromised vasculature of the pathological sites. This approach is 
currently under development by many research groups, with different PM 
formulations in different phases of clinical trial (Table 3) [141-144]. One clear 
example of passive targeting was reported by Hamaguchi, T. et al. [145] who showed 
that the incorporation of paclitaxel in PEG-b-P(Asp) PM resulted in about 90- and 
25-fold increase in plasma and tumor area under the concentration-time curves 
(AUC), respectively, compared to the free drug. This remarkable increase in the 
AUC, in spite of using equivalent doses, can be ascribed to the greater stability 
conferred by the micelles which permits long circulation and minimizes the drug 
leakage (4-6 times longer elimination half-life vs. the free drug) and allow the 
passage and accumulation of the drug in the tumor. Alternatively, passive targeting 
has been demonstrated after loading platinous drugs into micelles of PEG-b-
poly(glutamic acid) via polymer-metal complex interactions. Treatment of solid 
tumor-bearing mice with the micelle formulations reduced the nephrotoxicity, slowed 
down the clearance and allowed longer circulation time compared to the free cisplatin 
[146, 147]. Consequently higher and more sustained levels of drug in the tumor tissue 
were accomplished.  
Still, passive targeting remains a strategy that is difficult to demonstrate in 
vivo. Rather, micellar systems usually permit to decrease the toxicity of the entrapped 
drug, allowing for higher doses to be administered and for greater efficacy. Examples 
of formulations that have been used to deliver potent antitumor drugs such as 
paclitaxel and DOX and for which greater efficacy has been achieved will be given 
below. Paclitaxel was successfully incorporated into the core of either PEG-b-
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PDLLA or PVP-b-PDLLA micelles [143, 148, 149]. D. Le Garrec et al. [149] have 
shown that paclitaxel incorporated in PVP-b-PDLLA did not reach the MTD even at 
100 mg/kg and showed greater antitumor activity than Cremophor® EL micelles 
whose MTD was established at 20 mg/kg after single injection. Because of the higher 
MTD, paclitaxel could be injected at higher doses (i.e. 60 mg/kg) where it induced 
three- and twofold increase in the plasma and tumor AUCs, respectively, vs. 
Cremophor® EL at 20 mg/kg. Other formulations such as SP1049C, where DOX is 
physically loaded in mixture of poloxamers 181 and 407, or PEG-b-P(Asp), where 
DOX is conjugated to the P(Asp) residues, were used to formulate DOX. Both 
formulations could prolong the half-life and increase the MTD of the drug compared 
to the free DOX. Taken together, these data underscore the therapeutic potential of 
PM to improve cancer therapy. 
In addition to modifying the pharmacokinetics and biodistribution and 
decreasing the systemic toxicity of drugs, PM have been found to stabilize their 
incorporated drug, as in the case of amphotericin B. Amphotericin B is a membrane-
disruptive drug used to treat systemic fungal diseases in its monomeric form. Its 
direct administration, however, is associated with self-aggregation, leading to loss of 
selectivity and systemic toxicity. M. Adams et al. [150] have shown that when 
amphotericin B was incorporated into the core of PEG-b-poly(N-hexyl-L-
aspartamide-stearic acid) micelles, it was stabilized in its monomeric form, 
preventing the non-selective hemolysis of mammalian red blood cells in vitro. 
Moreover, the drug-loaded PM retained potent in vivo antifungal activity as 
compared to the standard clinical Fungizone® formulation.  
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The utilization of passive targeting to deliver different drugs was extended to 
different AON and siRNA (Table 4). For instance, PEG-AON/PEI PICM showed a 
superior antiproliferative activity against ovarian cancer cells where the intravenously 
injected micelles showed significantly higher accumulation level in the tumor region 
compared to the naked AON [43].  
Clinical data demonstrates the distinct pharmacokinetic advantages of 
micelle-delivered drugs over free drugs. In addition, some of these examples suggest 
the feasibility of passive targeting, i.e. favoring the local accumulation of PM through 
the EPR effect. Hence, paclitaxel formulated in PEG-b-PDLLA micelles is now in 
phase II clinical trial either alone or in combination with cisplatin and showing 
promising results [151, 152]. 
9.2 Targeted micelles 
Finest selectivity in the biodistribution of micelles and improved efficiency 
could theoretically be achieved by using systems which respond to external stimuli 
(such as pH and temperature variations) or by attaching specific ligands to the 
exposed hydrophilic ends of the carriers. These rather intricate targeting mechanisms 
are referred to as active targeting. 
9.2.1 pH-responsive micelles  
As mentioned in section 7.3.1, drug release from PM can be triggered by pH 
changes. If the change in pH is associated to a pathological process (e.g. solid tumors 
presenting acidosis), active targeting can be achieved [153, 154]. Hence, micellar 
devices have been designed to trigger and/or enhance drug release in response to pH. 
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An extended application of the pH-sensitive micelles has recently been 
introduced for the formulation of multiple anticancer agents in the context of 
combinatorial therapy. Advantages of the combinational therapy include better 
patient compliance and higher efficacy. Indeed, by simultaneously administering 
multiple drugs, the number of injections reduces, improving the quality of life of the 
patient. Furthermore, the combination of two or more drugs can amplify the activity 
of the drugs through a synergistic mechanism, thereby reducing the therapeutic dose 
and toxicity of the drugs. This synergistic action is usually brought about by 
rendering the tumor cells more sensitive to the drug. In this approach, pH-sensitive 
micelles become interesting seeing that the drugs can be conjugated to a polymer at a 
precise ratio. For instance, Bae, Y. et al. [155] conjugated DOX and wortmannin to 
PEG-poly(aspartate hydrazide) through an acid-sensitive hydrazone bond. The 
polymer–drug conjugates then assembled into micelles in which the drug mixing 
ratio between DOX and wortmannin was precisely controlled. It was shown that 
these mixed PM could reduce the DOX dose required for cytotoxicity through a 
synergistic drug action. Although the formulations have not yet been tested in vivo, it 
is expected that they would present several advantages over the conventional PM in 
the future. 
9.2.2 Temperature-sensitive micelles 
The efficiency of the micellar carriers can also be improved by combining the 
EPR effect with temperature-sensitivity. Thermo-responsive PMs were shown to 
release the loaded drug when the temperature increases beyond the LCST, thereby 
increasing their therapeutic efficacy. For instance, PM of (PNIPAM-co-N,N-
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dimethylacrylamide)-b-poly(benzyl methacrylate) [7] and PNIPAM-b-poly(butyl 
methacrylate) (PNIPAM-b-PBMA) [8] loaded with DOX not only showed a thermo-
responsive drug release behavior but also showed increased cytotoxicity towards 
bovine aortic endothelial cells in vitro above their LCST compared to the free drug. 
The higher cytotoxicity of the micellar formulation compared to the free drug at an 
identical dose suggests different routes of drug uptake by the cells. However, no in 
vivo data are available yet on the feasibility of hyperthermia targeting with PM.  
9.2.3 Functionalized micelles 
Up till this point, PM systems with highly hydrated, nonionic hydrophilic 
shells have mostly been discussed. The shell-components, primarily selected to 
hinder non-specific interactions and increase blood circulation times, may prevent 
internalization of the carriers by target cells [156]. Hence, systems presenting ligands 
at their water-exposed surface have been designed to enhance their selective binding 
to specific receptors on the cells, promote the uptake of the drug loaded micelles by 
receptor-mediated endocytosis and enhance efficacy. For efficient targeting, the 
receptors must be over-expressed by target cells (e.g. tumor cells) compared to 
normal tissues [157]. A variety of molecules including antibodies [158, 159], 
peptides [35, 160], aptamers [161, 162], vitamins and sugar moieties [163] have been 
used to achieve cell targeting (Table 3 and 4). The use of antibodies as the targeting 
moiety presents the advantage of selectivity, high affinity, and minimal competition 
for the receptor, contrary to what is observed with endogenous molecules such as 
folic acid (FOL) or transferrin [164-166]. Antibodies, however, might induce 
immunogenicity, can be difficult to produce/handle and present a large size, 
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potentially putting strain on micelle self-assembly. The use of small molecules such 
as sugars and vitamins can then become advantageous. As reported in many studies, 
it is important that the functional groups be readily available on the surface for 
efficient attachment to the receptors. The ligands can be attached either before or 
after the assembly of the particulate carrier.  
9.2.3.1 Monoclonal antibodies and antigen binding fragments.  
Targeting can be achieved by the whole antibody or its fragments such as the 
fragment antigen binding (Fab') and F(ab′)2 or scFV (single-chain variable) [167] 
(Figure 12). The advantage of using an antigen binding fragment (e.g. Fab') instead 
of the whole monoclonal antibody is that, in view of its lower molecular weight, a 
lower level of steric hindrance during complex formation can be accomplished. In 
addition, it can induce less immunogenicity when in vivo applications are sought. 
Micelles functionalized with either monoclonal antibody or Fab' have both shown 
higher cellular uptake compared to non-targeted micelles. For instance, targeting of 
ovarian carcinoma cells using Fab'-PEG-PEI/pDNA PICM was demonstrated by 
Merdan, T. et al. [159] who observed more than 6-fold greater binding of the targeted 
micelles to the OVCAR-3 cells and measured 80-fold higher luciferase reporter gene 
expression compared to the unmodified system. Increased cellular uptake was also 
reported by Torchilin and coworkers [168] for whole antibody-PM targeting lung 
cancer cells. The increased cellular uptake was associated with a four-fold higher 
tumor accumulation of the drug (paclitaxel) in vivo after 2 h and with higher anti-
tumor efficacy. 
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Figure 12. Targeting can be achieved with the whole antibody (A) or its fragments 
such as F(ab′)2 (B), (Fab') (C) or scFV (D). 
 
9.2.3.2 Aptamers.  
Nucleic acid ligands (aptamers) have been used recently for the targeting of 
drug encapsulated PMs. Such molecules can fold by intramolecular interactions into 
unique three-dimensional conformations capable of binding to target antigens with 
high affinity and specificity. They are usually selected by screening a random library 
of nucleic acids to specific molecular targets [169, 170]. An RNA aptamer targeting 
the prostate specific membrane antigen, a well-known prostate cancer tumor marker 
that is overexpressed on prostate acinar epithelial cells, was used to decorate PEG-b-
PLA or PEG-b-PLGA micelles [161, 162]. The targeted PM showed a marked 
increase in the cellular uptake over the non-targeted PM. When the targeted PEG-b-
PLGA PMs were loaded with docetaxel, this increased uptake translated into 
increased cytotoxicity in vitro and in increased anti-tumor efficacy in vivo. However, 
the instability of DNA or RNA molecules in the blood may limit the use of these 
ligands in the clinic.  
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9.2.3.3 Non-immune peptides and proteins.  
Proteins like transferrin, an iron transporter, can be used to target rapidly 
dividing cells that are in need of nutrients such as tumor cells. In this light, Hu-
Lieskovan et al. [171] developed a multicomponent delivery system for metastatic 
tumor treatment. The system included a cyclodextrin-containing polycation that self-
assembled with a siRNA inhibiting EWS-FLI1 (a gene that is found in 85% of 
patients with Ewing’s tumor). The surface of the complexes was then decorated with 
PEG and targeted with transferrin. Systemic administration of the targeted carriers 
downregulated oncoproteins and suppressed the spread of metastatic tumors. 
Removal of the targeting ligand eliminated the antitumor effects. While promising 
results were obtained with transferrin, this protein is a big molecule (80 kDa) that can 
put strain on micelles so that smaller peptides might be advantageous.  
Small, tightly binding peptides and proteins have been utilized for cancer-
targeted drug delivery. One example is the cRGD peptide, which targets the αvβ3 
integrin. This integrin is a cellular transmembrane protein that has a marked role in 
tumor growth and metastasis [37, 172]. The cRGD peptide was conjugated to 
maleimide-terminated PEG-b-PCL PM encapsulating DOX. A three-fold increase in 
cellular uptake was observed by flow cytometry when the surface density was 
adjusted to 5% cRGD. A more pronounced 30-fold increase was even observed with 
76% cRGD attachment [173]. Similar studies with a PEGylated branched PEI 
modified with an RGD peptide at the distal end of the PEG further demonstrated the 
possibility of in vivo targeting with this peptide [36]. Indeed, increased siRNA uptake 
in the tumor and decreased uptake in the lung and liver were observed following 
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intravenous administration of the modified complexes. This resulted in inhibition of 
both tumor angiogenesis and growth.  
9.2.3.4 Vitamins.  
The expression levels of FOL receptors in tumors have been reported to be 
100-300 times higher than those observed in normal tissues [157]. FOL has high 
affinity for the FOL receptor (especially for FOL receptors alpha) and retains its 
receptor binding affinity when it is covalently derivatized via its gamma-carboxyl 
group [157, 174, 175]. In view of this, Yoo and Park have functionalized PEG-b-
PLGA chains with FOL by covalently conjugating the ligand via its γ-carboxyl group 
[176]. The polymer was physically mixed with PEG-b-PLGA-DOX and free-DOX to 
produce targeted micelles. The micelles decreased the tumor growth rate compared to 
control non-targeted micelles and enhanced the antitumor efficacy when administered 
at the same dose level. However, selective derivatization through the γ-carboxyl 
group is difficult to be achieved, thereby decreasing the yield/potency of such 
systems.  
9.2.3.5 Sugars.  
One of the most common cancers affecting human is the hepatocarcinoma. 
The development of liver-targeted drug carriers is therefore highly desirable. 
Advances in this area rely on the fact that hepatocytes express carbohydrate receptors 
i.e., asialoglycoprotein receptors (ASGPR), that recognize different sugar moieties 
such as lactose, galactose or mannose, allowing for liver-specific delivery [177, 178]. 
Cho and coworkers [179] have prepared paclitaxel-loaded galactose-PEG-b-PBLG 
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micelles, and showed a greater in vitro uptake and cytotoxicity of the micelles in an 
ASGPR-expressing cancer cell line compared to an analogous non-ASGPR 
expressing cell line. Alternatively, lactose was attached to the surface of PICM for 
siRNA delivery. The formulation exhibited gene silencing of firefly luciferase 
expression in HuH-7 cells expressing ASGPR that was comparable to cationic 
liposomes (oligofectamine) [180]. 
9.3 PM for oral drug delivery 
Drugs administered by the oral route experience a pH gradient as they transit 
from the stomach to the jejunum. This pH gradient can be exploited to trigger drug 
release by using PM that exhibit a pH-dependant ionization/dissociation profile. 
These micelles are typically optimized to present minimal release of the encapsulated 
drug in the stomach, where the pH is acidic. As the micelles progress through the 
intestine (pH > 5), however, they become partially or completely ionized, thereby 
triggering the release of the entrapped drug in the small bowel (where absorption is 
maximal). Both multimolecular or unimolecular pH-responsive micelles have been 
reported [75, 181] and differ in their drug release mechanism. In the case of 
unimolecular systems, drug release is based on a decreased affinity of the ionized 
core for the encapsulated drug while release from multimolecular micelles further 
proceeds through micelle dissociation. Leroux and coworkers has shown that 
copolymers of PEG and poly(alkyl(meth)acrylate-co-methacrylic acid) (P(Al(M)A-
co-MAA)s) display pH-dependent micellization/release behavior in aqueous media 
[19, 75, 181-183]. The pH-sensitivity of the polymers is conferred by the pendant 
carboxylic acid groups of the MAA moieties, whereas the self-association into well-
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defined core-shell structure is facilitated by the inclusion of the hydrophobic non-
ionizable AI(M)A units. pH-dependent release profiles have been recorded for a 
number of hydrophobic drugs (i.e. indomethacin, fenofibrate, progesterone, and 
candesartan cilexetil (CDN)) using these micelles [19, 75, 181-183]. In rats, the PM 
were found to improve the oral bioavailability of fenofibrate and CDN. The oral 
bioavailability of fenofibrate from these self-assemblies was measured to be 156% 
and 15% greater than a fenofibrate coarse suspension and Lipidil Micro®, 
respectively [184]. In the case of CDN, the pH-sensitive PM yielded greater AUC 
compared to the non pH-sensitive PM, the commercial formulation and a CDN 
powder suspension [183]. These results suggest that pH-sensitive self-assemblies 
have potential for improving the oral bioavailability of poorly water-soluble drugs. 
The use of PM for oral administration has been also extended to different cancer 
therapeutic agents [185, 186].   
9.4 Reverse PM 
In non-aqueous media, amphiphilic polymers self-assemble into nanostructures, 
termed reverse PM, presenting a polar core and a hydrophobic shell (Figure 13). 
These micelles have been used to dissolve hydrophilic compounds (i.e. peptides) in 
non-aqueous solvents (i.e. oils). As for PM, the loading capacity of the reverse PM 
depends on the core size, the hydrophobic/hydrophilic balance and the affinity 
between the drug and the core segments. Reverse PM have been obtained from 
unimolecular dentritic [187-189] or hyperbranched structures [190-192] and from the 
self-assembly of amphiphilic polymers [193, 194]. For instance, it was shown that 
star-shaped alkylated poly(glycerol methacrylate)s could form multimolecular 
 130
micelles in different organic solvents and oils [195-197]. The assemblies were able to 
encapsulate hydrophilic dyes, peptides and proteins. As for conventional micelles, 
premature release of the encapsulated drug can follow from the rapid diffusion of the 
encapsulated molecules and/or the disassembly of the micelles upon dilution. Cross-
linking of either the shell [198] or the core [199] comes here again as a promising 
strategy to improve the stability of the micelles. For instance, core cross-linking of 
alkylated poly(glycerol methacrylate)s reverse PM with divinyl sulphone allowed for 
enhanced retention of the encapsulated dye without compromising the loading 
capacity (Figure 13) [199]. 
 
 
 
Figure 13. Assembly of reverse PM in organic solvent (CH2Cl2 (DCM)) and 
crosslinking of the micelle core. 
 
10. Conclusion 
Micelles are a promising nanomedicine platform for drug delivery. These core-
shell self-assemblies can be tailored to increase the solubility of poorly water-soluble 
drugs just as protect labile hydrophilic drugs from premature degradation. Because of 
their nanometer size and hydrated outer layer, micelles can prolong the circulation 
time of an encapsulated drug and passively accumulate at tumor sites, thereby 
reducing its systemic toxicity and enhancing its efficacy. Micelles that actively target 
tissues can also be prepared by utilizing stimuli-responsive components or by 
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attaching recognition groups at their surface. It must be emphasized that the 
polymeric carriers need to be stable and retain the encapsulated drug long enough for 
any of these applications to be achievable. To this end, both the thermodynamic 
stability and kinetic stability of the micelles can be improved by varying the nature of 
the hydrophobic block, increasing the hydrophobic/hydrophilic balance, increasing 
the hydrophobic block length or by accommodating hydrophobic molecules in the 
core. Alternatively, micelle stabilization can be achieved by cross-linking either the 
core or the corona of pre-formed micelles, by preparing crystalline micelles or by 
designing intrinsically stable UPM. The parameters affecting micelle stability, 
however, need to be carefully optimized as many also affect and influence the extent 
of drug solubilization, release kinetics and the pharmaceutical outcome.  
While many progresses have been achieved to modulate the stability and stimuli-
responsiveness of PM in vitro, many of the strategies put forth remain to be tested in 
vivo to demonstrate real control over the pharmacological properties of the 
encapsulated drugs. In view of the conflicting structural requirements for micelle 
stability and drug release, future work should focus on the development and clinical 
application of multifunctional yet easy to formulate micelles capable of delivering 
drugs at target sites in a controlled/triggered fashion. In the end, PM rise as very 
attractive drug delivery systems in that their physicochemical properties and in vivo 
fate are interrelated, creating opportunities for their performance to be fine-tuned. 
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Objectives and hypotheses of the thesis 
In this thesis, two types of polymeric micelles (PM) have been developed for 
the delivery of anticancer drugs (i.e. docetaxel) and nucleic acids (i.e. antisense 
oligonucleotides (AON) and short interfering RNA (siRNA)). The hypothesis of the 
research program to which this thesis belongs is that polymeric nanocarriers can 
overcome many disadvantages associated with the conventional formulations, such as 
toxicity and non-selectivity. More particularly, we assumed that entrapment of 
docetaxel into PM would increase its water-solubility and afford protection against 
hydrolytic degradation. In addition, encapsulation of nucleic acids (either AON or 
siRNA) in polyion complex micelles (PICM) may protect them against enzymatic 
degradation and increase their intracellular bioavailability. 
In Chapter 3, poly(ethylene oxide)-block-poly(butylene oxide/styrene oxide) 
micelles were investigated to solubilize and protect docetaxel from hydrolytic 
degradation. The objectives of this part were to formulate and characterize docetaxel-
loaded PM in terms of size, maximum loading capacity and stability against 
degradation. In addition, we compared the toxicity of the polymers vs. the surfactant 
used commercially to dissolve docetaxel (i.e. polysorbate 80).  
In Chapter 4, poly(ethylene glycol) (PEG)-oligonucleotide conjugates were 
assessed to protect AON against degradation and to release them in a sustained 
manner. When these conjugates were mixed with poly(amidoamine) (PAMAM) 
dendrimers, monodisperse PICM were formed. A fluorimetric assay was undertaken 
to monitor AON and siRNA degradation. With this assay, it was found that these 
PICM slowed down AON release and significantly protected it against enzymatic 
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degradation. In Chapter 5, PEG-block-poly(propyl methacrylate-co-methacrylic 
acid) was exploited to impart pH sensitivity to PAMAM-based PICMs. This system 
was composed of the previous copolymer mixed with PAMAM dendrimer. Such 
PICM were loaded with AON or siRNA targeting the Bcl-2 oncogene. Micelle 
uptake by the cancer cells was mediated by a monoclonal antibody fragment (i.e. 
Fab') positioned at the extremity of the PEG corona. We assumed that upon cellular 
uptake and protonation of the methacrylic acid units in the acidic endosomal 
environment, the micelles would lose their corona and expose their positively-
charged endosomolytic PAMAM/nucleic acid core. The objective of this part was to 
test whether these pH-sensitive micelles were able to increase the intracellular 
bioavailability of AON and siRNA. Chapter 6 summarizes and discusses the results. 
Finally, we propose the future work required to enhance the stability and potency of 
the formulations.  
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CHAPTER 3 - Solubilization of docetaxel in poly(ethylene 
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Abstract 
Poly(ethylene oxide)-block-poly(styrene oxide) (PEO-b-PSO) and PEO-b-
poly(butylene oxide) (PEO-b-PBO) of different chain lengths were synthesized and 
characterized for their self-assembling properties in water by dynamic/static light 
scattering, spectrofluorimetry and transmission electron microscopy. The resulting 
polymeric micelles were evaluated for their ability to solubilize and protect the 
anticancer drug docetaxel (DCTX) from degradation. The drug release kinetics as 
well as the cytotoxicity of the loaded micelles were assessed in vitro. All polymers 
formed micelles with a highly viscous core at low critical association concentrations 
(<10 mg/L). Micelle morphology depended on the nature of the hydrophobic block, 
with PBO- and PSO-based micelles yielding monodisperse spherical and cylindrical 
nanosized aggregates, respectively. The maximum solubilization capacity for DCTX 
ranged from 0.7 to 4.2% and was the highest for PSO micelles exhibiting the longest 
hydrophobic segment. Despite their high affinity for DCTX, PEO-b-PSO micelles 
were not able to efficiently protect DCTX against hydrolysis under accelerated 
stability testing conditions. Only PEO-b-PBO bearing 24 BO units afforded 
significant protection against degradation. In vitro, DCTX was released slower from 
the latter micelles but all formulations possessed a similar cytotoxic effect against 
PC-3 prostate cancer cells. These data suggest that PEO-b-P(SO/BO) micelles could 
be used as alternatives to conventional surfactants for the solubilization of taxanes. 
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1. Introduction 
Docetaxel (DCTX) is an anticancer drug which displays a broad spectrum of 
antitumor activity. It is currently approved for the treatment of advanced breast 
cancer, which remains a major cause of morbidity and mortality in women worldwide 
[1, 2]. Furthermore, it has been used with success in patients with various tumors, 
including advanced non-small cell lung cancer and ovarian cancer. Due to its poor 
aqueous solubility, DCTX is currently formulated in polysorbate 80 (Taxotere®). 
This formulation is devoid of water because DCTX degrades over time in protic 
solvents [2]. The polysorbate 80 formulation is known to cause severe allergic 
reactions and peripheral neuropathy [3, 4]. Early clinical studies of Taxotere® 
revealed that the incidence of hypersensitivity reactions ranged from 5 to 40% [4]. 
Moreover, after dilution with the hydroalcoholic vehicle provided, the Taxotere® 
formulation is physically unstable and must be administered to the patient within 8 h. 
To overcome the disadvantages of the current formulation and to increase the 
therapeutic index of DCTX, various colloidal drug carriers, such as emulsions [5], 
liposomes [6] and nanoparticles [7], are currently being investigated. Likewise, block 
copolymer micelles have recently attracted considerable attention for the delivery of 
taxanes [8-12]. In aqueous media, amphiphilic block copolymers can spontaneously 
self-assemble into nanoscopic core-shell type structures having different 
morphologies (spheres, small rods, worm-like geometries, etc) [13-16], wherein the 
hydrophobic blocks form the micelle core and the hydrophilic segments make up the 
corona. The hydrophobic core serves as a reservoir for poorly water-soluble drugs 
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while the hydrophilic shell interacts with the biological milieu and can alter the 
pharmacokinetics and biodistribution of the incorporated drug [17].  
Among the different amphiphilic block copolymers that have been evaluated 
for drug delivery applications, diblock copolymers of poly(ethylene oxide) (PEO) 
and poly(butylene oxide) (PBO) or poly(styrene oxide) (PSO) are of particular 
interest. These polymers can self-assemble at low concentrations into micelles of 
various shapes, depending on relative block lengths, concentration and temperature 
[18-21]. Their hydrophobic segments exhibit low glass transition temperatures (ca. 
40°C), allowing for the incorporation of drugs at temperatures that are compatible 
with thermolabile agents [22, 23]. Although PSO- and PBO-based copolymer 
micelles have been characterized in several studies [18-21], their role as solubilizers 
has been reported only for the antifungal drug griseofulvin, which is of low clinical 
significance as it is currently administered orally in a micronized form [22, 24].   
The aim of this project was to characterize the self-assembling properties of 
short PEO-b-PBOs and PEO-b-PSOs and assess their ability to dissolve and 
chemically protect DCTX. The molecular weight of the PEO segment was fixed at 
2000 while the nature and length of the hydrophobic block were varied. The micelles 
were analyzed by light scattering, transmission electron microscopy (TEM) and 
fluorescence spectroscopy. The effect of micellar solubilization on the aqueous 
stability of DCTX was examined by high performance liquid chromatography 
(HPLC). In addition, drug release and cytotoxicity were also evaluated in vitro.   
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2. Materials 
Methoxy-PEO and BO were purchased from Fluka via Sigma-Aldrich 
(Oakville, ON, Canada). Pyrene, SO, polysorbate 80 and 3-[4,5-dimethylthiaolyl]-
2,5-diphenyl-tetrazolium bromide (MTT) were procured from Sigma-Aldrich. DCTX 
was kindly provided by the Shanghai Fudan Taxusal New Technology Co. 
(Shanghai, China). 14C-labelled docetaxel (60 mCi/mmol) was obtained from 
American Radiolabeled Chemicals Inc. (St. Louis, MO). 1,3-bis-(1-pyrenyl)propane, 
RPMI medium, penicillin G and streptomycin were obtained from Invitrogen Canada 
Co. (Burlington, ON, Canada). 200-mesh copper grids, poly(L-lysine) and uranyl 
acetate for TEM sample preparation came from Canemco & Marivac Inc. (Montreal, 
QC, Canada). Franz diffusion cells and membrane filters were purchased from Cole 
Parmer (Vernon Hills, IL) and Avestin (Ottawa, ON, Canada), respectively. PC-3 
prostate cancer cells were purchased from American Type Culture Collection 
(Manassas, VA). Fetal bovine serum was purchased from Hyclone (Logan, UT). 
Ultima Gold™ was obtained from Perkin Elmer (Woodbridge, ON, Canada). 
Deionized water was generated by a Millipore Milli-Q system (Bedford, MA).  
 
3. Methods 
3.1 Characterization of unloaded polymeric micelles 
3.1.1 Synthesis and characterization of polymers 
EO45-SO26, EO45-SO15, EO45-BO24 and EO45-BO15 (subscripts denote number-
average block lengths in repeat units) diblock copolymers were prepared by 
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sequential oxyanionic polymerization, as described elsewhere [25]. Methoxy-PEO 
with a number-average molecular weight (Mn) of 2000 was partly converted to its 
potassium salt to initiate BO and SO polymerization. The monomers were dried over 
CaH2, and were vacuum-transferred to ampoules containing activated PEO. The 
polymerization temperature was set at 80°C. Weight-average molecular weight (Mw) 
and Mn were determined at 28°C using a Waters gel permeation chromatography 
(GPC) system equipped with a 1515 isocratic pump and 2410 refractive index 
detector (Waters, Milford, MA). Choloroform was the eluent and monodisperse PEO 
was employed as standard. 1H-NMR spectra were recorded on a Bruker ARX400 
spectrometer (Bruker, Milton, ON, Canada) in deuterated choloroform. The number 
of SO and BO units in each polymer was determined by 1H-NMR from Equations 1 
and 2, respectively: 
ppmppm InI 9.32.30.52.4 )45
34()(2
−−
=++                                                   (1) 
ppmppm InI 9.32.30.18.0 )45
34()(3
−−
=++                                                   (2) 
In both cases, n refers to the number of EO units while factor 3/45 takes into 
account the contribution of the methoxy end group of the PEO chain (Mn = 2000). In 
Equation 1, I4.2-5.0 ppm corresponds to the intensity of the methylene proton of the PSO 
backbone (OCH2CH(C6H5)), and was set to 1. In turn, I3.2-3.9 ppm corresponds to the 
intensity of the methylene groups of the PEO chain and methylene protons of the 
PSO backbone (OCH2CH(C6H5)). Solving the equation for n allows the 
determination of a SO/EO ratio (where SO = 1) that can be balanced for PEO 2000 
(45 EO units). Equation 2 is used in a similar fashion. In this case, I0.8-1.0 ppm 
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corresponds to the intensity of the methyl protons of the PBO pendant group 
(OCH2CH(CH2CH3)), and was set to 3. On the other hand, I3.2-3.9 ppm corresponds to 
the methylene groups of the PEO and PBO backbones. 
 
3.1.2 Determination of the critical association concentration (CAC) 
The apparent CAC of the polymers was estimated by a steady-state pyrene 
fluorescence method [26], based on shifts of the third excitation band of pyrene from 
333 to 336 and 339 nm due to its incorporation in the hydrophobic core of PEO-b-
PBO and PEO-b-PSO micelles, respectively. Serial dilutions of stock solutions of 
different copolymers were prepared to contain 2 x 10-7 M of pyrene and stirred 
overnight in the dark. Their excitation spectra were recorded at room temperature in 
an Aminco Bowman Series 2 luminescence spectrometer (Spectronic Instruments 
Inc., Rochester, NY) at λem = 390 nm (bandpass = 2 nm). The CAC was determined 
from the intersection of 2 straight lines (the horizontal line with an almost constant 
value of the ratio I336 or 339/I333, and the vertical line with a steady increase in the ratio 
value) on the graph of the fluorescence intensity ratio I336 or 339/I333 vs. log polymer 
concentration. Experiments were performed in triplicate. 
 
3.1.3 Measurement of core viscosity 
1,3-bis-(1-pyrenyl)propane, a hydrophobic probe similar to pyrene, diffuses 
from an aqueous phase to the hydrophobic core of micelles. Given that the extent of 
excimer formation depends on the viscosity of the surrounding environment, the ratio 
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of the excimer to monomer intensity (Ie/Im) at 376 and 480 nm can be exploited to 
measure effective micelle core viscosity. 1,3-bis-(1-pyrenyl)propane was dissolved in 
5 mL of chloroform to give a final concentration of 2 × 10−7 M. The solvent was then 
evaporated and replaced by 5 mL of aqueous polymer solutions at concentrations 
above the CAC (0.5 mg/mL). Sodium dodecyl sulfate (SDS) at 5 mg/mL served as a 
control, low molecular weight surfactant. The solutions were stirred for 24 h in the 
dark. The emission spectrum of 1,3-bis-(1-pyrenyl)propane was obtained at room 
temperature with an Aminco Bowman Series 2 luminescence spectrometer. The 
excitation wavelength and the emission bandwidth were set at 333 and 4 nm, 
respectively. All measurements were done in triplicate. 
 
3.1.4 Dynamic light scattering (DLS) measurements 
The mean hydrodynamic diameters (dh) and the polydispersity indices (PDI) 
of polymeric micelles were measured by DLS with a Malvern Autosizer 4800 
instrument (Malvern Instrument, Worcestershire, UK). All samples were filtered 
(Acrodisc® 13-mm syringe filter with 0.45-µm nylon membrane, Pall Co., 
Mississauga, ON, Canada) prior to analysis.  The different polymers were dissolved 
in water to a final concentration of 2 mg/mL. Measurements were taken at a fixed 
scattering angle of 90°. DLS measurements were also performed at different angles 
(50-140º) to examine micelle sphericity. For spherical particles, diameter is 
independent of detection angle due to the undetectable rotational motion [27]. The 
CONTIN program was used to extract size distributions from the autocorrelation 
functions.  Measurements were performed in triplicate at room temperature. 
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3.1.5 Multiangle static light scattering (MASLS) measurements 
Polymer solutions were prepared in Millipore water at room temperature and 
stirred overnight. All samples were passed through a 0.45-µm nylon filter prior to 
analysis. Then, samples were subjected to MASLS measurements in a Malvern 
Autosizer 4800 at 6 angles ranging from 50 to 120°, for 5 polymer concentrations 
above the CAC (0.25 to 2 mg/mL). The Mws of the micelles were extracted from 
Equation 3, which describes the intensity of light scattered from a dilute solution of 
macromolecules: 
( ) cA3cA2θPM
1
R
Kc 2
32
W0
++=                              (3)    
In this equation, c stands for the polymer concentration, R0 is the Rayleigh ratio of 
the solution, and A2 and A3 are the second and third virial coefficients. K is, in turn, 
defined by: 
Nλ
dc
dn
nπ4
K
4
2
2
0
2 ⎟⎠
⎞⎜⎝
⎛
=                                (4) 
where n0 is the refractive index of the solvent, λ is the laser wavelength in vacuo, and 
N is Avogadro’s number. Specific refractive index increments (dn/dc) were 
determined using a differential Rudolph J157 automatic refractometer (Rudolph 
Research Analytical, Flanders, NJ), at a wavelength of 589.3 nm. The dn/dc values 
for EO45-SO26, EO45-SO15, EO45-BO24,  and EO45-BO15 solutions were 0.160, 0.154, 
0.112, and 0.120 cm3/g, respectively. Aggregation number (Nagg) was calculated by 
dividing micelle Mw by that of the corresponding polymer. Radii of gyration (rg) were 
also extracted from MASLS analysis. 
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3.2 TEM 
Copper grids (200 mesh) were coated with a drop of aqueous poly(L-lysine) 
solution (0.1% w/v) 5 min prior to sample deposition to ensure good adhesion 
between the samples and the grids. Excess solution was wicked off, the grids were 
allowed to dry, and a drop of different micelle solutions (2 mg/mL) was placed on the 
grid for 2 min. After the removal of excess solution, a droplet of uranyl acetate (3% 
w/v in water) was added to provide negative staining. After 5 min, the grids were 
gently washed with water, and excess fluid was removed with filter paper. The 
samples were then analyzed under a Philips CM100 transmission electron 
microscope (FEI Company, Tokyo, Japan) operating at 60 kV. Micrographs were 
taken at a magnification of 50,000. 
 
3.3 Characterization of DCTX-loaded polymeric micelles 
3.3.1 Preparation and characterization of DCTX-loaded micelles 
Both DCTX and the polymer were dissolved in ethanol. The solvent was then 
evaporated under vacuum at room temperature, and replaced by Millipore water, and 
the solutions were stirred overnight prior to analysis. The solutions of drug-loaded 
micelles were centrifuged (18,000 g, 30 min), the supernatant was collected and 
passed through a 0.2-µm nylon filter. Drug concentration was assayed in the 
supernatant using a Waters HPLC system equipped with a 1525 binary pump, a 2487 
dual wavelength absorbance detector and Breeze chromatography software (Waters, 
Milford, MA). N-heptylbenzamide served as internal standard. The mobile phase 
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consisted of acetonitrile, methanol and water (48:11:41 v/v). The column was Waters 
Nova-Pack C18 60 Å 4 µm (3.9 × 300 mm). Flow rate, detection wavelength, 
temperature and injection volume were set at 1 mL/min, 232 nm, 4ºC and 55 µL, 
respectively. Size analyses were performed by DLS on freshly-prepared micelles and 
freeze-dried formulations after reconstitution in water. 
 
3.3.2 Determination of the partition coefficient (Kv)  
DCTX-loaded micelles were prepared with the drug present in large excess (2 
mg) and increasing polymer concentrations (from 2 to 10 mg/mL). The solutions 
were stirred overnight and then centrifuged (18,000 g, 30 min). Drug concentration 
was assayed in the supernatant with the HPLC method detailed above. Kv values 
were obtained by plotting the ratio of DCTX solubility in the presence of polymeric 
micelles (Stot) over that in pure water (Sw = 2 µg/mL) against micellar concentration 
according to Equation 5 [28]: 
Stot / Sw = 1 + Kv . Cmic .Vm                     (5) 
where Cmic is the micellar concentration (defined as the polymer concentration minus 
the CAC divided by Nagg). Vm is given by: 
Vm = (Mwmic. Qh)/dh                       (6) 
where Vm is the micellar partial molar volume, Mwmic is the micellar molecular 
weight (as determined by MASLS), and Qh is the hydrophobic block weight fraction. 
The density of the core, dh, was assumed to be that of a homopolymer of the 
hydrophobic segment of similar molecular weight.  
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3.4 Chemical stability of DCTX-loaded micelles 
DCTX-loaded micelles were subjected to accelerated stability testing by 
heating the polymer solutions at 50°C for 24 h. The polymer concentrations (5 
mg/mL) were kept above the CAC, and the drug concentration was set at 2 µg/mL in 
all solutions. At scheduled time intervals, samples were withdrawn and assayed by 
HPLC for intact DCTX, as described above. An aqueous solution of free DCTX was 
used as control. 
 
3.5 Calculation of solubility parameters by the group contribution 
method 
Total (δ t) and partial ( dδ , pδ and hδ ) solubility parameters of the drug, PEO, 
PBO and PSO blocks were calculated by the following 4 equations according to the 
group contribution method: 
 
V
F
=δ
∑ di
d                   (7) 
V
F
=δ
∑ 2pi
p                   (8) 
V
E
=δ
∑ hi
h                   (9) 
2
h
2
p
2
dt δ+δ+δ=δ               (10) 
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where Fdi, Fpi and Ehi describe the functional group contributions from van der Waals 
dispersion forces, dipole-dipole interactions and hydrogen bonding, respectively [29]. 
The total molar volumes (V) of DCTX, PEO, PBO and PSO polymer repeat units 
were obtained by the Fedors method [30]. 
 
3.6 In vitro release kinetics 
DCTX-loaded polymeric micelles (0.7% (w/w) for EO45-BO24, 0.7 and 3.5% 
(w/w) for EO45-SO26), spiked with 14C-labelled DCTX (2 µCi/mg DCTX) were 
prepared in phosphate buffered saline (PBS, pH 7.4) as previously described. The 
release of DCTX from the different formulations was studied by following the time 
course of drug transfer from the donor to the acceptor compartment using jacketed 
Franz diffusion cells. Both compartments were separated from each other by two 
superimposed 50-nm polycarbonate membranes. The release medium was maintained 
under continuous agitation (700 rpm) and at a constant temperature of 37±0.2°C 
using a circulating water bath. To ensure sink conditions, DCTX-loaded polymeric 
micelles were dispersed to a final drug concentration of 0.5 µg/mL in the donor 
compartment. At various time points, a 200-µL aliquot was withdrawn from the 
acceptor compartment and replaced by 200 µL of fresh PBS. Ultima Gold™ 
scintillation cocktail (5 mL) was added to the sample and DCTX was quantified by 
radioactivity counting (Liquid Scintillation Analyzer, Tri-Carb 2100TR, Packard, 
Meridan, CT). 
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3.7 In vitro cytotoxicity assay 
PC-3 prostate cancer cells were maintained in RPMI 1640 supplemented with 
fetal bovine serum (10%) and penicillinG/ streptomycin (100 units/mL). For the 
cytotoxicity assays, DCTX-loaded polymeric micelles (0.7% (w/w) for EO45-BO24, 
0.7 and 3.5% (w/w) for EO45-SO26) were passed through 0.45-µm nylon filters, then 
the drug content was assayed by HPLC. DCTX-loaded micelles and control DCTX 
solution mimicking Taxotere® (polysorbate 80/ethanol/DCTX 72.8:24.3:2.9 wt%) 
were serially diluted in cell culture medium prior to their addition. Control unloaded-
micelles were tested at polymer/polysorbate 80 concentrations ranging from 7x10-7 to 
4.2 mg/mL. Cells were seeded in 96-well plates at a density of 5x103 cells/well and 
cultured for 24 h at 37°C in a humidified atmosphere containing 5% CO2. The 
medium was then refreshed (100 µL) prior to the addition of 20-µL aliquots of either 
the micelle solutions or medium alone. After a 72-h incubation period, cells were 
rinsed with PBS, fed with 100 µL of fresh medium, and exposed to 10 µL/well of a 
MTT solution (5 mg/mL in PBS). After a 3.5 h-incubation, 100 µL of a SDS solution 
(10% in HCl 0.01 N) was added to each well to dissolve the blue formazan product 
generated by the oxidation of MTT by living cells. The absorbance was read 16 h 
later at 570 nm using Tecan Safire plate reader (Durham, NC). 
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4. Results and discussion 
4.1 Characterization of the polymers and unloaded micelles 
The molecular characteristics of PEO-b-PBO and PEO-b-PSO copolymers are 
reported in Table 1. Given that these polymers are not biodegradable, relatively low 
molecular weights were targeted (<6000) to avoid exceeding the renal filtration 
threshold for the elimination of unimers [31, 32]. GPC revealed that PEO-b-PBOs 
had narrow distribution peaks while the curves of PEO-b-PSOs showed a small 
shoulder on the low volume side of the main narrow peak, which was attributed to 
the initiation of homo PSO by moisture (data not included). The PEO-b-PSOs were 
further purified by precipitation of the copolymers from a product solution of 
dichloromethane into hexane to give the final products with a single peak in GPC. 
1H-NMR spectra were recorded and confirmed the compositions of the block 
copolymers [33].   
 
Table 1. Molecular characteristics of PEO-b-PBO and PEO-b-PSO 
Copolymer a Mna Mnb Mwb Mw /Mnb 
EO45-BO15 3080 2700 2900 1.05 
EO45-BO24 3730 3400 3600 1.05 
EO45-SO15 3800 3000 3350 1.11 
EO45-SO26 5120 3460 4150 1.20 
aThe subscripts denote the number of repeat units as measured by 1H-NMR. 
bMeasured by GPC. 
 
 
All polymers exhibited low CAC, ranging from 1 to 10 mg/L (Table 2). The 
CAC was found to decrease with increasing hydrophobic chain length and 
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substituting BO for SO. Indeed, the CAC of EO45-BO15 was twice that of the EO45-
SO15 copolymer, reflecting the stronger hydrophobic interactions conferred by the 
aromatic ring. In a recent review, Booth et al. [34] ranked the relative 
hydrophobicities of various oxyalkylene units and attributed values of 1, 6 and 12 to 
propylene oxide, BO and SO, respectively. All polymeric micelles possessed highly 
viscous cores, as evidenced by the low Ie/Im ratios (0.05 to 0.12) compared to that of 
SDS (0.69), which is liquid-like (Figure 1 and Table 2). PSO-based micelles 
presented higher core viscosity than their PBO counterparts. The latter showed Ie/Im 
values similar to those of PEO-b-poly(L-aspartamide) derivatives [35]. 
 
Table 2. Size, CAC and core viscosity of unloaded micelles. Mean of 3 independent 
experiments 
Copolymer dh (nm) PDI CAC (mg/L)  ± SD Ie/Im ± SD 
EO45-BO15 16 0.04 9.5 ± 0.5 0.15 ± 0.01 
EO45-BO24 21 0.07 4.0 ± 0.2 0.12 ± 0.02 
EO45-SO15 19 0.06 4.5 ± 0.2 0.05 ± 0.01 
EO45-SO26 21 0.17 1.5 ± 0.1 0.04 ± 0.01 
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Figure 1. Fluorescence emission spectra of 1,3-bis-(1-pyrenyl)propane in EO45-BO15 
(○), EO45-BO24 (●), EO45-SO15 (□), EO45-SO26 (■), and SDS (▲) micellar aqueous 
solutions. 
 
The size of micelles is controlled by various factors, among which the length 
and nature of the core-forming segment and corona-forming chain are predominant. 
As reported in Table 2, mean dh of the micelles ranged from 16 to 21 nm. Naggs were 
above 300 for all copolymers except EO45-BO15 which was about one-third of this 
value (Table 3). This polymer also formed the smallest micelles, as determined by 
DLS (16 nm). In all cases, size distribution was unimodal and of low polydispersity. 
Micelle diameter was augmented when chain length of the oxyalkylene block was 
increased. The latter observation is in agreement with earlier data obtained for similar 
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systems [19-21]. DLS measurements were also performed at different angles (50-
140°) to assess whether the micelles were spherical. Figure 2 shows mean diameter 
as a function of the scattering vector (K2). No angular dependence was found for 
EO45-BO24 and EO45-BO15 copolymers, the mean diameters being almost identical at 
every angle. This suggests that the BO polymers probably self-assembled into 
spheres. In contrast, angular dependence was evidenced in the case of both EO45-
SO15 and EO45-SO26 copolymers, indicating that the self-assemblies were not 
spherical in shape. 
 
Table 3. MASLS analysis of unloaded micelles 
 
Copolymer Mwmic Nagg rg/rha 
EO45-BO15 263,500 90 0.9 
EO45-BO24 1,193,700 330 0.9 
EO45-SO15 1,030,700 307 1.3 
EO45-SO26 1,235,000 310 3.6 
arh is the hydrodynamic radius. 
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Figure 2. Change of diameter with the magnitude of K2 for EO45-BO15 (○), EO45-
BO24 (●), EO45-SO15 (□), and EO45-SO26 (■) micelles (detection angles 50-140°). 
Each value is the mean of 3 experiments ± SD. The mean diameter was found to be 
independent on the polymer concentration above the CAC. 
 
The morphology of the unloaded micelles was then examined by computing 
the rg/rh ratio for the different polymers (Table 3). For PEO-b-PBO micelles, the rg/rh 
values were close to that of a hard sphere (0.78), in agreement with the formation of 
nearly spherical micelles. On the other hand, the ratios found for PEO-b-PSO 
copolymers were more than 1, consistent with significantly elongated micelles [36]. 
TEM imaging was undertaken in order to directly visualize the shape of the 
aggregates. As anticipated, PEO-b-PBO formed nearly spherical micelles in water 
(Figure 3 A-i and B-i), whereas the PEO-b-PSOs self-assembled into small rods 
(Figure 3 C-i and D-i). Under TEM, the diameters of all micelles were close to those 
obtained by DLS, while the mean length of the EO45-SO15 and EO45-SO26 rods were 
approximately 80 ± 15 and 90 ± 10 nm (n=20), respectively. PSO-based micelles 
have been proposed to adopt both spherical and cylindrical arrangements, depending 
on the length of the respective PSO and PEO blocks. Indeed, Crothers et al. [37] 
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found that the rg/rh of EO45-b-SO10 micelles (same PEO length but shorter PSO block) 
was consistent with spherical micelle formation, thus confirming the determining role 
of polymer hydrophilic/ hydrophobic balance on micelle morphology [38]. In another 
study, Yang et al. [21] compared the Nagg of EO17-BO8 and EO17-SO8. These 
polymers have lower molecular weight than those studied in the present work, but 
their EO/BO and EO/SO ratios are comparable. They found that substituting BO for 
SO brought about a rise of Nagg which was superior to the theoretical increase 
expected for spherical micelles. They hypothesized that the difference in Nagg 
between these 2 polymers could be explained by elongation of the micelles to 
accommodate the high Nagg. While the formation of rod micelles with PEO-b-PSO 
has been predicted theoretically [21, 22], this is the first time that the cylindrical 
morphology of PSO-based micelles is observed. Although the difference in shape 
between the 2 types of micelles can be related to differences in the hydrophobicity 
(being twice for the SO) [34] and conformations of BO and SO, it is worth 
mentioning that the possible residual homopolymer of SO dissolved in the micelle 
core may also have contributed to the formation of cylindrical PEO-b-PSO micelles 
[39]. 
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Figure 3. TEM imaging of unloaded (i) and DCTX-loaded (ii) EO45-BO15 (A), EO45-
BO24 (B), EO45-SO15 (C) and EO45-SO26 (D) micelles. 
 
4.2 Characterization of DCTX-loaded micelles 
The drug-loaded micelles were prepared according to a procedure which was 
initially proposed for PEO-b-poly(D,L lactide) (PEO-b-PDLLA) [40]. Attempts at 
dissolving DCTX into preformed micelles resulted in low drug loading, probably 
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because of slow diffusion of the drug into the viscous micelle core (data not shown). 
Accordingly, it was decided to first co-dissolve both the drug and polymer in a 
pharmaceutically-acceptable organic solvent (i.e. ethanol) to form a homogeneous 
polymeric matrix, evaporate the organic solvent, and then add the water phase. The 
size of DCTX-loaded micelles was measured by DLS (Table 4), and no difference 
was observed compared to unloaded micelles. Moreover, the loaded micelles 
preserved their initial shape (Figure 3 A-ii-D-ii). The micelles could be readily 
freeze-dried, and recovered their initial size distribution upon reconstitution in 
aqueous media (data not shown). In solution, no crystallization was apparent for at 
least 14 days. The solubilizing capacity (SCP) of each system was evaluated (Table 4). 
PSO-based micelles incorporated more DCTX (~3-4%) than PBO micelles (<1%), 
most likely because of the better compatibility between DCTX and PSO (see below) 
and to the micelle morphology. Micelles of cylindrical shape are usually associated 
with greater SCP, given their higher Nagg and core volume [22, 24]. Indeed, Crothers 
et al. [22] demonstrated that griseofulvin was also incorporated to a greater extent 
into PSO vs. PBO micelles having comparable characteristics. For both polymers, SCP 
rose when the length of the hydrophobic block was increased. More than 4% (w/w) 
drug loading could be achieved with EO45-SO26. With such loading, hydrosolubility 
of exceeding 2 mg/mL was reached, which was more than 1000-fold the aqueous 
solubility of free DCTX. 
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Table 4. Characteristics of DCTX-loaded micelles 
 
Copolymer SCP ± SD 
(mg/g)a 
Qh ρ (g/cm3)b Kv x 10-4 dh (nm) PDI 
EO45-BO15 4.2 ± 0.8 0.35 0.973 3.9 17 0.07 
EO45-BO24 7.4 ± 1.1 0.46 0.973 5.3 22 0.08 
EO45-SO15 34.8 ± 1.7 0.47 1.150 35.3 19 0.07 
EO45-SO26 41.7 ± 1.2 0.60 1.150 36.7 21 0.19 
aSolubilizing capacity expressed as mg of DCTX per g of copolymer. 
bThe densities of the hydrophobic block were taken from the literature [21, 24]. 
 
The Kv of DCTX between water and the copolymer micelles was calculated 
using Equations 5 and 6 (Table 4). The Kv values ranged from 4 x 104 to 53 x 104. 
The high affinity of DCTX for another hydrophobic block, i.e. PDLLA, has been 
reported earlier by our group [41]. The Kv value of DCTX in poly(N-vinyl-2-
pyrrolidone)-block-PDLLA micelles was found to be 2.46 × 104. It is similar to the 
Kv of the drug in PEO-b-PBO micelles, but substantially lower than the Kv for PEO-
b-PSO.  
Solubility parameters are useful to estimate compatibility, interactions and 
miscibility between drugs and various carrier systems [41]. Difference in loading 
capacity and the affinity of PEO-b-PSO and PEO-b-PBO for the drug were correlated 
with the solubility parameters and the enthalpy of mixing of both the drug and the 
polymers. As expected, the difference between the total solubility parameters of 
DCTX and each polymer block was found to be the least important for PSO (Table 
5). The enthalpy of mixing (∆HM) was then calculated using Equation 11 [42]: 
( ) ( ) ( )[ ]22122122121 hhppddMH δδδδδδφφ −+−+−=∆               (11) 
 175
where 1φ and 2φ  are volume fractions of the drug and the polymers. The ∆HM values 
for PSO and PBO were 79.7 and 87.3 MPa, respectively, corroborating the 
experimental data. Considering the differences in both solubility parameters and 
∆HM, PSO is more suitable than PBO for solubilizing DCTX. 
 
Table 5. Total (δ t) and partial ( dδ , pδ and hδ ) solubility parameters of DCTX and 
individual polymer blocks (MPa½) 
 
Molecule δ d δ p δ h δ t 
DCTX 20.6 3.1 14.6 25.5 
PEO 17.8 11.1 9.1 22.9 
PBO 16.6 5.8 6.6 18.8 
PSO 20.8 4.6 5.8 22.1 
 
 
4.3 In vitro evaluation of micelle formulations 
The effect of micellar solubilization on the chemical stability of DCTX in 
water was investigated over a period of 24 h at 50ºC (Figure 4). For comparison 
between the different systems, all micelles were loaded at the same drug level (0.04% 
w/w). Despite their higher affinity for the drug, both PSO-based micelles were 
inefficient at protecting DCTX from degradation under accelerated stability testing 
conditions. Likewise, EO45-BO15 did not afford any protection compared to the 
control drug solution. Surprisingly, only EO45-BO24 was able to preserve most DCTX 
chemical integrity (92%) after 24 h. This protective effect cannot be accounted for by 
differences between the drug affinity or core microviscosity of BO24 block, since 
both parameters were inferior to those of PSO block and almost similar to the BO15 
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segment (Tables 2, 4 and 5). One possible explanation for the observed effect is the 
difference in specific surface area between micelles. The specific surface area (S) 
was estimated for spherical and cylindrical micelles using Equations 12 and 13, 
respectively: 
S = 4 π r2/Mw                                                                                                         (12) 
S = 2 π r L /Mw                                                                                                                                       (13) 
where L is the length of the cylindrical micelles which was extracted from TEM 
analysis, r is the micelle radius (Table 4) and Mw is the molecular weight of micelles 
as ascertained by MASLS. BO24 micelles yielded the lowest specific surface area 
(760 m2/g), whereas the calculated values for BO15, SO15 and SO26 micelles were 
2050, 2800 and 2900 m2/g, respectively. Thus, the greater protection conferred by 
EO45-BO24 micelles could be partially ascribed to decreased interactions of DCTX 
with the aqueous medium at the water-micelle interface due to the lower specific 
surface area.  
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Figure 4. Effect of micellar solubilization on DCTX stability in EO45-BO15 (○), 
EO45-BO24 (●), EO45-SO15 (□), and EO45-SO26 (■) micelles. The stability of free 
DCTX in water (▲) is also shown. The experiments were carried out at fixed 
temperature (50ºC) for 24 h. DCTX loading and concentration were set at 0.04 (% 
w/w) and 2 µg/mL, respectively. Mean ± SD (n=3). 
 
The release of DCTX from EO45-BO24 and EO45-SO26 micelles was studied in 
vitro (Figure 5). The free drug diffused completely in about 24 h, indicating that the 
two superimposed 50-nm membranes influenced the release rate. However, this 
particular setting was necessary to prevent the transfer of micelles in the acceptor 
compartment (<5% after 5 days as estimated by DLS). All micelle formulations 
displayed similar profiles characterized by a fast initial release (~50% within 12 h) 
followed by a decelerated rate over 5 days. In order to eliminate the background 
effect, mathematical kinetic modeling was performed. In the model, the drug release 
measured in the acceptor compartment was divided into two different transfer rates, 
namely one from micelles to the donor compartment and one from donor to acceptor 
compartment. Each transfer relation was defined by a simple first order linear 
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differential equation defined by microconstant, Km for the rate of DCTX release from 
micelles and Kd for the transfer of DCTX to the acceptor compartment (see 
supporting information). To assess the effect of the two superimposed 50-nm 
membranes on the release, Kd was determined by fitting the equation on the free 
DCTX release curve and used subsequently to obtain the specific Km of each 
formulation. Comparison of the release rates of the formulations with 0.7% DCTX 
showed that release was faster for EO45-SO26 than for EO45-BO24 micelles (KmSO26 = 
1.31 d-1 vs. KmBO24 = 0.57 d-1,  and 83% of the drug had diffused out in 72 h vs. 73%, 
respectively). However, normalization of the constants by specific surface area 
(KmSO26/S = 4.51 10-4 g.m-2.d-1 vs. KmBO24/S = 7.56 10-4 g.m-2.d-1) tends to ascribe this 
difference to the surface dissimilarities between formulations, as previously 
discussed. Comparison of the release profiles of EO45-SO26 formulations with 
different drug loadings (0.7 and 3.5% DCTX) revealed that surface area was not the 
only factor affecting drug release. Indeed, similar release profiles were obtained 
despite the fact that there was a 5-fold difference in micelle concentrations between 
the 2 formulations. The drug loading may influence DCTX distribution in the 
micelles or its initial partition between micelles and donor compartment and therefore 
affect the drug release profile. 
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Figure 5. In vitro release kinetics of DCTX from EO45-BO24 (0.7% DCTX) (●) and 
EO45-SO26 (0.7% DCTX) (□), and EO45-SO26 (3.5% DCTX) (■) micelles. DCTX 
diffusion in the absence of micelles is represented by (▲).  The experiments were 
carried out at 37ºC in PBS (pH 7.4). Mean ± SD (n=3). The dotted lines represent the 
simulated release kinetics. 
 
The antimitotic activity of DCTX-loaded micelles was then evaluated on 
human prostate cancer cells PC-3. The cytotoxicity assays revealed that EO45-BO24 
and EO45-SO26 micelles formulations were as efficient as the control commercial 
formulation to inhibit the growth of these cells (Figure 6). No difference was found 
between the tested systems with IC50 values ranging from 2.2 to 2.5 nM (±0.3 nM). 
Indeed, the in vitro release data can be used to rationalize these results. After 72 h of 
incubation, most of the DCTX has been released from the polymeric micelles and is 
thus available to exert its cytotoxic activity. Indeed, Le Garrec et al. [8] obtained 
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similar findings with biodegradable poly(N-vinylpyrrolidone)-b-poly(D,L-lactide) 
micelles loaded with DCTX. These micelles exhibited IC50 values comparable to 
those of Taxotere®, indicating the complete release of drug from the hydrophobic 
core. Neither the unloaded-micelles nor polysorbate 80 caused a significant decrease 
in cell viability up to a polymer/polysorbate 80 concentration of 0.01 mg/mL 
(corresponding to a DCTX concentration of 5.4x10-9 M for the micelles loaded with 
0.7% drug) (data not shown). At high concentration (0.7 mg/mL), EO45-SO26 was 
fairly less toxic (86% viability) than polysorbate 80 (51% viability) and EO45-BO24 
(24% viability). Altogether these data suggest that, at high drug concentrations, PEO-
b-PSO may potentially improve the therapeutic index of DCTX by decreasing the 
formulation’s non specific toxicity. 
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Figure 6. Cell viability of PC-3 cells exposed to EO45-BO24 (0.7% DCTX) (●) and 
EO45-SO26 (□) (0.7% DCTX), and (3.5% DCTX) EO45-SO26 (■) DCTX-loaded 
micelles. A polysorbate 80/ethanol formulation of DCTX was used as control (▲). 
The data represent the mean of 3 experiments. For the purpose of clarity, the error 
bars of the standard deviation are omitted (CV < 12%). 
 
 
5. Conclusion 
In water, PEO-b-PBO and PEO-b-PSO block copolymers self-assembled at 
low concentrations to form spherical and cylindrical micelles, respectively. These 
micelles possessed diameters ranging from 16 to 21 nm, which make them suitable 
for sterilization by filtration and administration by intravenous injection. PSO-based 
copolymers were associated with higher solubilizing capacities for DCTX (~4% w/w) 
than PBO due to the aromatic structure of the core-forming polymer and the 
cylindrical morphology of the resulting micelles, However, the PBO copolymer 
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offered a greater protective effect against the hydrolytic degradation of DCTX. 
Nevertheless, the long term stability for all these systems is guaranteed by the fact 
that the micelles investigated in this work could be lyophilized and thus stored in 
dried form. Such polymers could provide useful alternatives to low molecular weight 
surfactants for the solubilization of taxane derivatives. 
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Supporting information 
 
The kinetic modeling was applied by using the following equation S1:  
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      (S1) 
where Po and P m are constants related to the amount of drug initially present in the 
donor compartment (free DCTX) and in the micelles, and Kd and Km are rate 
constants for diffusion out of donor compartment and micelles, respectively (Figure 
S1). The Kd used for all simulations was determined by fitting the equation on DCTX 
release profile with Km = 0.  
 
 
Figure S1. Kinetic model for DCTX release from micelles in jacketed Franz 
diffusion cells. 
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Abstract 
The objectives of the current study were to design and characterize 
poly(ethylene glycol) (PEG)-based carriers for antisense oligonucleotides (AON) 
delivery that would gradually release the AON upon the enzymatic degradation of a 
complementary nuclease-sensitive sequence (SON). A phosphodiester SON was 
conjugated to one extremity or to the central part of PEG (molecular weight 10 or 
20K). The PEG-SON was hybridized to a nuclease-resistant phosphorothioate AON 
analog. Compared to the non-PEGylated duplex, the PEG-SON/AON derivative had 
a modest impact on the degradation kinetics of SON as monitored by a fluorescence 
dequenching assay performed in the presence of DNase 1. The reaction rate depended 
on the grafting position of SON and on the PEG’s molecular weight. To further 
control the release rate, PEG-SON/AON conjugates were complexed to 
poly(amidoamine) (PAMAM) dendrimers of different generations (G). Interaction 
with PAMAMs of G3 and G5 yielded monodisperse polyion complex micelles 
(PICM) with average mean sizes ranging from 70 to 100 nm. The PICM were found 
to decrease the catalytic reaction rate by 20 to 100 fold; the slowest release kinetics 
being achieved with PEG10K-SON/AON/G5 PAMAM. The PEGylated conjugates 
reported in this manuscript as well as their self-assemblies with PAMAMs, could 
prove potentially useful to confer prolonged circulating properties to nucleic acid 
drugs and release them in a sustained manner. 
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1. Introduction 
Selective inhibition of gene expression by DNA/RNA oligonucleotides (ONs) has 
been shown to be promising in the treatment of numerous diseases, including cancer 
and viral infections [1-6]. However, the clinical use of nucleic acid based drugs is 
still largely hampered by their inability to reach their site of action in sufficient 
amount. Parameters such as the chemical stability [7-10], circulation time in the 
bloodstream [11, 12], deposition at the target site and intracellular transport [13] play 
a determinant role in the in vivo activity of ONs. Unmodified phosphodiester (PD) 
ONs are seldom tested in animal models as they rapidly degrade in biological fluids 
and in cells [7-10]. The chemical instability issue has been partially solved through 
specific modifications of the ON backbone. Chemically-modified ONs can exhibit 
enhanced nuclease resistance, prolonged biological half-lives [1, 9] and greater 
affinity for the target sequence [14]. Among all ON derivatives, phosphorothioate 
(PS) analogs have been the most widely studied [12]. PS modification confers 
resistance against nuclease degradation and increases the half-life in human serum 
compared to the native ON [9, 12].  
Likewise, conjugates have also been employed to improve cellular uptake and 
resistance to nucleases. Indeed, various lipophilic molecules have been attached to 
ONs. Of these compounds, cholesterol is perhaps the best characterized. It has been 
reported to slow down ON clearance [15, 16] and enhance cellular association and 
transport [17]. Concurrently, conjugation with poly(ethylene glycol) (PEG), a 
hydrophilic and flexible polymer, can extend the circulation time of macromolecular 
drugs such as ONs and enhance their stability by creating a zone of steric hindrance 
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around the drug [18]. The polymer chain can also serve as a linker for conjugating 
targeting ligands [19]. Another means to improve the delivery of ONs consists in 
complexing them with oppositely charged molecules such as cationic lipids [19] and 
polymers [20, 21]. Of particular interest are poly(amidoamine) (PAMAM) 
dendrimers which have been shown to increase the efficacy of nucleic acid drugs [20-
25]. The limited toxicity, high transfection efficiency, and the stability of the 
ON/PAMAM complexes confer significant advantages over other non viral gene 
delivery vectors [25-27].  
In the current study, both the PEGylation and PAMAM/ON complexation 
approaches were investigated as means to release an antisense ON (AON) in a 
controlled fashion. A nuclease- sensitive PD-ON sequence (SON) was attached to 
different functionalized PEGs via an amide linkage, and hybridized to its 
complementary PS-antisense sequence as depicted in Scheme 1A. Enzymatic 
hydrolysis of the PEGylated PD-SON is expected to gradually release the active 
nuclease-resistant PS-AON. In order to further increase the delivery time, the PEG-
SON/AON duplex was further complexed to PAMAM to generate polyion complex 
micelles (PICM). PICM possess a core-shell type structure whereby the neutralized 
SON/AON/PAMAM core is stabilized by a PEG corona [28, 29]. In this case, the 
enzymatic degradation of the SON would release the AON and/or AON/PAMAM 
complex which would then be available for transfection (Scheme 1B). Different 
PEG-SONs were synthesized and characterized for their hybridization properties and 
ability to release the AON in its intact form upon SON degradation by nucleases. The 
PEG-SON/AON duplexes were subsequently complexed to PAMAMs of different 
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generations, and the resulting PICM were analyzed for their size, size distribution and 
morphology. Finally, the impact of micellization on the degradation of SON was 
examined. 
 
 
 
Scheme 1. Approaches investigated to deliver nuclease-resistant AON: (A) PEG-
conjugation and (B) Self-assembly of PEG conjugate with PAMAMs to form PICM. 
The enzymatic degradation of the nuclease-sensitive SON releases the AON either 
free or complexed to the PAMAM. 
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2. Materials 
3′-Fluorescein (FAM)-5′-aminoalkyl-PD-SON (5’-
TGAAACTCACCAGCGAGAAC) was obtained from Alpha DNA (Montreal, QC, 
Canada). Both 5′-Cy3-labeled and non-labeled PS-AON (5’-
GTTCTCGCTGGTGAGTTTCA) were supplied by Midland Certified Reagent 
Company Inc. (Midland, TX). Linear methoxy PEG succinimidyl α-methyl butanoate 
(Mw = 10,500; PDI = 1.01 and Mw = 21,000; PDI = 1.00) (PEG10K and PEG20K) and 
branched dimethyl PEG succinimidyl butanoate (Mw = 21,000; PDI = 1.02) (PEG20K-
br) were purchased from NEKTAR (Huntsville, AL). The N-hydroxysuccinimide 
(NHS) functional group was attached either to the terminal or the middle positions of 
the linear and branched PEGs, respectively. Regenerated cellulose ultrafiltration 
membranes (Ultracel, molecular weight cut-off 10,000 and 30,000) were from 
Millipore (Bedford, MA). Diethylaminoethyl Sephadex® (DEAE Sephadex®) and 
PAMAM generations 0 (G0), 1 (G1), 3 (G3) and 5 (G5) corresponding to Mw of 517, 
1,430, 6,909 and 28,826 g/mol, respectively, and heparin sodium salt from porcine 
intestinal mucosa (Mw of ~6000) were obtained from Sigma-Aldrich (Oakville, ON, 
Canada). UltraPure™ Agarose and deoxyribonuclease 1 (DNase 1, 10,000-25,000 
units/mg) were obtained from Invitrogen Canada Co. (Burlington, ON, Canada). 
Fused silica capillary was purchased from Polymicro Technologies (Phoenix, AZ). 
All chemicals used were of analytical grade. Deionized water was generated by a 
Millipore Milli-Q system (Bedford, MA).  
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3. Methods 
3.1 Preparation of the PEGylated duplexes  
3.1.1 PEGylation of the SON  
PEG-SON conjugates were prepared through the formation of an amide bond 
between the NHS-functionalized PEG and 3′-FAM-5′-aminoalkyl-SON. The reactive 
group was positioned at one extremity (PEG10K and PEG20K) or in the middle 
(PEG20K-br) of the PEG chain. The SON (100 µg, 15.1 nmol) was dissolved in 150 µL 
of phosphate buffered saline (PBS) (pH 8.0, 10 mM NaH2PO4/Na2HPO4, 100 mM 
NaCl). Then, 0.47, 0.95 and 0.93 mg of PEG10K, PEG20K and PEG20K-br (45 nmol) 
was added to the SON solution (PEG/SON 3:1 mol/mol). The reaction was carried 
out at 30°C for 24 h under continuous agitation. The PEG-SON conjugate was 
purified by passage through a DEAE Sephadex® column. The unreacted PEG was 
eluted using Tris buffer (pH 8.0, 10 mM) containing no NaCl. Then, Tris buffer 
containing 1 M NaCl was used to elute the PEG-SON. The solutions were 
concentrated under vacuum and the free SON was removed by ultrafiltration using a 
cellulose membrane of molecular weight cut-off 10,000. 
 
3.1.2 Hybridization of the PEG-SON with the AON 
Equimolar ratios of PEG-SON or SON alone and AON were mixed together 
and added to the annealing buffer (0.1 M Tris pH 8, 5x10-4 M EDTA pH 8, 1 M 
NaCl) in a 5:1 volume ratio. The mixture was heated at 80°C for 3 min, cooled down 
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to 4°C and left overnight at this temperature. The PEG-SON/AON was purified by 
ultrafiltration (cellulose membrane of molecular weight cut-off 30,000) to remove the 
free AON. The purified solutions were stored at 4°C until use.   
 
3.2 Characterization of PEG-ON duplex  
3.2.1 Determination of the quenching efficiency 
The hybridization and release of the AON was monitored by 
spectrofluorimetry as described elsewhere [30]. Quenching of the fluorescence of 
FAM-labeled SON by the Cy3-labeled-AON was exploited to follow hybridization. 
The quenching efficiency was determined by measuring the fluorescence emission of 
FAM-labeled SON or PEG-SON in hybridization buffer (150 µL, 0.02 µM) at 
excitation (λex) and emission (λem) wavelengths of 490 and 520 nm, respectively, 
using a Tecan Safire plate reader (Durham, NC), in the presence of increasing 
concentrations of quencher Cy3-AON (up to 0.2 µM). The decrease in fluorescence 
was monitored until it reached a stable plateau, and the quenching efficiencies were 
determined as follows [30]:  
⎥⎦
⎤⎢⎣
⎡
×−= 100100
SON
SON/AON
E F
FQ       Eq. 1 
where QE is the quenching efficiency, FSON/AON and FSON are the respective 
fluorescence emission intensities of the FAM-labeled SON/AON and SON, when 
they are both excited at 490 nm. 
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3.2.2 Determination of melting temperature (Tm)  
The Tm of both SON/AON and PEG-SON/AON were measured by 
monitoring the fluorescence intensity as a function of temperature. The formulations 
were heated from 20 to 95°C and fluorescence emission at 520 nm was recorded 
using an Aminco Bowman Series 2 luminescence spectrometer (Spectronic 
Instruments Inc., Rochester, NY). The Tm was taken as the midpoint of the sigmoidal 
plot representing the increase in fluorescence intensity as a function of temperature 
[31, 32].  
 
3.2.3 Agarose gel electrophoresis 
Agarose gels (2%) were prepared in Tris-acetate-EDTA buffer (0.04 M Tris, 
0.001 M EDTA-Na2.2H2O, 0.02 M glacial acetic acid, pH 8.5). The samples were 
mixed with the loading buffer (10 mM Tris-HCl, pH 7.6, 60 mM EDTA and 60% 
glycerol) at 6:1 volume ratio. Gel electrophoresis was carried out using a Horizon® 
11.14 horizontal apparatus (Montreal Biotech Inc., Montreal, QC, Canada) at 122 V 
for 30 min. Qualitative fluorescence imaging of the separated ONs was performed 
with a TyphoonTM 9410 Workstation with variable mode imager (Amersham 
Biosciences, Pittsburgh, PA). The λex/λem were set at 488/526 and 532/670 nm for 
FAM and Cy3, respectively. 
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3.2.4 Capillary electrophoresis 
Laser-induced fluorescence detection coupled to capillary electrophoresis 
(CE-LIF) was performed with a 3-mW argon ion laser having an λex of 488 nm and 
with emission monitored at 520 nm. The analysis was performed on a Beckman 
P/ACETM MDQ Capillary Electrophoresis System (Beckman Coulter, Fullerton, CA) 
with a 61.4 cm long (50.6 cm to detector) fused silica capillary (50 µm ID, 360 µm 
OD). The capillary was flushed consecutively with 0.1 M NaOH, Milli-Q water and 
background electrolyte (BGE) for a minimum replacement of ten capillary volumes 
before each injection. The injection (approx. 10 nL) of samples was performed 
hydrodynamically at 3.4 kPa for 10 s. An electrolyte plug (3.4 kPa for 5 s) was 
always injected afterward. The separation voltage was set at 25 kV. The capillary 
temperature was maintained at 25°C while the samples were kept at 4°C until 
analysis. A sodium tetraborate buffer (55 mM and pH 8.22) was used as BGE. 
Detection was achieved on-column at 8.5 cm from the outlet after removing a 5-mm 
length of the polyimide coating with a resistive heating element. The NHS-PEG was 
detected by absorbance with a conventional CE-UV/Vis instrument (model HP3DCE, 
Agilent Technologies, Palo Alto, CA) equipped with a diode-array detector, under the 
same separation conditions.  
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3.3 Preparation and characterization of the PICM 
3.3.1 Preparation of the PICM 
Purified PEG-SON/AON duplexes were mixed with aqueous solutions of 
PAMAM of different generations at increasing nitrogen-to-phosphate (N/P) ratios in 
Tris buffer (pH 7.4) to form PICM. To compare the different formulations, the N/P 
ratio was adjusted to 2:1 because the micelles formed at this ratio exhibited the 
lowest polydispersity indices (PDI). The micelle solutions were filtered on 0.2 µm-
nylon membranes prior to analysis.   
 
3.3.2 Characterization of the PICM 
The mean hydrodynamic diameter, PDI, and scattering intensity of PICM 
were measured in Tris buffer (pH 7.4) at a temperature of 25°C by dynamic light 
scattering (DLS) using a Malvern Zetasizer Nanoseries ZS (Malvern, Worcestershire, 
UK) equipped with a backscattered light detector operating at 173º. The CONTIN 
program was used to extract size distributions from the autocorrelation functions. The 
effect of NaCl (0.1-1 M) on the stability of the PICM was studied by measuring the 
scattering intensity of the micelles after each addition of salt. To compare the stability 
between the different formulations, the inflection points (IP) of the scattering 
intensity plots were calculated by fitting a sigmoidal curve on the experimental data. 
The zeta potential was determined in Tris buffer (pH 7.4) at a temperature of 25°C by 
laser Doppler anemometry with Malvern Zetasizer Nanoseries ZS. The micelles’ 
morphology was examined by atomic force microscopy (AFM).39 A drop of micelle 
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solution (2 mg/mL) was deposited on a clean mica grid and nitrogen-dried at room 
temperature just before measurement. AFM images were recorded on a Nanoscope 
IIIa DimensionTM 3100 instrument (Digital Instruments, SantaBarbara, CA). The 
imaging was performed in tapping mode with a silicon tip (tapping mode etched Si 
probes-RTESP7) operating at a 250–300 kHz resonance frequency, and a 42 N/m 
constant force. 
 
3.4 Enzymatic degradation 
SON/AON, PEG-SON/AON or PICM were incubated with DNase 1 (60 U/µg 
ON) in the presence of MgCl2 (5 mM) at 37°C. AON release was indirectly measured 
by monitoring the dequenching of FAM-labeled SON. The λex and λem were set at 
490 and 520 nm, respectively. The fluorescence intensity corresponding to 100% 
release was determined at the end of the experiment by adding excess of the DNase 1 
and letting the reaction run for another 24 h. For PICM, the previous step was 
preceded by adding an excess of heparin before the addition of DNase 1 to destabilize 
the micelles. The degraded samples were loaded onto a 2%-agarose gel and the ONs 
were visualized directly on the gel.  
The enzymatic degradation reactions were analyzed with the Michaelis-
Menten equation [33]:  
[ ]
[ ]( )SK
SVV
+
=
m
max         Eq. 2 
where [S] is the concentration of SON, V is velocity, Vmax is maximal velocity, and 
Km is the Michaelis constant. 
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4. Results and discussion 
4.1 Preparation and characterization of PEG-SON  
The first step in designing the AON formulation involved the conjugation of 
the nuclease- labile SON to one extremity (PEG10K and PEG20K) or in the middle of 
the PEG chain (PEG20K-br) (Scheme 1A). The functionalized NHS-PEG was reacted 
with 5′-aminoalkyl-SON as illustrated in Scheme 2. The PEG-SONs were 
successfully purified by anion exchange chromatography and ultrafiltration to 
remove the unconjugated PEG and SON, respectively. The conjugates’ purity was 
first established by CE-LIF, whereby analytes were separated according to their size 
and charge [34]. Figure 1 presents the electropherograms of FAM-labeled SON (a), 
PEG20K-SON (b), PEG20K-br-SON (c) and PEG10K-SON (d). These electropherograms 
confirmed that no free SON remained in the formulations after purification. As 
expected, PEGylation of the SON reduced its electrophoretic mobility, and thus 
elution time, due to an increase in the size of the anionic analyte. The fastest 
migration rate was achieved with the conjugates having the highest molecular 
weights (i.e. PEG20K-SON and PEG20K-br-SON). CE-UV/Vis also established that 
there was no free functionalized PEG in the solution (data not shown). These results 
were confirmed by agarose gel electrophoresis (Figure 2A). In this case, the 
attachment of the different PEGs retarded the migration of the SON. PEG20K-SON 
and PEG20K-br-SON were associated with the slowest migration rate. 
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Scheme 2. Synthesis of PEG–SON conjugates and hybridization with AON. In this 
example, the SON is a PD ON whereas the AON is a PS analog. 
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Figure 1. Capillary electropherograms showing the migration of SON (a), PEG20K-
SON (b), PEG20K-br-SON (c) and PEG10K-SON (d). The separation was carried out in 
borate buffer (55 mM, pH 8.22). The voltage was set at 25 kV and the capillary 
temperature was maintained at 25°C. 
 
 
 
 
  
 
 
Figure 2. Migration profiles of (A) PEG10K-SON, PEG20K-SON and PEG20K-br-SON, 
and (B) PEG10K-SON/AON, PEG20K-SON/AON and PEG20K-br-SON/AON on 2%-
agarose gel. Control SON and AON are shown in the first lane. The green and red 
spots correspond to the fluorescence emission of FAM (λex = 488 nm) and Cy3 (λex = 
532 nm), respectively. 
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4.2 Preparation and characterization of PEG-SON/AON 
The duplexes were prepared by hybridizing the Cy3-labeled AON to the 
FAM-labeled PEG-SON (Scheme 2) and isolated by ultrafiltration. The purity of the 
PEG-duplex was established by gel electrophoresis (Figure 2B). It revealed the quasi 
absence of free AON. Duplex formation was associated with a distinguishable 
decrease in fluorescence intensity of SON, which reflected the quenching of the 
FAM-SON fluorescence by Cy3-AON. Upon hybridization, FAM comes into 
intimate contact with Cy3 (Scheme 2), thereby favoring the contact mode of 
quenching (static quenching) [30]. The traces of the free AON seen in Figure 2B are 
due to the high sensitivity of the image analysis used to visualize the quenched bands. 
Duplex formation was associated with a 93 ± 2% quenching of FAM fluorescence 
(Figure 3). This property was exploited to measure the Tm of the different conjugates. 
Heating of the duplexes draws the two strands away from each other resulting in an 
increase in the fluorescence emission intensity of the FAM-SON. All PEG-
SON/AON displayed a Tm of 64°C, similar to that of SON/AON, suggesting that the 
terminal or central attachment of SON to PEG did not affect its hybridizing capacity, 
at least under well controlled in vitro hybridization conditions. These findings 
corroborate those of Jeong et al. who demonstrated that the attachment of PEG2K to 
the AON did not sterically hindered duplex formation with the complementary SON 
sequence [31, 35].  
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Figure 3. Emission spectrum of FAM-labeled SON prior to (●) and after 
hybridization with Cy3-labeled AON (▲) (λex = 490 nm). 
 
4.3 Preparation and characterization of the PICM 
The electrostatic complexation of PEG-SON/AON to G3 and G5 PAMAMs, 
triggered the self-assembly of the duplexes into monodisperse PICM (Scheme 1, 
Table 1), where the PEG chains sterically stabilize the neutralized 
SON/AON/PAMAM core [31, 35, 36]. Comparatively, the addition of G0 and G1 
PAMAMs did not induce micelle formation (data not shown). The absence of 
micellization with the low Mw PAMAMs can be explained by insufficient 
cooperativity in the electrostatic interactions (4 and 8 surface amine groups for G0 
and G1 vs. 32 and 128 for G3 and G5, respectively). The multimeric binding through 
cooperative effects facilitates multiple simultaneous interactions with other molecules 
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resulting in an increase of binding affinity [37, 38]. Chen et al. [37] proposed a 
binding model for plasmid DNA-dendrimer complexes where the cooperative effect 
of high Mw PAMAMs (G7) allowed DNA wrapping. Conversely, “earlier generation” 
dendrimers (G2) were not able to form efficient complexes with the DNA.  
 
Table 1. Characteristics of the ternary PICM prepared at an N/P 2:1 ratio; 
mean ± SD (n=3). 
Formulation PAMAMa Diameter (nm) PDI ± SD Zeta potential ± SD
(mV) 
IP (M)b 
PEG10K-PICM G3 68 0.06±0.02 -1.8±0.3 0.31±0.01 
PEG20K-PICM G3 88 0.09±0.02 -3.2±1.5 0.23±0.01 
PEG20K-br-PICM G3 89 0.14±0.04 3.0±1.6 0.20±0.01 
PEG10K-PICM G5 88 0.08±0.05 -1.7±0.3 0.48±0.01 
PEG20K-PICM G5 93 0.07±0.04 0.5±0.6 0.37±0.01 
PEG20K-br-PICM G5 97 0.11±0.04 0.6±2.9 0.37±0.01 
aG3 = 6,909 g/mol, G5 = 28,826 g/mol. 
bInflection point of sigmoidal plot representing scattering intensity versus NaCl 
concentration (Fig. 5). 
 
In the presence of G3 or G5 PAMAM, and at an optimal N/P ratio of 2:1, 
PICM with mean hydrodynamic diameters ranging from 68 to 97 nm, a narrow size 
distribution (PDI<0.15) and nearly neutral surface charge (-1.7 – 3.0 mV) were 
obtained. Size increased slightly with both PEG (10 vs. 20 K) and PAMAM (G3 vs. 
G5) molecular weights. No significant differences were observed between PEG20K- 
and PEG20K-br-PICM in terms of size or PDI. Figure 4 shows the AFM images of 
PICM formed between PEG20K-SON/AON and G5 PAMAM on a mica surface. The 
particles were relatively spherical; however, the average diameter was 139 ± 11 nm, 
which is about 1.5 times that measured by DLS (Table 1). The difference found here 
could be due to flattening of the PICM on the mica surface during the drying process 
[41]. This hypothesis is supported by the fact that the mica-deposited micelles had a 
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thickness of only 55 ± 5 nm. Dufresne et al. [39] have studied the morphology of the 
PEG-b-P(2-(N-amino)ethyl methacrylate)-heparin PICM by AFM. These micelles 
were smaller (25 nm) and relatively spherical. There was also a good correlation 
between the sizes measured by AFM and DLS. Similarly, Jeong et al. [35] have 
measured the size of the PEG2K-AON/polyethylenimine (branched, Mw = 25,000) 
PICM by both DLS and AFM. The two methods yielded comparable diameters, 
while the AFM analysis also demonstrated that the PICM were spherical. In the 
current study, the observed flattening of the micelles upon drying might be explained 
by a less dense micelle core due to a less efficient compaction of the oppositely 
charged polyions. 
  
     
Figure 4. AFM image of PEG20K-SON/AON/G5 PAMAM based PICM. 
 
It is known that the stability of PICM is dependent on the ionic strength of the 
surrounding medium [39]. Chen et al. [37] found that the binding constant between 
PAMAM and polynucleotides at lower ionic strength is higher which is in agreement 
with electrostatic contributions to the binding. Salts can compete with the ON-
PAMAM interactions, thereby destabilizing the PICM [37, 38]. The influence of 
NaCl concentration on the stability of micelles was therefore studied by measuring 
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the scattered light intensity (Figure 5). Apart from the PICM prepared with PEG20K or 
PEG20K-br and G3 PAMAM, most micelle formulations were stable up to an NaCl 
concentration of about 0.2 M (>80% of initial scattering intensity retained), which is 
above the physiologic isotonic conditions (0.15 M). The inflection point (IP) of the 
scattering intensity versus salt concentration curves was calculated to compare the 
stability among the different micellar systems (Table 1). The PICM prepared with G5 
PAMAM were more resistant towards dissociation than those containing G3 
PAMAM (closed vs. empty symbols, Figure 5) This reflects the enhanced 
cooperative interaction afforded by the greater surface amine content of G5 
PAMAM. Among the different PEG-SON/AON conjugates, the greater stability 
against destabilization was afforded by the PICM prepared with the PEG10K 
derivative (higher IP values, Table 1). These findings can be rationalized in terms of 
micelle thermodynamics. Owing to its shorter PEG chain, the PEG10K-
SON/AON/PAMAM complexes self-assemble at lower concentrations than the 
PEG20K counterparts (unpublished observations).  
 208
0.0 0.2 0.4 0.6 0.8 1.0
0
20
40
60
80
100
120
Sc
at
te
rin
g 
in
te
ns
ity
 (%
)
NaCl (M)
(A)
 
0.0 0.2 0.4 0.6 0.8 1.0
0
20
40
60
80
100
120
Sc
at
te
rin
g 
in
te
ns
ity
 (%
)
NaCl (M)
(B)
 
0.0 0.2 0.4 0.6 0.8 1.0
0
20
40
60
80
100
120
Sc
at
te
rin
g 
in
te
ns
ity
 (%
)
NaCl (M)
(C)
 
Figure 5. Effect of ionic strength on scattering intensity of PEG10K- (A), PEG20K- (B) 
and PEG20K-br-SON/AON/PAMAM (C) based PICM prepared with G3 (○) or G5 (●) 
PAMAM. Mean ± SD (n=3). 
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4.4 Enzymatic degradation 
 The main objective of this project was to design a delivery system that 
releases a nuclease-stable PS-AON upon the enzymatic degradation of the 
complementary PD-SON sequence. Accordingly, the AON release from PEG-
SON/AON systems alone as well as complexed to G3/G5 PAMAMs (PICM) was 
investigated in the presence of the endonuclease DNase 1 (Figures 6-8, Table 2). The 
degradation of SON was first monitored by measuring the dequenching of FAM 
fluorescence which occurs upon the dissociation of the duplex. As shown in Figure 6, 
the SON in unconjugated SON/AON was rapidly degraded by DNase 1 (>90% of 
dequenched fluorescence after 5 min incubation). The PEG-SON/AON conjugates 
appeared more resistant, although 100% of dequenching was achieved after 20 min. 
The protective effect of PEGylation could be ranked as follows PEG20K-
br>PEG20K>PEG10K. The kinetic parameters were calculated by fitting the data to the 
Michaelis-Menten equations (Table 2). PEGylation of the SON brought about a 50% 
decrease in Vmax. Surprisingly, the Km value remained virtually unchanged, implying 
that PEGylation did not influence the endonuclease affinity for SON (or at least for 
the SON nucleotides located away from the PEG chains). However, PEGylation 
slowed down the enzyme catalytic activity. PEG conjugation has been previously 
shown to confer resistance against the attack of nucleases. For example, Lee et al. 
[40] reported that siRNA was completely degraded after the RNase treatment for 15 
min, whereas the siRNA-PEG5K conjugate maintained more than 40% of intact 
siRNA. 
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Table 2. Michaelis-Menten kinetic parameters for SON degradation by DNase 1a 
Formulation Vmax (nM min-1) Km (nM) Relative Vmax 
SON/AON 8.15 16.4 1 
PEG10K-SON/AON 5.49 16.4 0.670 
PEG20K-SON/AON 4.72 16.4 0.580 
PEG20K-br-SON/AON 4.01 16.4 0.490 
PEG10K-SON/AON/G3 0.39 16.3 0.048 
PEG20K-SON/AON/G3 0.43 16.3 0.053 
PEG20K-br-SON/AON/G3 0.47 16.4 0.057 
PEG10K-SON/AON/G5 0.11 16.2 0.014 
PEG20K-SON/AON/G5 0.19 17.3 0.022 
PEG20K-br-SON/AON/G5 0.20 16.2 0.025 
aThe enzyme concentration used in all experiments was set at 0.049 nM. G3 and G5 
refer to the PAMAM used. 
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Figure 6. Dequenching of FAM-labeled SON fluorescence following the incubation 
with DNase 1 (60 U/µg ON, 37°C, pH 7.4) with SON/AON (■), PEG10K- (▲), 
PEG20K- (∆) and PEG20K-br-SON/AON (○). Mean ± SD (n=3). 
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(A) FAM-detection                     (B) Cy3-detection 
                 
Figure 7. Migration profiles of PEG10K-, PEG20K- and PEG20K-br-SON/AON on 2%-
agarose gel after degradation by DNase 1 (60 U/µg ON, 1 h, 37°C, pH 7.4) and of 
intact SON and AON. The gel was scanned for FAM-labeled SON (λex = 488 nm) 
(A) and Cy3-labeled AON (λex = 532 nm) (B) detection. The empty white box 
corresponds to the original bands of the non-degraded PEG-SON/AON duplexes. 
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Figure 8. Dequenching of FAM-labeled SON fluorescence following the incubation 
with DNase 1 (60 U/µg ON, 37°C, pH 7.4) of PEG10K- (triangles), PEG20K- (squares), 
PEG20K-br- (circles) SON/AON/PAMAM based PICM prepared with G3 (open 
symbols) or G5 (closed symbols) PAMAM. Mean ± SD (n=3). 
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To confirm that the dequenching of the FAM fluorescence was associated 
with the degradation of SON and the release of intact AON, the digests were 
analyzed by agarose gel electrophoresis (Figure 7). The exposure of SON/AON to 
DNase 1 resulted in the degradation of the SON as shown by the difference in FAM-
SON migration compared to the control SON (panel A). Conversely, the AON from 
the DNase 1-exposed SON/AON migrated to the same level as the control AON 
(panel B), suggesting the release of the intact antisense strand. With respect to the 
PEG-SON/AON conjugates, the disappearance of the signal at the bottom of the gel 
(box area, panels A-B) confirmed the cleavage of the DNA strands from PEG. As for 
SON/AON, this was accompanied by the release of degraded SON (panel A) and 
intact AON (panel B). 
As illustrated in Figure 8, the release rate of the AON could be further slowed 
down by complexing PEG-SON/AON conjugates to G3/G5 PAMAMs. Indeed, a 
reduction in Vmax of up to ~20-100 fold was achieved with the PICM. As with the 
uncomplexed PEG-SON/AON conjugates, Km values remained unchanged. Given 
that the DNA is sequestered in the core of the PICM (Scheme 1B), it is unlikely that 
the endonuclease was able to access the entrapped SON with the same affinity as the 
uncomplexed strand. As PICM are in dynamic equilibrium with free unimers [39], 
the enzymatic attack most probably occurred on the unimers (the dotted arrows in 
Scheme 1B). The degradation of unimers (PEG-SON/AON and/or non-micellized 
PEG-SON/AON/PAMAM) then shifted the equilibrium towards the unimer side, 
progressively depleting the micelle population. Generally, G3 PAMAM yielded 
PICM with faster release rates than G5 PAMAM (Table 2). The greater protection 
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against enzymatic attack was afforded by the PICM prepared with the PEG10K 
derivative which might be owing to the fact that these micelles self-assemble at lower 
concentration making the unimers less available for reacting with DNase 1. These 
findings are in accordance with the NaCl-stability assays which revealed the greater 
stability of PEG10K- and/or G5 PAMAM micelles. 
 
5. Conclusion 
Conjugates comprised of PEG and a nuclease-sensitive PD-SON were 
prepared and hybridized with a nuclease-resistant PS-AON. PEGylation did not 
change the in vitro hybridization capacity of the SON for its complementary 
sequence. The PEGylated derivatives released the AON upon degradation of SON. 
The cleavage rate was slowed down by about 50-65% versus the SON/AON duplex. 
Complexation of the PEG-SON/AON with G3/G5 PAMAMs yielded the formation 
of monodisperse PICM with average diameters in the 70-100 nm range, depending on 
the PAMAM generation and PEG molecular weights. Compared to the SON/AON 
duplex, the PICM slowed down SON degradation Vmax by about 20-100 fold. The 
reaction rates were influenced by both the PEG and PICM molecular weights. The 
PEGylated conjugates reported in this manuscript as well as their complexes with 
PAMAMs could prove potentially useful to confer prolonged circulating properties to 
nucleic acid drugs and release them in a sustained manner. 
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Abstract 
In this study, novel pH-responsive polyion complex micelles (PICMs) were 
developed for the efficient delivery of nucleic acid drugs such as antisense 
oligonucleotide (AON) and short interfering RNA (siRNA). The PICMs consisted of 
a poly(amidoamine) (PAMAM) dendrimer-nucleic acid core and a detachable 
poly(ethylene glycol)-block-poly(propyl methacrylate-co-methacrylic acid) (PEG-b-
P(PrMA-co-MAA)) shell. The micelles displayed a mean hydrodynamic diameters 
ranging from 50 to 70 nm, a narrow size distribution and a nearly neutral surface 
charge. They could be lyophilized without any additive and stored in dried form. 
Upon redispersion in water, no change in complexation efficiency or colloidal 
properties was observed. Entry of the micelles into cancers cells was mediated by a 
monoclonal antibody fragment positioned at the extremity of the PEG segment via a 
disulfide linkage. Upon cellular uptake and protonation of the MAA units in the 
acidic endosomal environment, the micelles lost their corona, thereby exposing their 
positively-charged endosomolytic PAMAM/nucleic acid core. When these pH-
responsive targeted-PICMs were loaded with AON or siRNAs that targeted the 
oncoprotein Bcl-2, they exhibited a greater transfection activity than non-targeted 
PICMs or commercial PAMAM dendrimers. Moreover, their non specific 
cytotoxicity was lower than that of PAMAM. The pH-responsive PICMs reported 
here appear as promising carriers for the delivery of nucleic acids. 
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1. Introduction 
The use of nucleic acids such as antisense oligonucleotides (AON) and short 
interfering RNA (siRNA), which are capable of selectively suppressing genes 
involved in pathological processes is an elegant strategy to tackle diseases such as 
cancer and viral infections.[1-5] Unfortunately, the efficacy of oligonucleotide-based 
drugs is still largely hampered by their inability to reach their site of action in 
sufficient amounts. Parameters such as systemic circulation time, deposition at the 
target site and intracellular transport play a pivotal role in their in vivo activity.[6-8] 
Unmodified nucleic acids have limited cellular uptake due to their polyanionic 
nature. In addition, they are rapidly cleared from the body because of their 
degradation by nucleases in the blood and rapid renal excretion. The chemical 
instability and fast elimination issues can be partly overcome through specific 
modifications of the oligonucleotide backbone[9] but achieving high intracellular 
concentrations solely through chemistry is hardly achievable. Of particular 
importance is the fate of the nucleic acid after cellular internalization. The 
intracellular bioavailability of oligonucleotides is poor due to their sequestration in 
endosomal/lysosomal compartments. Membrane-destabilizing agents are therefore 
used to permit the escape of biomolecules from endosomes before they reach the 
lysosomes, where they are otherwise extensively degraded.[10, 11]  
An approach to enhance the stability of nucleic acids but also to improve their 
deposition at the target site consists of loading them into polymeric nanocarriers such 
as polyion complex micelles (PICMs).[12, 13] PICMs decorated with a targeting ligand 
are conceptually one of the best vehicles for the delivery of nucleic acids.[14, 15] 
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PICMs result from cooperative electrostatic interactions between the AON or siRNA 
and one or several charged polymers presenting a water-soluble nonionic segment. 
Upon complexation, the charge-compensated nucleic acid/polymeric chains self-
assemble into a micellar core while the hydrophilic segments form a protecting 
corona. Entrapment of nucleic acids in such carriers has been shown to protect them 
from enzymatic degradation while allowing a greater proportion of intact drug to 
reach the target cell.[16-18]  
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Scheme 1. a) Approach investigated to deliver AON or siRNA: self-assembly of 
PEG115-b-P(PrMA-co-MAA)/Fab'-PEG145-b-P(PrMA-co-MAA) and AON or siRNA 
with PAMAM to form PICM. b) Proposed mechanism by which the PICM can 
trigger the endosomal destabilization and facilitate endosomal escape of nucleic 
acids. 
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In this work, a PICM system combining several of the essential attributes 
required for the efficient delivery of polynucleotides into cancer cells is described. 
The PICMs were designed to exhibit long shelf-life, protection against premature 
degradation by nucleases, low non-specific cytotoxicity, minimal interactions with 
blood proteins, efficient uptake by the tumoral cell and high intracellular 
bioavailability for nucleic acid cargo. They consisted of a poly(amidoamine) 
(PAMAM) dendrimer-nucleic acid core and a poly(ethylene glycol)-block-
poly(propyl methacrylate-co-methacrylic acid) (PEG-b-P(PrMA-co-MAA)) shell[19, 
20] (Scheme 1a). Generally, dendrimers of low molecular weights (generation (G) 5 or 
less) have low toxicity and are subjected to rapid renal clearance.[21] However, those 
with cationic surface charge are particularly cleared from the circulation by the 
liver.[21-23] At physiological pH (7.4), the shell and the core are linked through 
electrostatic interactions between positive charges of PAMAM and deprotonated 
MAA moieties of PEG-b-P(PrMA-co-MAA). Entry in the cell via receptor-mediated 
endocytosis is mediated by a model targeting ligand (fragment antigen binding 
(Fab')) positioned at the extremity of the PEG segment. Upon cellular uptake and 
protonation of the MAA units in the acidic endosomal environment, the micelles lose 
their corona, thereby exposing their positively-charged PAMAM/nucleic acid core 
(Scheme 1b). PAMAM dendrimers have been shown to destabilize the endosomal 
membrane through their interaction with the latter and/or via the proton sponge 
effect.[24, 25] We show here that when these pH-responsive Fab'-PICMs are loaded 
with AON or siRNAs that target the oncoprotein Bcl-2,[26] they exhibit a greater 
transfection activity than non-targeted PICMs or PAMAM dendrimers. 
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2. Results and discussion 
PEG-b-P(PrMA-co-MAA) were initially developed to prepare pH-sensitive 
polymeric micelles for oral drug delivery.[19, 20] The PrMA units were copolymerized 
with MAA to prevent extensive H-bonding between the later and PEG block in 
aqueous media. It was discovered that PEG-b-P(PrMA-co-MAA) could also interact 
with conventional PAMAM dendrimers to form core-shell type PICMs. More 
importantly, these PICMs accommodated nucleic acids in their cores. Two different 
MAA copolymers, i.e. PEG115-b-P(PrMA28-co-MAA53) and PEG115-b-P(PrMA51-co-
MAA33), were synthesized (supplementary Scheme S1 and Table S1) and 
investigated for the preparation of pH-responsive PICMs. In the presence of G3 or 
G5 PAMAM, and at an optimal nitrogen-to-(phosphate + carboxylate) (N/(P + COO-
)) molar ratio of 1.5, PICMs with mean hydrodynamic diameters ranging from 50 to 
70 nm, narrow size distribution (polydispersity indices (PI) < 0.2) and nearly neutral 
surface charge (1–10 mV) were obtained (supplementary Table S2). Size and PI 
increased slightly with the PAMAM generation (G3 vs. G5) and when the siRNA 
duplex was used instead of the single stranded AON. The efficient complexation of 
both MAA copolymer and nucleic acids with the PAMAM dendrimer was assessed 
by gel electrophoresis. Figure 1 shows the migration of PEG115-b-P(PrMA28-co-
MAA53) and siRNA alone (lanes 1 and 2), and after PICM formation (lanes 3 and 4) 
using G5 PAMAM. By comparing the PICMs lanes to that of the free components, 
one can see that the nucleic acid and PEG115-b-P(PrMA28-co-MAA53) were 
quantitatively incorporated into the micelles. Entrapment was less efficient when 
PEG115-b-P(PrMA51-co-MAA33) or G3 PAMAM were used (data not shown), 
 225
possibly due to reduced cooperative electrostatic interactions.[17] Interestingly, these 
PICMs could be freeze-dried and easily redispersed without any change in 
complexation efficiency (Fig. 1, lane 4 vs. 3), size, PI and zeta-potential 
(supplementary Table S2). This remarkable resistance to aggregation during the 
freeze-drying steps in the absence of a lyoprotectant[27] or chemical modification (i.e. 
core crosslinking),[28] might be attributed to a high PEG density in the corona.[29]  
 
 
 
 
Figure 1. Gel electrophoresis of PICM prepared at N/(P + COO-) molar ratio of 1.5 
using PEG115-b-P(PrMA28-co-MAA53), siRNA and G5 PAMAM before and after 
freeze-drying. First 2 lanes represent PEG115-b-P(PrMA28-co-MAA53) and siRNA 
controls. The white inset corresponds to the same gel but following iodine staining to 
reveal PEG. 
 
In order to study the pH-dependent complexation of PEG-b-P(PrMA-co-
MAA) to the PAMAM-nucleic acid core, the zeta potential and light scattering 
intensity of the PICMs were monitored as a function of pH (Fig. 2). At pH 7.0 and 
above, micelle formation occurred and was characterized by a strong intensity of 
scattered light and a zeta potential close to neutrality. The acidification of the external 
medium resulted in a drastic decrease of scattered light and an increase in zeta 
potential value (Fig. 2a). These data indirectly suggest that upon protonation, PEG-b-
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P(PrMA-co-MAA) dissociated from the PAMAM/nucleic acid core, leaving excess 
positive charges available to interact with the endosomal membrane (Fig. 2b). 
 
 
 
 
 
 
 
Figure 2. a) Effect of pH on scattering intensity (●) and zeta-potential (▲) of 
PEG115-b-(PrMA28-co-MAA53)/AON/G5 PAMAM based PICM. Mean ± SD (n=3). 
b) Proposed mechanism of shell dissociation. 
 
The protection against nucleic acid degradation by nucleases afforded by the 
PICMs was studied by a fluorescence dequenching assay using dually labeled 
siRNA, and by gel electrophoresis. The complete degradation of siRNA in fetal 
bovine serum (FBS) was accompanied by a strong increase in fluorescence intensity 
of the fluorescein probe and the disappearance of the band corresponding to intact 
2 3 4 5 6 7 8 9 10 11
0
20
40
60
80
100
120
140
0
10
20
30
40
50
Sc
at
te
rin
g 
in
te
ns
ity
 (%
)
pH
 Zeta-potential (m
V)
a)      
 227
siRNA (supplementary Fig. S1). The stability of the siRNA, either free, complexed 
solely to PAMAM or entrapped within the PICMs, was monitored in 50% FBS as a 
function of time. Free siRNA was rapidly degraded in serum (>90% after 1-h 
incubation). The siRNA/G3 and G5 PAMAM complexes were more resistant (70 and 
45% degradation after 1 h-incubation, respectively). The PICMs were extremely 
more resistant with less than 30% of the siRNA degraded after 1 h (Fig. 3). The 
enzymatic attack most probably occurred on the unimers and/or non-micellized 
PAMAM/siRNA as access to the micelle core was previously shown to be highly 
restricted.[17] The greatest protection against enzymatic attack was afforded by the 
PICMs prepared with G5 PAMAM and PEG115-b-P(PrMA28-co-MAA53), probably 
due to enhanced cooperative interactions between the nucleic acids and the charged 
polymers. These findings are in accordance with the gel electrophoresis experiments 
which revealed the presence of larger fraction of free nucleic acids for micelles 
formed with G3 PAMAM and/or PEG115-b-P(PrMA51-co-MAA33) (data not shown). 
The stability of the nucleic acid could be further improved by increasing the N/(P + 
COO-) molar ratio from 1.5 to 3. In this case only 12% of the siRNA was degraded 
after 1-h incubation with 100% serum (supplementary Fig. S2).[30]    
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Figure 3. siRNA degradation following incubation with 50% FBS (10 µg/mL 
siRNA, 37°C, pH 7.4) of free siRNA (◊), siRNA complexed with G3 (□) or G5 (■) 
PAMAM, PEG115-b-P(PrMA51-co-MAA33) (triangles) and PEG115-b-P(PrMA28-co-
MAA53) (circles) PICM prepared with G3 (open symbols) or G5 (closed symbols) 
PAMAM. Mean ± SD (n=3).  
 
 
The toxicity of the polymers and PICMs was then investigated on prostate 
cancer (PC-3) cells using MTT assay. Figure 4 presents the cytotoxicity data 
generated with free PEG115-b-P(PrMA28-co-MAA53), G5 PAMAM and PICMs 
resulting from the complexation of these two polymers. PEG115-b-P(PrMA28-co-
MAA53) exhibited no measurable cytotoxicity up to 0.5 mg/mL. In contrast, G5 
PAMAM was appreciably more toxic above 0.01 mg/mL. A marked decrease in the 
cytotoxicity of PAMAM was noted when the dendrimer was complexed with PEG115-
b-P(PrMA28-co-MAA53) to form PICMs. This decrease in cytotoxicity could be 
explained by the neutralization of the positive charges at the dendrimer surface by the 
PEG chains.[31] Due to its high complexation efficacy, greater stability against 
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enzymatic degradation and low cytotoxicity, the PEG115-b-P(PrMA28-co-MAA53)/G5 
PAMAM combination was selected for the cellular uptake experiments and 
transfection assays (vide infra). 
 
 
Figure 4. Cell viability of PC-3 cells exposed to PEG115-b-P(PrMA28-co-MAA53) 
and G5 PAMAM (0.01-0.5 mg/mL) and PEG115-b-P(PrMA28-co-MAA53)/G5 
PAMAM PICM (N/COO- molar ratio of 1.5). Mean ± SD (n=3).  
 
In order to trigger the internalization of the PICMs, the later were decorated with 
anti CD71 Fab' which targets the transferrin receptors, that are overexpressed by 
tumor cells.[32] The antibody fragment was linked to PEG-b-P(PrMA-co-MAA) 
through disulfide coupling at the PEG extremity (supplementary scheme S1). PEG of 
longer chain length (145 vs. 115 repeat units, supplementary Table S1) was used to 
attach the Fab' to ensure its availability on the micelle surface for efficient binding to 
the receptors. The micelle size and zeta-potential were not changed significantly after 
decoration with the targeting moiety incorporated at 2 mol% (data not shown). The 
cellular uptake and intracellular trafficking of the delivered nucleic acid were 
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examined by flow cytometry and laser scanning confocal microscopy (LSCM), 
respectively (Fig. 5). The free nucleic acid showed limited uptake (Fig. 5a and 
supplementary Fig. S3). As expected, the PAMAM/nucleic acid complexes interacted 
avidly with the cell membrane, as revealed by the strong cell-associated fluorescence. 
However, a large fraction of AON was localized in acidic compartments (Fig. 5b) as 
indicated by the yellow color in the merged fluorescence image (Panel A-iii) of the 
LysoTracker (green, Panel A-i) and the Cy3-labeled oligonucleotide (red, Panel A-ii). 
Decoration of the PICMs with the anti CD71 Fab' increased the uptake compared to 
non-targeted micelles (Fig. 5a). The uptake was reduced when the cells were 
preincubated with free CD71 antibody (supplementary Fig. S4), confirming the 
specificity of the binding. Interestingly, although targeted PICMs were taken up to a 
lesser extent than PAMAM/nucleic acid complexes, the oligonucleotide was able to 
escape more from the lysosomal pathway as indicated by the bright red fluorescence 
of the cells (Fig. 5b, Panel B-ii). These cells also exhibited a decreased green 
fluorescence suggesting some leakage from acidic organelles (Panel B-iii).[33, 34]  
The formulation of AON or siRNA in Fab'-PICMs prepared with G5 PAMAM 
and PEG115-b-P(PrMA28-co-MAA53) was associated to an increased 
antisense/silencing activity against the oncoprotein Bcl-2 in PC-3 cells vs. the nucleic 
acids in their free form, complexed to PAMAM or incorporated into non targeted 
micelles (Fig. 5c). In addition, the targeted micelles showed higher activity than 
lipofectamine (supplementary Fig. S5). Preincubation with excess free antibody 
(saturation of CD71 receptors) or bafilomycin (inhibition of endosomal acidification) 
greatly reduced the transfection efficiency. The reduced downregulation after 
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preincubation with bafilomycin suggests that the endosomal acidification played a 
pivotal role, possibly by releasing the positively charged PAMAM/nucleic acid 
complex which became available for endosomal destabilization. As shown in Figure 
5c, the PICM activity was only slightly reduced in the presence of serum in the 
incubation medium. This effect of serum could be ascribed to some degradation of 
the nucleic acid as the PEGylated shell should prevent non-specific interactions with 
blood proteins.[14] Targeted micelles prepared at N/(P + COO-) of 3 were able to 
efficiently downregulate the Bcl-2 oncoprotein in the presence of 50% FBS. On the 
contrary, in the presence of the same serum concentration, there was no Bcl-2 
inhibition by AON or siRNA that complexed to lipofectamine (supplementary Fig. 
S5). As opposed to G5 PAMAM, Fab'-PICMs prepared with G3 PAMAM were 
inefficient at downregulating Bcl-2 (Fig. 5c). The lower transfection efficiency of G3 
PAMAM-based PICM can be partially attributed to the reduced entrapment 
efficiency and enzymatic stability of these micelles. The enhanced activity of 
AON/siRNA when formulated in G5 PAMAM-based Fab'-PICMs can be rationalized 
in terms of efficient cellular uptake and greater escape from the endosomal 
compartment. At the endosomal pH (~5), the dissociation of the micelle corona 
produced > 10-fold increase in the N/P ratio, leaving positively charged 
PAMAM/nucleic acids complexes available for interacting with the membrane. 
Moreover, the protonated PEG-b-P(PrMA-co-MAA) may also have contributed to 
the release of the nucleic acid in the cytoplasm, as it has been previously shown that 
MAA copolymers possess endosomolytic properties.[35]   
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b) 
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Figure 5. a) Flow cytometry experiment showing the fluorescence intensity of PC-3 
cells incubated with Cy3-labeled AON (400 nM) free, complexed to G5 PAMAM or 
entrapped in plain or Fab'-PEG115-b-P(PrMA28-co-MAA53)/G5 PAMAM PICM 
(N/(P + COO-) molar ratio of 1.5). b) Confocal microscopy images of PC-3 cells after 
treatment with Cy3-AON (red, panel ii) complexed to (A) G5 PAMAM or (B) Fab'-
PEG115-b-P(PrMA28-co-MAA53)/G5 PAMAM PICM. Endosomes/lysosomes were 
stained by LysoTracker (green, panel i), and the images were merged in panel iii. c) 
Bcl-2 gene silencing in PC-3 cells transfected for 5 h with AON (400 nM) or siRNA 
(25 nM) complexed to G5 PAMAM or entrapped in plain or Fab'-PEG115-b-
P(PrMA28-co-MAA53)/G5 or G3 PAMAM PICM. Control cells were treated with 
medium alone. The effect of preincubation with 10% FBS, free CD71 or bafilomycin 
is indicated on the graph. The inset is representative of immunoreactive Bcl-2 and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as determined by 
immunoblotting. The molar ratio of the Fab'-PEG145-b-P(PrMA27-co-MAA58) vs. 
PEG115-b-P(PrMA28-co-MAA53) is 2% for all the experiments. The results are 
representative of several independent experiments. 
 
 
 
 
 234
In conclusion, stable PICMs were prepared and found to efficiently protect 
nucleic acids against enzymatic degradation. The long-term stability of the 
formulations is also guaranteed by the fact that these micelles could be lyophilized 
without any additive and thus stored in dried form. pH-triggered deshielding in the 
acidic organelles was found to unmask the positive charge of the PAMAM/nucleic 
complexes and facilitate the diffusion of the nucleic acids into the cytoplasm. Herein, 
the exposure of the membrane destabilizing components does not rely on the 
chemical hydrolysis of a pH-sensitive bond.[11] This approach would be preferred to 
ensure fast dissociation kinetics at acidic pH and higher chemical integrity of the 
construct. The pH-responsive targeted PICMs were endowed with improved 
transfection efficacy compared to either non-targeted micelles or PAMAM 
complexes. This in vitro proof of concept constitutes our first step toward the 
development of clinically viable systemic delivery systems for nucleic acid drugs.  
 
3. Experimental Section 
Synthesis of PEG115-b-(PrMA-co-MAA) and Fab'-S-S-PEG145-b-(PrMA27-
co-MAA53) (supplementary sections S1 and S2, Table S1 and Scheme S1): PEG 
macroinitiator, i.e. α-(2-bromoisobutyrylate bromide)-ω-methyl PEG, was 
synthesized using methoxy-PEG (Mn = 5000) and 2-bromoisobutyryl bromide [32]. 
The polymerization reactions were carried out by atom transfer radical 
polymerization (ATRP) of PrMA and tert-butyl methacrylate (tBMA) as reported 
previously [33]. For the targeted copolymer, tBu-S-PEG145-OH was synthesized and 
converted to ATRP macroinitiator by reaction with 2-bromoisobutyryl bromide as 
 235
reported previously [34]. The unprotected copolymer was dissolved in a reductive 
solution (10 mg/mL, DTT in phosphate-buffered saline (PBS) pH 7.4) and recovered 
by passage through a Sephadex G25 column (GE healthcare, Piscataway, NJ). 
Fractions containing the copolymer were added directly to an aldrithiol solution in 
methanol and the reaction was stirred overnight. The solvent was evaporated and the 
copolymer was purified by passage through a Sephadex G25 column and recovered 
by freeze-drying (the yield of functionalization ~90%). Antitransferrin antibody was 
digested to produce (Fab')2 antibody fragments according to (Fab')2 preparation kit 
(Pierce, Rockford, IL). The Pyr-S-S-PEG copolymer was then added to the freshly 
reduced Fab' (1.4-fold excess) and the coupling reaction was carried out overnight. 
The excess antibody was removed by passage through an anion exchange column 
(Hitrap, GE healthcare).  
Preparation and characterization of pH-sensitive PICM (supplementary S3 
and S4): PEG115-b-P(PrMA-co-MAA) and either AON or siRNA were mixed with 
G3 or G5 PAMAM at increasing N/(P + COO-) molar ratio in Tris buffer (10 mM, 
pH 7.4) to form PICM. The mean hydrodynamic diameter, PI, and scattering 
intensity of PICM were measured by dynamic light scattering (DLS) using a Malvern 
Zetasizer Nanoseries ZS. PICM prepared with fluorescein-labeled siRNA (50 mol%) 
were used for the gel electrophoresis assays [35]. The stability of siRNA in serum 
was monitored by spectrofluorimetry as described elsewhere for similar systems [36].  
Evaluation of cellular toxicity by MTT assay (supplementary S5): PEG115-b-
P(PrMA28-co-MAA53), G5 PAMAM or PICM were added at increasing 
concentrations to PC-3 cells for 4 h. After a total incubation period of 72-h, the cells 
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were exposed to 10 µL/well of tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) solution for 3.5 h. Then, 100 µL of sodium 
dodecyl sulfate solution was added to each well and the absorbance was read 24 h 
later at 570 nm using a Tecan Safire plate reader.  
Flow cytometry and intracellular trafficking (supplementary S5): The final 
concentration of the AON (labeled with Cy3) in the different formulations was 
adjusted to 400 nM. The plate was then incubated for 2 h under mild agitation at 
37°C. Cells were then washed three times with cold PBS, fixed with 1% 
formaldehyde and resuspended in 0.5 mL PBS. Red fluorescence distributions for 
10,000 cells was recorded at the appropriate wavelength with a FacsCalibur flow 
cytometer (Becton Dickinson, San Jose, CA) at a laser excitation wavelength of 530 
nm. For intracellular trafficking, the formulations were incubated with the PC-3 cells 
for 4 h. Two hours before the end of the incubation period, LysoTracker green was 
added to each well at a final concentration of 200 nM. Cells were examined by 
LSCM under a Leica DMIRBE inverted microscope coupled with a Leica TCS SP 
confocal system (Leica Microsystems, Heidelberg, Germany).  
Assessment of the antisense activity: The transfection of the PC-3 cells was 
carried out as reported elsewhere (See section S5 in the supporting information for 
detailed method) [22].   
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Supporting information 
 
S1. NMR analysis and molecular weight determination  
1H NMR spectra were recorded on a Bruker AMX 300 spectrometer (Bruker 
Spectrospin, Milton, ON, Canada) in CDCl3 or D2O at 25°C. Mn and polydispersity 
indices (PI) were determined by size exclusion chromatography with an Alliance 
GPCV 2000 system (Waters, Midford, MA), using high sensitivity refractive index 
detector as reported earlier [1]. Monodisperse PEG standards served to establish the 
calibration curve. 
 
S2. Synthesis of PEG115-b-(PrMA-co-MAA) and Fab'-S-S-PEG145-b-(PrMA27-co-
MAA58) (supplementary Scheme S1) 
PEG macroinitiator, i.e. α-(2-bromoisobutyrylate bromide)-ω-methyl PEG, 
was synthesized using methoxy-PEG (Mn = 5000) and 2-bromoisobutyryl bromide 
[1]. The polymerization reactions were carried out by atom transfer radical 
polymerization (ATRP) of PrMA and tert-butyl methacrylate (tBMA) as reported 
previously [2]. The transformation of tBMA into MAA was achieved by cleaving the 
PEG-b-P(PrMA-co-tBMA) in concentrated HCl and dioxane, as described elsewhere 
[3]. Two copolymers with different compositions were synthesized and characterized 
(supplementary Table S1). 
tBu-S-PEG145-OH was synthesized and converted to ATRP macroinitiator by 
reaction with 2-bromoisobutyryl bromide for 48 h at room temperature as reported 
previously [3]. Then, 500 mg of the macroinitiator was dissolved in 2 mL of THF and 
transferred to flask containing PrMA (280 µL, 25 equiv), tBuMA (630 µL, 50 equiv), 
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bipyridine (24 mg, 2 equiv) and CuBr (I) (7.8 mg, 0.7 equiv). The reaction mixture 
was degassed, stirred for 15 min and then the flask was placed overnight in an oil 
bath thermostated at 65°C. The block copolymer was purified by silica column. The 
terminal thiol and carboxylic acid groups (from MAA units) were generated by 
adding TFA-DMSO (95:5 v/v) and let the reaction proceed for 3 h. After removing 
TFA, the product was basified to pH 10 and washed with ethyl acetate. Aqueous 
phase was dialyzed against water and lyophilized (23% yield). The unprotected 
copolymer (9 mg) was dissolved in a reductive solution (10 mg/mL, DTT in 
phosphate-buffered saline (PBS) pH 7.4, 0.1 M, 0.15 M NaCl) for 6 h. Then the 
copolymer was recovered by passage through a Sephadex G25 column (GE 
healthcare, Piscataway, NJ). Fractions containing the copolymer were added directly 
to an aldrithiol solution in methanol (8 mg in 40 mL), and the reaction was stirred 
overnight. The solvent was evaporated and the copolymer was purified by passage 
through a Sephadex G25 column and recovered by freeze-drying. The yield of 
functionalization (~90%) was determined by reacting an aliquot with DTT and 
measuring the absorbance at 343 nm (thiopyridone was used as a standard). 
Antitransferrin antibody (Medicorp, Montreal, QC, Canada) directed against the 
transferrin receptors was digested to produce (Fab')2 antibody fragments according to 
(Fab')2 preparation kit (Pierce, Rockford, IL). The Pyr-S-S-PEG copolymer was 
dissolved in degassed Tris (10 mM, pH 7.4), and freshly reduced Fab' (1.4-fold 
excess) was then added. The coupling reaction was carried out overnight. The excess 
antibody was removed by passage through an anion exchange column (Hitrap, GE 
healthcare). The amount of Fab' per copolymer was determined by UV-absorbance at 
 243
280 nm and BCA protein assay kit using BSA standards (Pierce) (~15% 
functionalization).  
 
S3. Preparation and characterization of pH-sensitive PICM 
Unlabeled and Cy3-phosphorothioate-AON (5′-
TGAAACTCACCAGCGAGAAC) that target the initiation codon of Bcl-2 mRNA 
[4] was obtained from Alpha DNA (Montreal, QC, Canada). Unlabeled and 5′-
DY547 (sense strand)-3′-fluorescein (antisense strand) Bcl-2 targeting siRNA (5′-
GCAUGCGGCCUCUGUUUGA) [4], was purchased from Dharmacon (Chicago, 
IL). PEG115-b-P(PrMA-co-MAA) and either AON or siRNA were mixed with G3 or 
G5 PAMAM corresponding to Mw of 6,909 and 28,826 g/mol (Sigma-Aldrich, 
Oakville, ON, Canada) at increasing N/(P + COO-) molar ratio in Tris buffer (10 
mM, pH 7.4) to form PICM. The N correspond to the amino groups of the PAMAM 
while P and COO- account for the phosphate and carboxylate groups of the nucleic 
acid and MAA copolymer, respectively. To compare the different formulations, the 
N/(P + COO-) ratio was selected at 1.5 (unless otherwise indicated) because the 
micelles formed at this ratio exhibited the lowest PI. The final concentrations of the 
micelles were adjusted to have 0.1 mg/mL of PEG-b-(PrMA-co-MAA). The mean 
hydrodynamic diameter, PI, and scattering intensity of PICM were measured by 
dynamic light scattering (DLS) using a Malvern Zetasizer Nanoseries ZS (Malvern, 
Worcestershire, UK) equipped with a backscattered light detector operating at 173°. 
The CONTIN program was used to extract size distributions from the autocorrelation 
functions. The scattering intensity and zeta potential of the PICM were determined in 
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Tris buffer of pH values ranging from 3 to 10 by DLS and laser Doppler 
anemometry, respectively, with Malvern Zetasizer Nanoseries ZS. Stoichiometric 
PICM were frozen in liquid ethanol at -50°C, kept at -80°C for 2 h and freeze-dried 
for 48 h. Changes in micelle size, PI and zeta-potential were evaluated after 
redispersion of the dried cakes in Tris buffer. For gel electrophoresis experiments, 
PICM were prepared using siRNA solutions mixed with fluorescein-labeled siRNA 
(50 mol%). Samples were mixed with glycerol and loaded onto a 20% (w/v) 
acrylamide gel. Following migration, the siRNA was visualized by UV irradiation 
using a TyphoonTM 9410 Workstation with variable mode imager (Amersham 
Biosciences, Pittsburgh, PA). The λex/ λem were set at 532/670 nm. Then, the gel was 
fixed and stained with iodine, as reported elsewhere [5] to assess the presence of free 
PEG chains. The gel was photographed without destaining using ChemiImager 5500 
imaging system (Alpha Innotech Corp., San Leandro, CA). 
 
S4. Stability of siRNA in serum  
The degradation of siRNA was monitored by spectrofluorimetry as described 
elsewhere for similar systems [6]. FRET from fluorescein-labeled antisense strand to 
the DY547-labeled-sense strand was exploited to follow the degradation of the 
siRNA as follows (Equation 1): 
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where I(Fl/Dy) is the fluorescence intensity of fluorescein (λem = 525 nm)/DY547 (λem 
= 565 nm) when they are both excited at 488 nm, measured using a Tecan Safire 
plate reader (Tecan, Durham, NC). I(Fl/Dy)t=0, I(Fl/Dy)t=t and I(Fl/Dy)t=∞ correspond to the 
FRET before siRNA degradation, at different time intervals and at the end of the 
experiment, respectively. PICM of different compositions were incubated with FBS. 
At the end of the experiment, heparin was added to destabilize the complexes. The 
FRET corresponds to 100% degradation was then determined after 24 h-incubation. 
To assess the siRNA degradation, samples were loaded into 20% acrylamide gel and 
visualized by UV irradiation. 
 
S5. Cell culture 
Evaluation of cellular toxicity by MTT assay: PEG115-b-P(PrMA28-co-MAA53), 
G5 PAMAM or PICM (sterilized by filtration) were prepared in Tris buffer at 
increasing concentrations. PC-3 cells (American Type Culture Collection, Manassas, 
VA) were maintained in RPMI medium. Cells were seeded in 96-well plates at a 
density of 5x103 cells/well and cultured for 24 h at 37°C in a humidified atmosphere 
containing 5% CO2. The medium was then replaced with Opti-Mem I medium (100 
µL) prior to the addition of 20-µL aliquots of the polymers. After a 4-h incubation 
period, cells were rinsed with PBS, fed with 100 µL of fresh medium. After a total 
incubation period of 72-h, the cells were exposed to 10 µL/well of tetrazolium salt 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) solution (5 
mg/mL in PBS). After 3.5 h of incubation, 100 µL of sodium dodecyl sulfate solution 
(10% in HCl 0.01 N) was added to each well to dissolve the blue formazan product 
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generated by the oxidation of MTT by living cells. The absorbance was read 24 h 
later at 570 nm using a Tecan Safire plate reader.  
 
Flow cytometry: PC-3 cells were plated in a 24-well tissue culture plate (1 mL 
medium containing 3x105 viable cells). After 24 h, the cells were washed 3 times 
with 1 mL Opti-MEM and finally 0.3 mL of the medium was added to the cells prior 
to the addition of 100-µL aliquots of the formulations. The final concentration of the 
AON (labeled with Cy3) in the different formulations was adjusted to 400 nM. The 
plate was then incubated for 2 h under mild agitation at 37°C. Cells were then 
washed three times with cold PBS, fixed with 1% formaldehyde, washed once more 
with cold PBS and resuspended in 0.5 mL PBS. Red fluorescence distributions for 
10,000 cells was recorded at the appropriate wavelength with a FacsCalibur flow 
cytometer (Becton Dickinson, San Jose, CA) at a laser excitation wavelength of 530 
nm. Profiles are representative of at least 3 replicates. 
 
Intracellular trafficking using LSCM: PC-3 cells were plated in 6-well plates 
(5x105 cells/well) containing coverslips. After 24 h, uncomplexed AON, PAMAM-
AON or Fab'-PICM-AON (20 µg Cy3-AON) were incubated with cells for 4 h at 
37°C in a humid atmosphere containing 5% CO2. Two hours before the end of the 
incubation period, LysoTracker green (Invitrogen, Burlington, ON, Canada) was 
added to each well at a final concentration of 200 nM. After 4 h, the cells were 
washed five times with cold PBS, fixed in paraformaldehyde for 20 min. The cells 
were then washed with PBS and stored at 4°C. Cells were then examined by LSCM 
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under a Leica DMIRBE inverted microscope coupled with a Leica TCS SP confocal 
system (Leica Microsystems, Heidelberg, Germany). The cells were excited at 488 or 
568 nm, and fluorescence was collected by emission windows set at 505-555 and 
585-635 nm, respectively. Images collected by LCS Lite software (Leica 
Microsystems) were exported as TIFF files and prepared for publication by Adobe 
Photoshop v 7.0 software (Adobe Systems, San Jose, CA). 
 
Assessment of the antisense activity: PC-3 cells were plated in a 6-well plate 
(1.5x105 cells/well). After 24 h, the medium was replaced by Opti-Mem I reduced 
serum medium. The cells were incubated for 5 h at 37°C with the different 
formulations in the absence or presence of 10% or 50% FBS. Then, the cells were 
washed with complete RPMI medium. After total incubation time of 72 h, they were 
washed with PBS, and extracted in 200-µL lysis buffer consisting of Tris–HCl, pH 
8.0 (0.01 M), NaCl (0.14 M), Triton X-100 (1% v/v), aprotinin (0.1 U/mL) and 
phenylmethylsulfonyl fluoride (0.5 mM). The cell lysates were incubated for 1 h at 
4°C, and centrifuged at 8000 g for 10 min at 4°C. Samples protein contents were 
determined with the BCA protein assay kit. The remaining samples were 
electrophoresed through a 15% (w/v) poly(acrylamide) gel, and the resolved proteins 
were transferred to a poly(vinylidene fluoride) membrane by electrotransfer. Bcl-2 
expression was quantified by the use of an anti-Bcl-2 monoclonal antibody 
(Medicorp). To confirm equal loading, the expression of GAPDH was measured 
using an anti-GAPDH monoclonal antibody (Advanced Immunochemical Inc., Long 
Beach, CA). Both the mismatched AON sequence (5'-TCTCCCAGCATGTGCCAT) 
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(Alpha DNA) and the control siRNA (5'-UAGCGACUAAACACAUCAAUU) 
(Dharmacon) failed to downregulate the Bcl-2 protein.[4]   
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Table S1. Molecular characteristics of PEG-b-P(PrMA-co-MAA) 
Diblock copolymera Mna Mnb PIb 
PEG115-b-P(PrMA28-co-MAA53) 13,300 13,500 1.19 
PEG115-b-P(PrMA51-co-MAA33) 14,500 11,900 1.20 
tBu-S-PEG145-b-(PrMA27-co-MAA58) 14,800 14,400 1.30 
a The subscripts denote the number of repeat units as measured by 1H NMR. 
b Measured by GPC. 
 
 
Table S2. Characteristics of the ternary PICM prepared at N/(P + COO-) molar 
ratio of 1.5 before and after lyophilization; mean ± SD (n=3). 
 
Diameter [PI] Zeta potential ± SD 
 (mV) 
Copolymer PAMAMa Nucleic 
acidb 
Before 
lyophilization 
Rehydrated 
PICM 
Before 
lyophilization 
Rehydrated 
PICM 
PEG115-b-P(PrMA28-co-MAA53) G5 AON 60 [0.13] 60 [0.11] 6.3 ± 1.1 3.3 ± 1.5 
PEG115-b-P(PrMA28-co-MAA53) G3 AON 58 [0.16] 56 [0.14] 1.2 ± 3.1 2.5 ± 0.5 
PEG115-b-P(PrMA28-co-MAA53) G5 siRNA 70 [0.14] 68 [0.15] 9.3 (1.3) 5.6 (0.3) 
PEG115-b-P(PrMA28-co-MAA53) G3 siRNA 67 [0.17] 66 [0.15]  0.9 (0.2) 2.0 (0.7) 
PEG115-b-P(PrMA51-co-MAA33) G5 AON 58 [0.16] 56 [0.15] 4.3 ± 3.6 5.4 ± 4.6 
PEG115-b-P(PrMA51-co-MAA33) G3 AON 56 [0.15] 54 [0.13] 2.3 ± 4.1 6.5 ± 2.8 
PEG115-b-P(PrMA51-co-MAA33) G5 siRNA 62 [0.17] 62 [0.16] 4.0 (0.9) 2.6 (1.8) 
PEG115-b-P(PrMA51-co-MAA33) G3 siRNA 61 [0.17] 58 [0.15] 3.6 (1.1) 6.7 (0..8) 
aG3 = 6,909 g/mol, G5 = 28,826 g/mol. 
bThe AON or siRNA represents 5% of the negative charges in the formulations. 
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Scheme S1. Synthesis of the targeted block copolymer; Fab'-S-S-PEG-b-(PrMA-co-
MAA). n, x, and y represent the number PEG, PrMA and MAA repeat units, 
respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Emission spectrum of fluorescein- and DY547-labeled siRNA prior to 
(▲) and after (●) degradation in serum (λex = 488 nm). The inset is the gel 
electrophoresis of the siRNA before (1) and after (2) degradation in serum when 
scanned at λex/λem of 488/526 nm.  
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Figure S2. The stability of siRNA in PEG115-b-P(PrMA28-co-MAA53)/ G5 PAMAM 
PICM following incubation with 100% FBS could be enhanced by increasing the 
N/(P + COO-) molar ratio from 1.5 (▲) to 3 (●) (10 µg/mL siRNA, 37°C, pH 7.4). 
Mean ± SD (n=3). 
 
 
 
Figure S3. Confocal microscopy images of PC-3 cells after treatment with 
uncomplexed Cy3-AON (red, panel b). Endosomes/lysosomes were stained by 
LysoTracker (green, panel a), and the images were merged in panel c. 
 
 
 
Figure S4. Red fluorescence intensity of PC-3 cells incubated with Cy3-labeled 
AON entrapped in Fab'-modified PEG115-b-P(PrMA28-co-MAA53)/G5 PAMAM 
PICM either preincubated with free CD71 antibody or not. Fluorescence of unstained 
control cells is indicated. 
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Figure S5. Bcl-2 gene silencing in PC-3 cells transfected for 5 h with AON (400 nM) 
or siRNA (25 nM) complexed lipofectamine (1 µg/mL) or entrapped in Fab'-PEG115-
b-P(PrMA28-co-MAA53)/G5 PAMAM PICMs at N/(P + COO-) of 3 (final volume of 
the transfection medium is 2 mL). Control cells were treated with medium alone. The 
effect of preincubation with 50% FBS is indicated on the graph. The molar ratio of 
the Fab'-PEG145-b-P(PrMA27-co-MAA58) vs. PEG115-b-P(PrMA28-co-MAA53) is 2% 
for all the experiments. The results are representative of several independent 
experiments. 
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CHAPTER 6 – Discussion 
 
1. Hurdles facing current delivery systems 
The general objective of this thesis was to develop polymeric nanocarriers for 
the delivery of hydrophobic anticancer drugs and nucleic acids. We selected 
docetaxel as a poorly water-soluble drug (2 µg/mL) because it is a clinically well-
established treatment of breast, ovarian and non-small cell lung cancer. However, 
there are some problems associated with the current formulation used to dissolve 
docetaxel (i.e. Taxotere®), such as hypersensitivity reactions and premedication 
requirement1. Hence, a new delivery system is needed to overcome these 
disadvantages. For nucleic acids, we selected an antisense oligonucleotide (AON) 
and a short interfering RNA (siRNA) targeting the antiapoptotic oncogene Bcl-22. 
This gene has been implicated in a number of human cancers, including breast, 
prostate and lung carcinoma3. It is also involved in the resistance to conventional 
cancer treatment. Downregulation of this gene by either AON or siRNA can sensitize 
cancer cells to chemotherapy3,4. Despite encouraging clinical results after treatment 
of cancer with G3139 (the Bcl-2-targeting AON), there are many hurdles to 
overcome. After intravenous injection, the α and β half-lives of the oligonucleotide 
were 5 and 37 min, respectively5. Thus, it was difficult to maintain a sustainable level 
of intact oligonucleotide after administration. Even with this low concentration, the 
polyanionic nature of AON and siRNA impairs their ability to penetrate the cellular 
membranes.  Hence, we have focused our efforts on developing targeted polymeric 
delivery systems to overcome the problems associated with the current therapies. In 
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this thesis, two types of polymeric micelles (PM) have been developed for the 
delivery of docetaxel and nucleic acids.    
 
2. PM for drug delivery 
2.1 Micellar characterization 
Diblock copolymers of poly(ethylene oxide) (PEO) and poly(butylene oxide) 
(PBO) or poly(styrene oxide) (PSO) can self-assemble at low concentrations into PM 
of various shapes, depending on relative block lengths, concentration and 
temperature6,7. Although these polymers have been characterized in several studies, 
their role as solubilizers has been reported only for the antifungal drug griseofulvin 
(at the time of publication)8. PM for docetaxel delivery were prepared using these 
copolymers. Low critical micelle concentration (CMC) values and high core 
viscosities were characteristic features of these micelles (Chapter 3, Table 2). 
Increasing the hydrophobicity by using PSO instead of PBO, or increasing the chain 
length of PBO or PSO resulted in lower CMC and higher core viscosity. Low CMC 
values and high core viscosities are indicative of a greater stability upon dilution after 
intravenous administration. This study also showed, for the first time, the different 
morphologies (i.e. spherical vs. cylindrical) of free or docetaxel-loaded PEO-b-
PBO/PSO micelles by transmission electron microscopy. The importance of 
investigating micelle morphology lies in the fact that aggregates of different 
morphologies might display different characteristics. For example, cylindrical 
assemblies are usually associated with greater solubilization capacity than spherical 
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assemblies, given their larger core volume8-11. The pharmacokinetics are also 
expected to vary. Discher and coworkers12-14 found that cylindrical poly(ethylene 
glycol) (PEG)-b-poly(ethylethylene) PM persist in the circulation (in rodents) about 
10 times longer than their spherical counterparts. It was observed that the long 
cylindrical micelles were not taken up by the macrophages. In contrast, shorter 
micelles are taken up by cells, thus resulting in faster clearance.     
2.2 Factors affecting drug-loading 
The method of drug-loading, the common solvent utilized for the dissolution of 
polymer and drug, compatibility between the drug and micellar core, micelle 
morphology and nature of the drug are the main factors that affect loading capacity. 
Several procedures have been exploited for the incorporation of docetaxel into PEO-
b-PBO/PSO micelles. The direct dissolution of docetaxel into a solution of pre-
formed micelles resulted in low levels of loading. Hence, both the drug and polymer 
were dissolved in an organic solvent followed by evaporating the solvent under 
vacuum. Then, the resulting film was rehydrated with water. The success of this 
procedure was shown to depend on the nature of the organic solvent employed to 
form the polymer/drug matrix. Among the different solvent used, only ethanol gave a 
clear solution after rehydration with water. In another study, Zhang et al.15 found that 
to incorporate paclitaxel in PEG-b-poly(D,L-lactide) (PEG-b-PDLLA) PM, only 
acetonitrile gave a clear solution after reconstitution in water.  
PSO-based micelles incorporated more docetaxel (~3-4%) than PBO-micelles 
(<1%) likely because of the expanded micelle morphology (i.e. cylindrical vs. 
spherical). The higher loading capacity of PSO-micelles can be also due to the better 
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compatibility between docetaxel and PSO (Chapter 3, Tables 4 and 5). The 
solubilization capacities obtained here were comparable with published data on 
similar copolymers with different drugs (e.g. griseofulvin, furosemide and 
nabumetone). These are the only other results available for the solubilization of drugs 
in closely-related copolymers16.   
2.3 In vitro evaluation of the micelle formulations 
PEO45-b-PBO24 PM were able to preserve most of docetaxel’s chemical 
integrity against hydrolytic degradation compared to the free drug. The micelles were 
also able to slow drug release (Chapter 3, Figure 5). The antimitotic activity of 
docetaxel-loaded micelles was evaluated on human prostate cancer cells (PC-3) 
(Chapter 3, Figure 6). The PEO45-b-PBO24 and PEO45-b-PSO26 micelles were as 
efficient as the control commercial formulation in inhibiting the growth of these cells. 
However, at high polymer concentration, PEO45-b-PSO26 was fairly less toxic than 
polysorbate 80. D. Le Garrec et al.17 obtained comparable in vitro cytotoxicity of 
docetaxel-loaded poly(N-vinylpyrrolidone) (PVP)-b-PDLLA PM against C26 murine 
colon tumoral cells. The PVP-b-PDLLA-unloaded micelles also showed less 
cytotoxicity than polysorbate 8017. Thus, at high drug concentrations, PEO-b-PSO 
may potentially improve the therapeutic index of docetaxel by decreasing the 
formulation’s non-specific toxicity. Such polymers could provide useful alternatives 
to low molecular weight surfactants for the solubilization of taxanes.  
 257
2.4 Limitation of the systems 
The limitation of the presented systems is their limited loading capacities (~0.4-
4% w/w) (Chapter 3, Table 4). High loading efficiency is crucial in order to reduce 
the amount of vehicle to be administered. It is required to limit the toxicity or adverse 
effects that can be associated with the carrier and to minimize the overall cost of the 
formulation. Hence, we looked for another drug that had a greater affinity for the 
micellar cores. Indeed, we could obtain up to 10% (w/w) loading with a new drug for 
the treatment of hepatitis C that was provided by a pharmaceutical company (data not 
shown in this thesis for confidentiality reasons). No changes in size and 
polydispersity indices (PDI) of these loaded micelles were observed for 14 days 
when they were examined by dynamic light scattering. In addition, no crystals were 
apparent under the microscope (i.e. no precipitation). What remains to be achieved is 
to test whether drug-loaded micelles can alter the pharmacokinetics of free drug in 
vivo and improve the therapeutic outcomes. PM, when properly designed, can alter 
the pharmacokinetics of free drugs and reduce the toxicity associated with 
commercial surfactants. For example, Genexol-PM is a paclitaxel-encapsulated PEG-
b-poly(D,L-lactide) (PEG-b-PDLLA) micelle formulation18, administered to 
overcome the side-effects (e.g. hypersensitivity reactions) associated with 
Cremophor® EL-based system1. Cremophor® EL and Genexol-PM formulations have 
similar drug pharmacokinetics at the 230 mg m-2 dose level (Table 1). Both 
Cremophor® EL and Genexol-PM have similar half-lives and clearance rates. 
However, Genexol-PM is associated with less toxicity and side-effects (e.g. 
hypersensitivity reactions), allowing for a considerable increase in the maximum 
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tolerated dose (MTD) (Table 1). This dose increment has led to better tumor 
responses to therapy among patients18,19.  
 
 
 
Table 1. Comparison of the clinical pharmacokinetics of Taxol® (commercial 
formulation) and Genexol (micellar nanocarrier). Adopted from reference20.   
 
Formulation Taxol® Genexol 
Drug Paclitaxel Paclitaxel 
Carrier Cremophor® EL PEG-PDLLA 
Dose (mg m-2) 230 230  
Number of patients 34 21 
T1/2, β (h) 8.9±1.8 11.0±1.9 
Clearance (mL min-1 kg-1) 3.9±1.1 4.8±1.0 
MTD (mg m-2) 230 390 
Reference 19 18 
 
 
 
 
3. Polyion complex micelles for nucleic acid delivery 
3.1 Preparation of polymeric nanocarriers for nucleic acid delivery 
The objective of the second part of this thesis was to prepare polymeric 
delivery systems that would protect nucleic acids against enzymatic degradation and 
improve their transfection efficiencies. Two different polyion complex micelle 
(PICM) systems were developed for the sustained release and intracellular delivery of 
nucleic acids. Firstly, oligonucleotide (ON) conjugates were prepared by covalently 
attaching a phosphodiester sense ON (SON) to a PEG chain of various molecular 
weights. The purified PEG-SON was then hybridized to phosphorothioate (PS)-AON 
and the PEG-duplex was further purified (Chapter 4, Scheme 1). These conjugates 
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were proposed to gradually release the AON upon the enzymatic degradation of a 
complementary SON. The PEG conjugates were able to provide a partial protection 
for the ON against enzymatic degradation. To improve the stability, the PEG-
SON/AON duplex was electrostatically complexed to generation (G) 3 or G5 
poly(amidoamine)s (PAMAMs) to trigger the self-assembly of the duplexes into 
monodisperse PICM. Secondly, the incorporation of PEG-block-poly(propyl 
methacrylate-co-methacrylic acid) (PEG-b-P(PrMA-co-MAA)) was exploited to 
impart pH sensitivity to PAMAM-based PICMs. This system was composed of the 
anionic copolymer mixed with cationic PAMAM dendrimer. Such PICM could 
accommodate AON or siRNA in their cores (Chapter 5, Scheme 1). Generally, both 
types of PICM showed mean hydrodynamic diameters ranging from 50 to 100 nm, 
narrow size distribution (PDI <0.2) and nearly neutral surface charge (-4–10 mV) 
(Table 1). The smaller size of PEG5K-b-P(PrMA-co-MAA)-PICM compared to 
PEG10 or 20K-ON duplex-PICM could be explained by the lower molecular weight of 
PEG used in the preparation of the micelles (5 K vs. 10-20 K). The systems were 
freeze-dried and easily resuspended without any change in size, PDI, zeta-potential 
and complexation efficacy (Chapter 5, Figure 1 and Supplementary section, Table 
S2). Thus, lyophilization was achieved without any additive and the micelles could 
be stored in dried form. Their size and PDI are comparable to the values obtained 
earlier for similar systems. For example, PICM formed of PEG-ON conjugate/ 
polyethylenimine had a size of 70 nm and low PDI21,22. However, this is the first time 
that these PICM were shown to be lyophilized without lyoprotectant23 or chemical 
modification (i.e. core crosslinking)24 and to retain their characteristics after 
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reconstitution with water. This remarkable resistance to aggregation might be 
attributed to high PEG density in the corona25. 
 
 
Table 2. Characteristics of ternary PICM-AON; mean ± SD (n=3). 
Corona-forming polymera PAMAMb Diameter
(nm) 
PDI  Zeta potential 
± SD (mV) 
PEG10K-ON G3 68 0.06 -1.8±0.3 
PEG20K-ON G3 88 0.09 -3.2±1.5 
PEG20K-br-ON G3 89 0.14 3.0±1.6 
PEG10K-ON G5 88 0.08 -1.7±0.3 
PEG20K-ON G5 93 0.07 0.5±0.6 
PEG20K-br-ON G5 97 0.11 0.6±2.9 
PEG5K-b-P(PrMA28-co-MAA53) G5 60 0.13 6.3±1.1 
PEG5K-b-P(PrMA28-co-MAA53) G3 58 0.16 1.2±3.1 
PEG5K-b-P(PrMA51-co-MAA33) G5 58 0.16 4.3±3.6 
PEG5K-b-P(PrMA51-co-MAA33) G3 56 0.15 2.3±4.1 
aIn PEG-ON conjugates, the ON is attached to one extremity (PEG10 or 20K) or to the 
central part (PEG20K-br) of the PEG chain. 
bG3 = 6,909 g/mol, G5 = 28,826 g/mol. 
  
3.2 Enzymatic stability of entrapped nucleic acids 
A fluorimetric assay was developed to assess AON and siRNA degradation26. 
This was achieved by labeling the two complementary ON strands by two different 
fluorescent probes (fluorophore (i.e. fluorescein (FAM)) and quencher (i.e. Cy3)). 
Depending on the relative position of the fluorophore and quencher, two types of 
quenching can occur; fluorescence resonance energy transfer (FRET) and contact 
(static) quenching.  
If the fluorophore and quencher are close to each other within a range of 20-100 
Å (e.g. siRNA (Figure 1A)), FRET is the predominant mode of quenching. Here, 
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upon excitation of FAM, energy is transferred through non-radiative dipole-dipole 
coupling, resulting in increase in the emission fluorescence intensity of Cy3 (i.e. 
FRET)27. The FRET is detected by the increase in the Cy3 fluorescence intensity and 
the decrease in FAM fluorescence intensity 28. In our case, the siRNA degradation 
could be monitored by measuring the decrease in FRET which occurs upon the 
degradation of the duplex (Figure 1A).  
On the other hand, if the fluorophore and quencher are brought any closer (i.e. 
<20 Å), contact quenching occurs (e.g. ON duplex (Figure 1B)). In this case, the 
fluorescence intensity of both FAM and Cy3 is reduced because at these intimate 
distances, most of the absorbed energy is dissipated as heat and only a small amount 
of energy is emitted as light. The degradation of ON duplex brings the FAM and Cy3 
apart from each other, resulting in an increase in the fluorescence intensity of FAM 
and Cy3 (Figure 1B).  
The interesting feature of this fluorimetric assay is that degradation of the nucleic 
acids can be monitored in real time. In addition, this method is much simpler than gel 
electrophoresis and less time-consuming. 
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Figure 1. (A) siRNA: the fluorophore (FAM) and the quencher (Cy3) are placed at a 
distance from each other so that FRET is the predominant mode of quenching. (B) 
ON duplex: the fluorophore and the quencher are placed close to each other so that 
contact quenching occurs. In both cases, upon the degradation of DNA or RNA 
duplexes, the fluorophore and quencher become apart from each other and 
fluorescence dequenching occurs.  
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Conjugation of ON to PEG partially protected it against enzymatic degradation 
by DNAse 1. However, the entrapment of nucleic acids (i.e. AON or siRNA) in the 
core of PICM provided greater protection for them against enzymatic degradation by 
nucleases. Higher generations of PAMAM (i.e. G5 vs. 3) imparted greater stability to 
the nucleic acids. Thus, multimeric binding through cooperative effects played a 
great role in determining the stability of the formed micelles (Chapter 4, Table 2 and 
Figure 8). 
To further study the effect of serum and different plasma proteins on the stability 
of entrapped siRNA, PEG-b-P(PrMA-co-MAA)/PAMAM PICM were incubated 
with serum. Increasing the serum concentration resulted in a faster rate of siRNA 
degradation (Figure 2). siRNA degradation went from 10 to 40% upon increasing the 
serum concentration from 20 to 100%. The effects of albumin (40 mg/mL), α- and β-
predominant globulins (15 mg/mL), γ-globulins (10 mg/mL) and heparin (6 x 10-4 
mg/mL) on the degradation profile of the siRNA entrapped in the micelles were 
examined (Figure 3). These concentrations are representative of the corresponding 
plasma levels. All plasma proteins and heparin were found to contribute equally to 
micelle destabilization. A slightly more significant effect was observed for α- and β-
globulins. Park, K. and coworkers29 have recently shown that that α- and β-globulins 
are major factors for the destabilization of PEG-b-PDLLA micelles while other 
plasma proteins play minor roles. The different results here might be attributed to the 
difference in micelle composition. PICM are formed via electrostatic complexation 
and are more vulnerable to destabilization by charged plasma proteins. 
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Figure 2. Effect of serum concentration on the stability of siRNA complexed in 
PEG115-b-P(PrMA28-co-MAA53)/G5 PAMAM PICM (10 µg/mL siRNA, 37°C, pH 
7.4). The formulations were incubated in 20% (●), 50% (▲) or 100% (■) FBS. Mean 
± SD (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effect of albumin, 40 mg/mL (▲), γ-globulins, 10 mg/mL (∆) and α- and 
β-predominant globulins, 15 mg/mL (□) and heparin, 6 x 10-4 mg/mL (■) on the 
stability of siRNA formulated in PEG115-b-P(PrMA28-co-MAA53)/G5 PAMAM 
PICM (10 µg/mL siRNA, 37°C, pH 7.4) when incubated with 20% FBS. The 
stability of PICM in 20% (○) and 100% (●) FBS is also shown. Mean ± SD (n=3). 
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3.3 Active targeting  
An easy way to enhance the intracellular delivery of nucleic acids and to 
compensate for excessive drug degradation either extra- or intracellularly, is by 
increasing micelle net positive charge. However, the increase in positive charge 
usually comes at the expense of toxicity and specificity. These positively-charged 
complexes are rapidly inactivated in the presence of serum. Moreover, after 
intravenous injection, the large size and positive character of the complexes result in 
their rapid opsonization, clearance from the circulation, and the risk of lung capillary 
occlusion30-32. In one study, siRNA-targeting vascular endothelial growth factor 
(VEGF)-based PICM were tested for anti-angiogenic therapy33. The siRNA was 
conjugated to PEG via cleavable disulfide linkage and complexed with cationic 
polyethylenimine (PEI) for PICM generation. The formulations showed transfection 
efficiencies superior to PEI/siRNA, even in the presence of serum and despite the 
absence of any targeting ligand on the micelle surface. This can be explained by the 
high charge ratio of the formulations (i.e. nitrogen-to-phosphate (N/P) = 16). The 
formulations effectively suppressed VEGF expression after intra-tumoral or 
intravenous injection, compared to PEI/siRNA. Though interesting, the future 
applications of such formulations might be limited because of their high charge ratios 
which can cause toxicity without specific accumulation at target sites. Instead, a 
targeting ligand should be included to promote the uptake of these micelles at N/P 
ratio near stoichiometry.   
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Choosing the antibody as a targeting moiety is advantageous in terms of 
selectivity, high affinity, and minimal competition for receptors. This is contrary to 
what is observed with endogenous molecules, such as folic acid or transferrin34-36. 
Whole or fragmented antibodies (i.e. fragment antigen binding (Fab')) have been 
employed to functionalize micelles. In general, targeted micelles show higher cellular 
uptake than the non-targeted micelles37,38. The whole antibody, however, is large and 
potentially hinders the self-assembly of PICM. Moreover, it can favor the systemic 
clearance of the carrier via Fc region recognition by the mononuclear phagocytic 
system. In this work, PICM were decorated with anti CD71 Fab' which targets the 
transferrin receptor. The latter is over-expressed by tumor cells39. Decoration of the 
micelles with the Fab' increased the uptake due to receptor mediated internalization. 
Then, lowering of pH encountered in the endosomes triggered the deshielding of the 
micelle corona and released positively-charged AON or siRNA-dendrimer complexes 
with membrane-destabilizing properties (Chapter 5, Scheme 1). It is worth 
mentioning that micelles uptake was reduced when the cells were preincubated with 
free CD71 antibody and became comparable to non-targeted micelles, indicating the 
specificity of uptake (Chapter 5, Figure S4). Moreover, the micelles were able to 
escape from the lysosomal pathway as revealed by the confocal microscopy 
experiments (Chapter 5, Figure 5). In accordance, the Fab'-targeted micelles were 
able to increase the activity of AON and siRNA directed against Bcl-2 in PC-3 cells 
more than AON or siRNA that were either free or complexed to plain micelles or 
PAMAM (Chapter 5, Figure 5). Protection of nucleic acids in the core of the 
micelles, enhanced cellular uptake and probably the contribution of the MAA 
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copolymer to endosomal destabilization at acidic pH of the endosomes might be 
responsible for the enhanced activity of the targeted micelles40-42. In addition, at 
endosomal pH (~5), the deshielding of the micelle corona produced >10-fold increase 
in (N/P) molar ratio, leaving a positively-charged partially-PEGylated 
PAMAM/nucleic acids complexes available for interaction with endosomal 
membranes.  
Indeed, targeted and pH-sensitive PICM are promising nanocarriers for 
siRNA delivery. For example, Kataoka and coworkers43 prepared lactosylated PEG-
siRNA/poly(L-lysine) PICM where the PEG was conjugated to the siRNA via β-
thiopropionate pH-sensitive linkage. The formulation exhibited gene silencing of 
firefly luciferase expression in HuH-7 cells that was comparable to cationic 
liposomes (oligofectamine). However, the application of this formulation may be 
limited in the treatment of hepatocarcinoma because the targeting ligand (i.e. lactose) 
is used to target hepatocytes. Hepatocytes express carbohydrate receptors (i.e. 
asialoglycoprotein receptors) that recognize different sugar moieties such as lactose, 
galactose or mannose, allowing liver-specific delivery44,45. In addition, our system is 
preferred because exposure of the membrane-destabilizing components does not rely 
on the chemical hydrolysis of a pH-sensitive bond46. Our approach would also ensure 
fast dissociation kinetics at acidic pH and higher chemical integrity of the construct. 
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4. Designing polymeric nanocarriers for drug and nucleic 
acid delivery 
 
Polymers of different structures and compositions can be used for drug and 
nucleic acid delivery. Recent data highlight 4 important features of nanocarriers for 
drug delivery. Firstly, it is essential to incorporate biodegradable polymers. Polymer 
structure and composition can be changed or even modified according to therapeutic 
requirements. In many situations, polymer biodegradability and biocompatibility are 
perquisites for patient safety. Biodegradability can be attained, for example, by 
endowing polymers with ester47,48 or disulfide linkages49,50. However, the 
introduction of disulfide bridges in polymer structure might create other problems, 
such as instability in blood. Disulfide bridges (when not properly designed) can be 
cleaved in the systemic circulation51. Secondly, nanoparticles should be coated with 
PEG or other neutral polymers to prevent opsonization, decrease clearance and 
consequently prolong circulation time. The latter allows nanoparticles leakage in 
leaky vasculature areas (e.g. tumors)52,53. Thirdly, targeting ligands on the surface of 
nanoparticles is beneficial in terms of enhancing accumulation at target sites and 
decreasing the drug exposure of normal cells. Nanoparticles can be decorated with 
different targeting ligands depending on the purpose of the treatment. For example, 
targeting transferrin receptors is generally helpful in tumor therapy as they are 
overexpressed in tumor cells34,39,54,55. Alternatively, targeting asialoglycoprotein 
receptors is particularly beneficial against hepatocellular carcinoma45,56-58. Other 
targeting ligands can be specific in the treatment of prostate cancer59,60. Finally, these 
 269
nanocarriers can be exploited for combinational therapy, meaning that more than one 
drug can be incorporated in the same carrier. This can improve drug efficacy (e.g. by 
synergism), reduce the number of injections and ameliorate patient quality of life. For 
instance, Bae et al.61 combined doxorubicin and wortmannin in PM and could reduce 
the doxorubicin dose required for cytotoxicity through a synergistic drug action. In 
addition, Lee et al.62 tested a combination of siRNA and fluorescent dye in magnetic 
nanoparticles for molecular imaging and siRNA delivery. 
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Conclusion and perspectives 
PM are a promising nanomedicine platform for drug and nucleic acid 
delivery. These core-shell assemblies can be tailored to increase the solubility of 
poorly water-soluble drugs just as to protect labile hydrophilic drugs from rapid 
inactivation. Because of their nanometer size and hydrated outer layer, micelles can 
prolong the circulation time of encapsulated drugs and passively accumulate at tumor 
sites, thereby reducing drug systemic toxicity and enhancing its efficacy. Micelles 
that actively target tissues can also be prepared by utilizing stimuli-responsive 
components or by attaching recognition groups at their surface. 
In this thesis, poly(ethylene oxide)-block-poly(butylene oxide/styrene oxide) 
PM were prepared and found to enhance the aqueous solubility of docetaxel. 
Poly(ethylene oxide)-block-poly(butylene oxide) PM were able to protect docetaxel 
against hydrolytic degradation. Docetaxel-loaded micelles demonstrated in vitro 
efficacy comparable to the commercial formulation, indicating drug release from the 
hydrophobic core. In addition, the polymers showed lower toxicity than the 
commercial surfactants which may increase the therapeutic index of the drug by 
reducing the adverse reactions associated with the commercial formulations. 
Pharmacokinetic studies still need to be performed to determine if the half-life of 
docetaxel can be changed by using these PM. 
On the other hand, stable PICM were prepared and found to slow AON and 
siRNA degradation and increase their intracellular bioavailability. Long-term 
stability of the formulations is guaranteed by the fact that these micelles can be 
lyophilized without any additive and thus stored in solid form. Such polymeric 
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nanocarriers could prove potentially useful to confer prolonged circulating properties 
to nucleic acids and enhance their intracellular bioavailability. 
What remains to be accomplished is further diminution of formulation 
toxicity compared to current PAMAM systems while providing greater protection for 
siRNA against degradation in serum. These objectives might be achieved by 
imparting biodegradability to PAMAM dendrimers and by exploiting chemically-
modified siRNA. PAMAM dendrimers of different molecular weights (i.e. number of 
surface amine groups) will be synthesized by convergent method63. The dendrimers 
will be grown via ester linkages (Figure 4), which will confer them with 
biodegradability. Biodegradable PAMAM of G3 to G6 will be synthesized. These 
PAMAM generations will be selected because they have been shown to form PICM 
when reacted with PEG-b-P(PrMA-co-MAA)/siRNA. Lower generations of 
PAMAM dendrimers do not form PICM26.  
 
 
Figure 4. Biodegradable PAMAM dendrimers endowed with ester linkages. 
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Chemically-modified siRNA will be employed to provide greater protection 
against enzymatic degradation and possibly greater affinity for the sequences 
targeted. Indeed, some chemically-modified siRNA have been originally synthesized 
for our laboratory (Table 3). These siRNA combine more than one kind of chemical 
modification (2′-deoxy-2′-fluoro-β-D-arabinonucleic acid, 2'fluoro-RNA and locked 
nucleic acid) but they are still under investigation. 
 
Table 3. Chemically modified siRNA. 
Name Sequence 
BCL2-FF611 
 
5' -         GCAUGCGGCCUCUGUUUGAUU    -3' 
3'-    UUCGUACGCCGGAGACAAACU              -5' 
BCL2-LFL3 
 
5' -         GCAUGCGGCCUCUGUUUGAUU    -3' 
3' -  UUCGUACGCCGGAGACAAACU                -5' 
BCL2-1 
 
5' -         GCAUGCGGCCUCUGUUUGAUU    -3' 
3' -  UUCGUACGCCGGAGACAAACU            -5' 
BCL2-2 
 
5' -         GCAUGCGGCCUCUGUUUGAUU    -3' 
3' -  UUCGUACGCCGGAGACAAACU             -5' 
Legend: RNA, 2'F-ANA, 2'F-RNA, LNA 
 
 
Despite the significant progress that has been made in formulating nucleic 
acids with PICM, no systems have demonstrated sufficient efficacy in animal and/or 
human models for clinical use. Hence, a pharmacokinetic study will be conducted to 
determine the half-life of the siRNA in vivo. In addition, the feasibility of these 
systems to efficiently knock down the Bcl-2 oncogene in targeted cells in vivo still 
needs to be established. The long term objective of this research is to construct a 
clinically-viable pH-responsive PICM system for siRNA systemic administration that 
would combine most of the essential attributes required for efficient delivery to 
appropriate cellular compartments.  
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Appendix 
Protection of the siRNA against degradation in different biological 
media 
 
Control siRNA or siRNA entrapped in PICMs of PEG115-b-P(PrMA28-co-
MAA53)/PAMAM G5 (prepared at N/(P + COO-) molar ratio of 1.5) were incubated 
with 20, 50 and 100% FBS. Then, the effect of albumin (40 mg/mL), α- and β-
predominant globulins (15 mg/mL), γ-globulins (10 mg/mL) and heparin (6 x 10-4 
mg/mL) on the degradation profile of the siRNA entrapped in the same micelles was 
examined. The calculation of the % of siRNA degradation was performed according 
to Equation 1 (Chapter 5, supplementary S4). 
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